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Background
This thesis describes the results of a number of clinical studies that explore the 
relationship between thiazolidinedione (TZD) treatment and fluid accumulation. 
Fluid accumulation includes conditions such as fluid retention, oedema formation 
and symptomatic heart failure, which, though being different clinical entities, 
are used interchangeably in the literature. While fluid accumulation has been 
recognized as one of the most important side effects of thiazolidinediones, the 
underlying mechanism of action remained unclear. In a series of experiments, we 
have tested various hypotheses.
All studies have been performed with rosiglitazone as a representative of the 
thiazolidinedione class. In  this introduction, we will outline the scenery of diabetes 
mellitus and its treatment before the introduction of the thiazolidinediones. Then 
we will describe the clinical effects of thiazolidinediones and the techniques used 
in the studies. Finally, the  outline of this thesis will be summarized.
Diabetes mellitus type 2  and insulin resistance
Diabetes is defined as a state of chronic hyperglycaemia and is classified into several 
subtypes. Type 1 diabetes is characterized by absolute insulin deficiency due to 
destruction of islet cells. Type 2 diabetes mellitus is defined as a combination of a 
decreased biological action of insulin (insulin resistance) and a defect in insulin 
production (insulin deficiency)(1). Insulin is produced in the β-cells located in the 
islets of Langerhans in the pancreas and has its main influence on muscle, liver 
and fat tissue(2). Insulin plays an important role in the energy balance of the body 
where it functions as anabolic hormone for carbohydrates, proteins and fats. 
Normally, insulin resistance is compensated by increased insulin production. If 
insulin production can no longer match the increased insulin need, (chronic) 
hyperglycaemia and thus diabetes will develop.
Diabetes type 2 is nowadays epidemic. In 2011 there were 801,000 people 
in the Netherlands diagnosed with diabetes mellitus of which around 90% had 
type 2 disease(3). Worldwide, the number of people suffering from diabetes is 
estimated as close to 400 million(4). Insulin resistance is not only associated with 
type 2 diabetes, but also with other metabolic disorders such as hypertension, 
dyslipidaemia and obesity, together clustered under the term insulin resistance 
syndrome or the metabolic syndrome(5). 
Despite effective treatment for correction of acute hyperglycaemia, the 
morbidity and mortality burden of type 2 diabetes remains high especially 
due to chronic, cardiovascular complications(6). Macrovascular complications, 
like myocardial and cerebral infarction, are caused by  atherosclerosis which 
is accelerated by hyperglycaemia(7) and by other risk factors associated with 
the insulin resistance syndrome. The relative risk for myocardial infarction in 
patients with diabetes who are not intensively treated is between 2 and 4(8). As 
a result of therapeutic improvements over the last two decades this relative risk 
declined, but is still 1.8(9).
The microvascular complications, retinopathy, nephropathy and neuropathy 
are strongly related to the duration and level of hyperglycaemia(10). A subtype of 
peripheral neuropathy is diabetic autonomic neuropathy, in which the autonomic 
nerve fibers are damaged, and which can lead to dysfunction of several organ 
systems. The clinical manifestations are diverse, such as resting tachycardia, 
orthostatic hypotension, silent myocardial ischaemia, gastroparesis, and erectile 
dysfunction(11). Especially cardiovascular autonomic neuropathy (CAN) has a 
serious impact on morbidity and mortality. Autonomic neuropathy is one of the 
most overlooked complications of diabetes(12). 
Altogether, diabetes is associated with several, potentially serious 
complications, but the severity of the disease is often underestimated. The severity 
of  the complications of diabetes mellitus are nicely illustrated in a phrase listed 
in the strategic planning report of the diabetes mellitus interagency coordinating 
committee: ‘Diabetes kills with neither speed nor precision, but with stealth and 
the slow accumulation of insults. It can rob a person of the ability to see, feel, 
think, walk, and have sex’(13).
Treatment of type 2 diabetes
From the above, it will be clear that therapy in type 2 diabetes is aimed at prevention 
of the complications by (near) normalization of plasma glucose levels(14). Lifestyle 
modification including weight reduction and increased physical exercise are 
first line interventions and the cornerstone of type 2 diabetes treatment(14). 
This approach is effective on glucose lowering and moreover beneficial for the 
traditional cardiovascular risk factors, such as hypertension and dyslipidaemia 
and therefore reduce cardiovascular risk(15), however ineffective in the long term 
due to a high rate of weight regain(16). For subjects with treatment failure on lifestyle 
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modification, oral drug treatment is available from the 1950s. Sulphonylurea 
derivatives(17) were introduced first. These drugs stimulate pancreatic β-cell 
insulin secretion and are effective in lowering plasma glucose levels, however, it 
has not been proven that this class of drugs is effective in reducing cardiovascular 
disease(18). A number of years after the sulphonylurea derivatives, the biguanides 
(with its main representative metformin) were introduced, which primarily lower 
hepatic glucose output(17) and additionally offer cardiovascular protection(19, 20). 
Together with insulin treatment, these drug classes have dominated diabetes 
treatment in the pre-thiazolidinedione era. Although these drugs are effective 
in lowering glucose, it has also been found that type 2 diabetes is a progressive 
disease. Over time more and different compounds are needed to sustain good 
glycaemic control(21). This phenomenon is explained by a progressive failure of 
the β-cells in the pancreas. Therefore, in the “pre-thiazolidinedione” era, there 
was a need to find better and more compounds to prevent chronic complications, 
β-cell failure and to meet tailor-made requirements. In addition, optimal therapy 
would not only lower blood glucose levels, but also decrease the cardiovascular 
risk.
Thiazolidinediones 
Thiazolidinediones are synthetic ligands of the nuclear peroxisome proliferator-
activated receptor-γ (PPAR-γ)(22). After binding, PPAR-γ either activates or 
suppresses the expression of genes, including many genes involved in glucose 
and lipid metabolism(23). The first thiazolidinedione that was clinically tested was 
ciglitazone (1982), but this compound was withdrawn from further development 
due to adverse effects on the liver(24). Troglitazone reached the market in 1997 but 
was withdrawn in 2000 because of hepatotoxicity(25). Finally, in 2000, rosiglitazone 
and pioglitazone were approved for the treatment of diabetes mellitus type 
2. Thiazolidinediones lower plasma glucose(26, 27). The many effects on gene 
expression in various target tissues was the reason for a scientific dispute on 
the key-mechanism of the insulin-sensitizing effects in humans(28). The leading 
view is that hepatic and muscle sensitivity to insulin are increased. Interestingly, 
PPAR-γ is mainly expressed in adipocytes(22). The accepted explanation for this 
apparent paradox is that thiazolidinediones stimulate free fatty acid storage in 
adipose tissue, leading to decreased substrate competition for glucose in the 
citric acid cycle of skeletal muscle. In addition, this will also reduce ectopic fat 
distribution in both liver and skeletal muscle(29). 
As a consequence of the non-specific action on gene expression, 
thiazolidinediones have a broader therapeutic effect than improvement 
of glycaemic control only. Thiazolidinediones modulate the traditional 
cardiovascular risk factors, lipid profile(27, 30) and blood pressure(31, 32), but also have 
beneficial effects on inflammation(33) and on ischaemia-reperfusion injury(34).
Despite somewhat conflicting results and limited evidence, the general opinion 
at the start of this thesis project on thiazolidinediones was that this class was 
‘unremarkable in glucose lowering but potentially great in vascular prevention’. 
Notwithstanding this optimistic view, also adverse events were reported shortly 
after the introduction. Oedema formation(35) and especially chronic heart failure(36) 
were considered potentially serious side effects and viewed as the Achilles heel of 
this new class of drugs.
Thiazolidinediones and fluid accumulation
The incidence of oedema ranges from 3-5% during monotherapy with 
rosiglitazone or pioglitazone. In combination with other glucose lowering drugs 
the incidence is higher, for instance in combination with sulphonylureas 7-8% (36, 
37) and with insulin 13-16%(38). Apart from systemic oedema formation also cases 
with macula oedema(39) were described, but further discussion of this side effect 
is beyond the scope of this thesis. 
The incidence of chronic heart failure is higher during thiazolidinedione 
treatment. The incidence in clinical trials during monotherapy is very low (<1%), 
but in combination with insulin up to 2-3%. Epidemiologic studies show a 
hazard ratio for developing heart failure of around 1.6 associated with the use of 
thiazolidinediones(36). 
Potential mechanisms of fluid accumulation
At the start of this PhD fellowship several potential mechanisms for 
thiazolidinedione-related fluid accumulation had been postulated. In chapter 8, 
these hypothesized mechanisms are described in detail. The knowledge at the 
start of this project is briefly summarized below. First, thiazolidinedione-related 
reduction in cardiac function (cardiac hypothesis) was suggested, as this could 
explain both the development of oedema and of heart failure. However, no negative 
effects of rosiglitazone on cardiac systolic function were found(40). Secondly, renal 
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sodium reabsorption (primary renal hypothesis) was proposed to be the initial 
event leading to oedema formation and symptomatic heart failure (Figure 1A). A 
shortcoming of this view is that it cannot explain the observed reduction in blood 
pressure during thiazolidinedione treatment. Finally, thiazolidinedione-induced 
arterial vasodilation (primary vascular hypothesis) with subsequent, secondary, 
renal sodium retention was proposed as initiating mechanism, explaining 
both blood pressure reduction and oedema formation (Figure 1B). Also other 
hypotheses were proposed, such as thiazolidinedione-increased sympathetic 
nervous system activity, or alterations in endothelial permeability(36). 
At the start of this thesis there seemed to be scientific agreement that the vast 
majority of oedema cases was not caused by decreased cardiac function but that 
thiazolidinedione-induced fluid retention unmasked previously asymptomatic 
and unrecognized diastolic dysfunction. There was no scientific agreement on 
the cause of fluid accumulation but the leading views were primary renal sodium 
retention or arterial vasodilation with secondary renal sodium retention.
Figure 1A:  Primary renal sodium retention raises plasma volume. In the local vascular bed this will 
elevate hydrostatic pressure with subsequent capillary leak and development of oedema. This rise 
in plasma volume will increase preload and increase blood pressure. The rise in preload can unmask 
asymptomatic heart failure.
Asymptomatic 
heart failure
Symptomatic 
heart failure
Hydrostatic pressure Capillary leak Oedema formation 
Sodium retention
Preload Cardiac output Hypertension
Plasma Volume
Figure 1B:  Arterial vasodilation couples local increase in hydrostatic pressure and subsequent oedema 
development to systemic reduction in blood pressure. As a consequence the Renin-Angiotensin- 
Aldosterone System (RAAS) will be activated and the sympathetic tone will be increased both inducing 
sodium retention. Sodium retention and subsequent rise in preload could again unmask asymptomatic 
heart failure.
local
local
systemic
Hydrostatic pressure Capillary leak Oedema formation 
Sympathetic activity
Hypotension RAAS
Arterial Vasodilation
systemic
Asymptomatic 
heart failure
Symptomatic 
heart failure
Plasma volume
Sodium retention
Preload
Techniques to determine endovascular permeability and the size 
of body fluid compartments
Several studies in this thesis investigate the mechanism of rosiglitazone-
induced fluid accumulation by measuring changes in plasma, extracellular and 
interstitial volumes and vascular permeability. The techniques used to measure 
these variables are briefly outlined below. Venous occlusion plethysmography 
is another important technique in several studies of this thesis, but we did not 
use it for measurements on vascular permeability or body fluid compartments. 
Therefore, we only briefly summarize some aspects in this part of the thesis. The 
keypoint of venous occlusion plethysmography is that the rate of volume increase 
of the arm during venous outflow impediment with unrestricted arterial inflow, is 
precisely measured with mercury-in-silastic strain gauges(41). In this way, baseline 
forearm blood flow and the local vascular response to infusion of vasoactive 
drugs into the brachial artery (chapter 2, 3, 6) or the response to activation of the 
sympathetic nervous system (chapter 6) were measured.
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Transcapillary escape rate of albumin (TERalb)(42)
The amount of albumin leaking out of the vascular system is a measure of 
capillary permeability. Assuming first order kinetics implies that, each hour 
the same percentage of total vascular albumin leaks out of the circulation. The 
technique involves intravenous injection of radioactively labeled human albumin, 
followed by drawing eight exactly timed blood samples from an arterial line over 
a one hour period. Arterial blood sampling prevents against sampling error by 
haemoconcentration due to venous occlusion(43). After centrifugation, labeled 
albumin concentration is assessed by measuring radioactivity with a radioactivity 
counter. The measurements represent a declining exponential curve from which 
the fraction leaving the circulation per hour can be calculated. Plotting the 
extinction curve on a semi-logarithmic scale results in a straight line (Figure 2). 
The same procedure can be used to assess plasma volume. The theoretical peak 
concentration just after the injection is calculated from the extinction curve of 
the radioactivity in plasma. The injected amount of  radioactivity divided by the 
calculated peak concentration results in the plasma volume.
Water displacement method for measurement of oedema in the foot(44)
Oedema usually occurs around the foot and ankles as a result of gravity and is 
generally limited to this region. Therefore, systemic measures of interstitial fluid 
Figure 2:  On the left side of this Figure, the extinction curve for radioactivity is plotted on a semi-
logarithmic scale. This results in a straight line due to the leakage of a constant percentage of albumin 
out of the circulation in each time interval, while the backflow from the interstitial space is not 
containing radioactivity during the first hour after injection. The right side of this panel represents the 
formula for calculation of TERalb. A(0) = concentration radioactive albumin at t=0 (just after injection). 
A(1hr) = concentration of radioactive albumin at 1 hour (chapter 2, 3)
volume are not sensitive enough to detect mild depending oedema. Assuming that 
variation in the volume of the foot represents change in interstitial fluid, changes 
in measured foot volume are equal to the changes in interstitial fluid, ie oedema. 
The volume of parts of the body can be measured in a measuring cup using the 
water displacement method. However, due to the size of the foot, measuring cups 
will only provide a rough estimate of the foot volume as it needs to have a wide 
opening (Figure 3). In this thesis we have used a device that measures changes 
in water displacement indirectly but with a one milliliter accuracy. As shown in 
Figure 4, a Perspex water bath was placed on an electronic balance. To provide 
foot support, a stainless steel construction was suspended in the water bath. This 
construction rested fully on the floor on both sides of the balance. The water bath 
was filled with tap water until the balance indicated a weight of 15,000 grams. 
Immersion of the foot into the water resulted in water displacement and increase 
Figure 3:  Two different methods to measure the volume of an object, for example two stones.
A) Traditional method to measure 
the volume of an object using a 
cylinder with water. This provides 
a rough estimate of volume by 
subtraction of the two measured 
volumes (250 to 270 ml).  
B) Water displacement method. 
The amount of displaced water 
provides increased pressure on  the 
electronic balance. The volume of 
the object is equal to the weight 
recorded on the balance divided 
by the relative weight of water. The 
volume of the stones is 267 ml.
A
B
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in weight recorded on the balance (Archimedes principle). Foot volume is equal 
to the weight recorded on the balance divided by the relative weight of water 
(0.998 g/ml at 22 oC). To reduce immersion depth differences, the subject sat on 
a stable chair with an adjustable height. A standardized position was sought with 
the thigh in a horizontal position, with a 90o angle at the knee. The temperature 
of the water was always 22oC. A simple conversion of 1g to 1 ml was used, which 
gave systemic underestimation by only 0.2 %.
Measurment of body fluid compartments with bio-electrical impedance 
measurement(45)
Several methods exist to assess body fluid compartments. Most of these methods 
are based on dilution techniques and are invasive, time-consuming, expensive 
and require the use of radioactive substances. To overcome these problems, we 
used bio-electrical impedance with a soft tissue analyzer. Body compartments 
were measured indirectly with the use of specific formulas. Subjects rested supine 
for approximately 15 minutes to equalize fluid compartments. Four surface 
electrodes were applied (two to an arm and two to a leg). Bio-electrical impedance 
was measured by recording the voltage drop caused by body impedance 
modulus when applying an alternating and constant current. Phase sensitive 
sensors separate the components of the modulus into reactance and resistance. 
Extracellular water and total body water are then calculated from these values.
Outline of the thesis
In the present thesis we investigate the effects of thiazolidinediones beyond 
glycaemic control, especially the mechanism of action, risk factors and treatment 
of fluid retention and oedema formation. In addition, our investigations 
involve the influence of thiazolidinediones on autonomic neuropathy and 
ischaemia-reperfusion injury. We have performed four clinical trials with the 
thiazolidinedione rosiglitazone.
In this thesis, the primary hypothesis regarding the mechanism of 
thiazolidinedione-related fluid accumulation is arterial vasodilation, because 
it can explain the observed combination of blood pressure lowering and fluid 
retention associated with the use of thiazolidinediones (Figure 1B). Because 
thiazolidinedione treatment is associated with insulin sensitization(28), 
vasodilation during thiazolidinedione treatment may be either insulin-dependent 
or independent. In support of insulin-dependency is the notion that insulin itself 
has vasodilatory properties(46) and the observation that the oedema incidence is 
higher, when thiazolidinediones are combined with insulin(26). We hypothesized 
that rosiglitazone amplifies insulin-dependent arterial vasodilation or insulin-
dependent vascular permeability. This hypothesis was tested in a population 
characterized by insulin resistance and the results are described in chapter 2.
When thiazolidinediones indeed induce arterial vasodilation, this effect will 
normally be counterbalanced by activation of the autonomic nervous system. 
This would imply that the vascular effects of thiazolidinediones should be more 
pronounced in patients with autonomic neuropathy. In support of this assumption 
are the observations that the haemodynamic effects of insulin are exaggerated 
in subjects with autonomic neuropathy(47) and that insulin-induced oedema can 
be treated with ephedrine, an α-adrenergic agonist(48). In chapter 3, we report 
the results of a study that tested this hypothesis in subjects with autonomic 
neuropathy. We assumed that these patients would be more prone to oedema 
formation when treated with rosiglitazone and insulin, due to an uncontrolled 
rise in capillary hydrostatic pressure followed by an exaggerated secondary renal 
fluid retention to restore systemic hypotension. 
Figure 4:  Measurement of foot volume 
1) A: electronic balance; B: Perspex box filled with water; C: Foot support without either contact to 
Perspex box or electronics balance; D: Frame
2) Standard immersion of the foot
3) Accurate measurement of foot volume 1190g = 1190ml
1 2 3
A B C D
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In the literature, evidence had emerged that primary renal sodium retention 
would be, at least in part, an important underlying pathophysiological 
mechanism of thiazolidinedione-related fluid accumulation. Several animal 
and in vitro experiments had found upregulation of the renal epithelial sodium 
transporter (ENaC) in thiazolidinedione-related fluid retention(49, 50) and found 
that amiloride, an inhibitor of ENaC, prevented oedema formation. Human in 
vivo evidence for such a mechanism, however, was lacking. An upregulation of 
ENaC by thiazolidinediones would indeed explain the clinical observation that 
thiazoldinedione-related oedema is resistant to therapy with loop diuretics(51). 
In chapter 4 we investigated whether rosiglitazone did upregulate ENaC and 
whether loop diuretic resistance developed in insulin-resistant subjects treated 
with rosiglitazone. 
In clinical studies it has been widely suggested that thiazolidinedione-
induced change in plasma volume is reflected by a change in haematocrit(26, 52). 
Haematocrit is the ratio of erythrocyte volume and blood volume(53). Haematocrit 
could be a marker for changes in plasma volume, but only if erythrocyte volume 
remains constant. Firm human in vivo data on the effects of thiazolidinediones 
on erythrocytes were lacking. Interestingly, an in vitro human cell study had 
shown suppression of erythroid-colony forming cells by thiazolidinediones(54). 
In chapter 5, we explored whether changes in haematocrit were associated with 
changes in plasma volume during rosiglitazone treatment in a pooled data analysis 
of the studies described in chapter 2 and 3.
In our studies on thiazolidinedione-related fluid accumulation, we acquired 
extensive information regarding autonomic nervous system function as 
determined (non)invasively in patients with diabetes mellitus. In scientific 
literature cardiac autonomic neuropathy is an overlooked complication of 
diabetes, with a high impact on morbidity and mortality(11). The diverse actions 
of the autonomic nervous system and the lack of a gold standard test panel may 
contribute to the paucity in data. So far, there is limited information available 
regarding the responsiveness of the sympathetic nervous system in patients 
with cardiovascular autonomic neuropathy in general and the effects of glucose 
lowering therapies on this response in particular. As we studied rosiglitazone-
induced vascular leakage in the context of autonomic neuropathy (chapter 3), 
we were also able to assess the responsiveness of the sympathetic nervous system 
in patients with type 2 diabetes with and without autonomic neuropathy. We 
hypothesized that baseline sympathetic tone (α-adrenergic tone) and response 
to orthostatic stress would be decreased in patients with autonomic neuropathy. 
In addition, we were interested in the effects of rosiglitazone, as there is some 
evidence that PPAR-γ agonists like rosiglitazone may restore the autonomic 
imbalance in diabetes(55). Chapter 6 describes the results of these studies.
Several preclinical studies have shown beneficial effects of rosiglitazone on 
ischaemia-reperfusion injury(56,57), but thus far evidence from human in vivo 
studies was lacking. In chapter 7 we tested whether rosiglitazone prevents against 
ischaemia-reperfusion injury in insulin-resistant subjects. In this study we applied 
annexin A5 scintigraphy(58) to visualize and quantify ischaemia-reperfusion 
injury in the skeletal muscle of the forearm of insulin-resistant subjects.
A summary of the results is provided in the first part of chapter 8. In the second 
part of this chapter the context and outcomes are put in perspective and used as 
a framework to construct an overall mechanistic pathway for thiazolidinedione-
related fluid accumulation. 
As noted, this thesis has applied rosiglitazone, to study the relationship between 
fluid accumulation and thiazolidinediones. There was no scientific guidance for 
choosing rosiglitazone over pioglitazone, and we believe the results described in 
this thesis are applicable to thiazolidinediones in general. Over the last decade, 
rosiglitazone has reached the market, created great expectations but finally has 
been withdrawn, at least in Europe, because of safety concerns. Although these 
issues were not the scope of this thesis, they are important in the context of our 
studies. In addition, pioglitazone is still widely used as is rosiglitazone in several 
parts of the world, and as such the relevance of the findings in this thesis has not 
changed. For this reason, we have included a paragraph in chapter 8 in which we 
provide a summary of the dispute over rosiglitazone’s cardiovascular unsafety. 
The last paragraph briefly illustrates the present position of thiazolidinediones 
and newer PPAR-γ agonists in view of the current drug treatment options for 
type 2 diabetes.
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Abstract 
Objective: The use of thiazolidinedione derivatives is associated with fluid 
retention, especially when combined with insulin. Since thiazolidinediones improve 
the metabolic effect of insulin, they may also reverse the blunted vascular response to 
insulin. We hypothesize that improvement of the action of insulin on vascular tone 
or permeability is the key mechanism of thiazolidinedione-related fluid retention. 
Research design and methods: In a randomized, double-blind, placebo-
controlled, crossover study in 18 obese, nondiabetic subjects with features of 
the metabolic syndrome, we investigated the effects of a 12-week treatment 
with 4 mg rosiglitazone twice a day on glucose disposal, haemodynamics 
(including forearm vasoconstrictor response to nitric oxide (NO) synthase 
inhibition by N-monomethyl-L-arginine-acetate, L-NMMA), vascular 
permeability (transcapillary escape rate of albumin) and plasma volume during 
a hyperinsulinaemia euglycaemic clamp (120 minutes, 120 mU/m2/min). 
Results: As expected, rosiglitazone increased glucose infusion rate during 
clamping. However, neither vascular permeability nor forearm blood flow response 
to hyperinsulinaemia or L-NMMA were affected by rosiglitazone. Compared 
with placebo, rosiglitazone decreased diastolic blood pressure by 5 mmHg (95% 
CI: 2.35, 6.87, P = 0.0005) and increased plasma volume by 255 ml/1.73m2 
(95% CI: 80, 430, P = 0.007). Interestingly, the positive effect of rosiglitazone on 
glucose disposal correlated with change in foot volume (R2 = 0.53, P = 0.001). 
Conclusions: Rosiglitazone improved insulin sensitivity but had no effect on 
NO-dependent vasodilation in the forearm or vascular permeability in obese, 
insulin-resistant, nondiabetic subjects. As such, thiazolidinedione-related fluid 
retention was not caused by improvement of the vascular actions of insulin. 
Nonetheless, rosiglitazone-induced improvement in insulin sensitivity appears to 
be correlated to oedema formation.
Introduction
Thiazolidinedione derivatives improve insulin sensitivity and hence are 
valuable in the treatment of type 2 diabetes(1). Important adverse effects are fluid 
retention and peripheral oedema formation. The precise mechanism(s) of these 
adverse effects are unclear and probably are multifactorial(2). Although multiple 
factors are involved, the existence of an initial trigger or main mechanism could 
be of clinical importance. In theory, the initial trigger of fluid retention may 
originate either from kidney, heart or peripheral circulation. As thiazolidinedione 
treatment is associated with a reduction in blood pressure(3-6), a primary renal 
mechanism seems unlikely. A primary cardiac origin also seems improbable, 
since long-term studies with rosiglitazone have not revealed any negative effect 
on myocardial structure or function(7).
The combination of blood pressure reduction, fluid retention and oedema 
formation is compatible with changes in the peripheral circulation resulting in 
capillary leakage. This may be induced by certain actions of thiazolidinediones, 
such as improved insulin-mediated vasodilation, direct vasoactive effects(8), or 
increased endothelial permeability(9). Interestingly, the incidence of oedema 
increases substantially when rosiglitazone(10) or pioglitazone(11) are used in 
combination with insulin. A number of findings suggest that the tendency of fluid 
retention is coupled to the effect of thiazolidinediones on the metabolic actions 
of insulin. For example, both glycaemic efficacy and oedema formation are dose-
dependent features of thiazolidinedione therapy(10). Furthermore, peroxisome 
proliferator-activated receptor-γ (PPAR-γ agonists) with more potent glucose-
lowering effects seem to be associated with a higher incidence of oedema 
formation(12). Besides a metabolic effect, insulin has also important vascular 
properties on several sites of the vascular tree. For instance, insulin increases 
vascular permeability(13) and induces vasodilation in resistance arteries(14), 
venules(15), and precapillary arteriolae(16), thereby inducing capillary recruitment(17) 
and resulting in a decrease in capillary resistance. Acute hyperinsulinaemia has 
been reported to increase the transcapillary escape rate of albumin(13), consistent 
with a direct effect of insulin on arteries and capillaries promoting vascular 
leakage and therefore oedema formation. If thiazolidinediones augment both the 
metabolic and vascular effects of insulin, the effect on glycaemic control and fluid 
retention would indeed be coupled.
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In the present study, we investigated whether rosiglitazone treatment, besides 
improving the metabolic action of insulin, can also reverse the blunted vasodilator 
response to insulin(18) and/or change vascular permeability in insulin-resistant 
subjects. To avoid confounding by improved glycaemic control, we studied 
nondiabetic subjects with characteristics of the metabolic syndrome.
Research design and method
The study population consisted of 18 healthy, obese volunteers (BMI 
between 27 and 36 kg/m2, age: 30-65 years) with either two or more features 
of the metabolic syndrome as defined by the National Cholesterol Education 
Program(19) or one of these features in combination with a first-degree relative 
having type 2 diabetes. Subjects were not eligible for inclusion if they had 
fasting plasma glucose > 7.0 mmol/L, glycosylated haemoglobin (HbA1c) >6.5%, 
if they used non-steroidal anti-inflammatory drugs, fibrates, anticoagulants, 
antihypertensives, any investigational drug or a PPAR-γ agonist, or if they had just 
started lipid-lowering therapy. Additional exclusion criteria were: blood pressure 
exceeding 160/100 mmHg, unstable or severe angina or congestive heart failure, 
presence of clinically significant hepatic or renal disease or anaemia, pregnancy, 
lactation, lack of appropriate contraception for women of child-bearing potential, 
and alcohol or drug abuse. Study participants were selected by advertisement, 
received a payment and gave written informed consent. This study was approved 
by the hospital ethics committee and was performed according to good clinical 
practice guidelines.
Within six weeks after screening, participants were randomly assigned to 
either rosiglitazone (4 mg twice daily), or placebo for 12 weeks in a double-blind, 
crossover design. The primary end points of the study were measured at the end 
of each 12-week treatment period, and we considered this long enough to avoid 
a carryover effect. Therefore, we decided to not include an extra washout period 
between both treatment periods. At week 2 and 6 of each treatment period, 
adverse events and pill compliance were recorded. Physical examination was 
performed, foot volume was measured, and safety chemical, hematological, and 
glycaemic profiles were determined. At the end of each 12-week treatment period 
the haemodynamic and metabolic effects of insulin were quantified during a 
hyperinsulinaemia euglycaemic clamp procedure. During this test, vascular 
permeability was assessed by measurement of the transcapillary escape rate of 
labeled albumin (TERalb). Two weeks after the final treatment period there was 
a follow-up visit. Participants were strictly advised to maintain their diet and not 
to change lifestyle. 
Protocol experimental day 
After an overnight fast of at least 10 hours the subject entered a quiet temperature-
controlled room (23-24 oC) at 8:00 A.M. A 20-gauge catheter (Angiocath, Becton 
Dickinson, Sandy, UT) was inserted into the left brachial artery under local 
anaesthesia (0.3-0.4 ml lidocaine HCl; 20 mg/ml), connected via an arterial 
pressure monitoring line to a Hewlett Packard 78353B Monitor and kept patent 
with saline and heparin (0.9% NaCl and 2units/ml heparin; NaCl, 3ml/h). 
This catheter was used for both intra-arterial drug infusion (automatic syringe 
infusion pump, type STC-521, Terumo, Tokyo, Japan) and for blood sampling. 
One venous catheter (Venflon, 20 G, 32 mm) was inserted antegrade into a deep 
arm vein for the infusion of insulin and glucose.
After a 30-minute equilibration period, the intra-arterial pressure wave signal 
was recorded for 5 minutes to calculate cardiac output and systemic vascular 
resistance using “model flow analysis”(20). Subsequently, forearm blood flow 
(FBF)(21,22) was measured simultaneously in the experimental and control arm 
using mercury-in-Silastic strain-gauge venous occlusion plethysmography. The 
FBF of the contralateral arm was used as a time-control value to observe systemic 
effects. After these baseline measurements, the hyperinsulinaemia- euglycaemic 
clamp(23,24) was started. Insulin (Actrapid, Novo-Nordisk, Denmark) was infused 
intravenously at a dose of 720 pmol/m2/min (120 mU/m2/min). Insulin (50 
units/ml) was diluted in 47.5 ml of 0.9% NaCl with the addition of 2 ml of the 
subject’s blood to a concentration of 1unit/ml. Euglycaemia was maintained at 
5.0 mmol/L by a variable infusion of 20% glucose solution, adjusted at 5-min 
intervals according to arterial glucose measurements. Glucose infusion rate 
(GIR) was defined as the GIR during the last 30 min of the clamp expressed in 
micromoles per kilogram per minute(25). Potassium chloride (1 mmol/ml) was 
infused to prevent hypokalaemia. 
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Throughout the clamp procedure, FBF measurements were performed, intra-
arterial pulse wave was recorded and 125I-albumin was injected for calculation of 
TERalb and plasma volume. Moreover, blood samples for insulin measurement 
were drawn. After two hours of hyperinsulinaemia-euglycaemic clamping, 
the specific nitric oxide (NO)-synthase inhibitor NG-monomethyl-L-arginine 
(L-NMMA) was infused into the brachial artery at a rate of 0.4 mg/min/dL and 
the subsequent vasoconstrictor response was measured. L-NMMA (100 mg, 
Clinalpha, Läufelfingen, Switzerland) solution was freshly made with 25 ml 
0.9% NaCl immediately before use. After the experiment was finished, glucose 
infusion was continued and the participants were served a carbohydrate-rich 
meal in order to avoid hypoglycaemic events after the test.
TERalb
At 60 minutes, an additional venous needle (BD Valu-set, 0.6 x 20 mm) was inserted 
and 2-4 μCi 125I-albumin (Shering Nederland BV, Weesp, the Netherlands) was 
given as an intravenous bolus injection. During the next 60 minutes, seven plasma 
samples were collected from the arterial line for radioactivity measurements. 
Plasma volume and TERalb were calculated using the following formulas(26,27):
Plasma volume (PV) (milliliters)/ 1.73 m2 = [counts per minute injected / 
counts per minute t=0/milliliters] / surface (square meters)/ 1.73 m2
TERalb = fraction of the intravascular mass of albumin leaving the vascular 
system per hour.
TERalb = [1- e3600 x slope] x 100% (%/h).
Analytical methods
Arterial plasma glucose was measured in duplicate with the glucose oxidation 
method (Beckman Glucose Analyzer 2, Beckman Instruments Inc, Fullerton, 
CA). Atrial natriuretic peptide (ANP) concentrations were analyzed by 
radioimmunoassay after cartridge extraction. Insulin levels were measured using 
the Perkin-Elmer AutoDELFIA Insulin kit with an automatic immunoassay 
system. C-peptide was analyzed with C-peptide double-antibody (125I) 
radioimmunoassay kit. 
Control visits 
During all control visits (0, 2, 6, 14 and 18 weeks), blood pressure and heart rate 
were assessed after the subject had been sitting quietly for at least 5 minutes. 
Blood pressure was measured by auscultation method with the nondominant 
arm supported at heart level. Moreover, foot volume was assessed using the water 
displacement method which measures volume displacement in an indirect way 
with an electronic balance (coefficient of variation is 0.30%)(28).  The balance 
recorded the force necessary for a standardized immersion of the foot, which 
depends solely on the volume of the foot (Archimedes principle). The mean 
temperature of the water was 22.9 oC and did not differ >1 oC between visits of 
one subject. 
Statistical analysis
The study was powered (90%) to detect a 50% increase in percentage change in 
FBF between the treatment groups with 16 evaluable subjects. All significance 
tests and confidence intervals (CI) were two-sided and the overall type I error 
was 5%. Descriptive statistics of population characteristics are presented as 
means ± SD. The comparison between rosiglitazone and placebo was conducted 
within each subject. The response was measured at the end of each treatment 
period, assuming any carryover from the first treatment period should be 
washed out. All data were analyzed using analysis of variance  (ANOVA), with 
adjustment for period if applicable. We used paired Student’s t-test or Wilcoxon 
rank test, if appropriate, and ANOVA repeated measures for sequential data to 
derive P-values. Treatment effects are presented as means  ± SD or, for relative 
changes, as mean percentage change derived from the geometric mean with 
CIs. Correlations were calculated using Pearson’s or Spearman’s correlation tests 
if appropriate. All statistical analyses were performed using the SPSS personal 
computer software package. 
Results
Included subjects represented an overweight (98±12 kg; BMI 32±3 kg/m2), 
middle-aged (46±9 years) population of 11 men and 7 women. Obvious features 
of the metabolic syndrome present in our population were increased waist 
circumference (109±7 cm), diastolic blood pressure (DBP) (93±5 mmHg) and 
plasma triglyceride levels (1.9 ± 0.9 mmol/l). Other characteristics were systolic 
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blood pressure (SBP) (134 ± 10 mmHg), plasma total cholesterol (5.7 ± 1.0 
mmol/l), plasma HDL levels (1.2 ± 0.3 mmol/l), plasma fasting plasma glucose 
(5.5 ± 0.4 mmol/l), and HbA1c (5.50 ± 0.33%).  Ten subjects were randomized 
to receive placebo first, and the remaining 8 subjects received rosiglitazone first. 
All subjects completed both treatment regimens. Drug compliance, measured by 
tablet counting, was excellent. Subjects reported only mild side effects, equally 
distributed between both treatments. One subject developed moderate oedema 
during rosiglitazone treatment.
Effect of rosiglitazone on insulin’s metabolic actions 
During rosiglitazone, the fasting values of plasma glucose (0.28 mmol/l [95% CI 
0.05-0.50] P = 0.02), insulin and C-peptide concentrations (14 pmol/l [2-26] P < 
0.05 and 0.13 nmol/l [0.01-0.25] P < 0.05, respectively) were significantly decreased 
as compared with placebo. During the final 30 minutes of the clamp procedure, 
blood glucose values were equal during rosiglitazone and placebo treatment (4.96 
± 0.12 and 4.96 ± 0.15 mmol/l, respectively) and stable (coefficients of variation; 
4.36 ± 2.08 and 4.15 ± 1.96 %, respectively). Also, steady-state plasma insulin 
concentrations were similar (1,664 ± 533 pmol/l versus 1,795 ± 688 pmol/l P 
= 0.29). Insulin sensitivity, measured by GIR, significantly improved during 
rosiglitazone (39.6±9.2 μmol/kg/min) treatment compared to placebo (33.7 ± 
11.7 μmol/kg/min) resulting in a period-adjusted treatment effect of 5.26 μmol/
kg/min (95% CI 1.68-8.83, P = 0.007). 
Effect of rosiglitazone on insulin’s vascular actions 
Hyperinsulinaemia (≈1,700 pmol/L) did not change FBF during either treatment, 
consistent with persistent vascular insulin resistance (treatment effect for 
rosiglitazone; –8.2% [95% CI-27.2 to 8.0], P = 0.318) (Figure 1A). 
During L-NMMA infusion, blood flow decreased, but the reductions were 
similar during rosiglitazone and placebo treatment (–22.9% [-13.5 to -31.3] vs. 
–25.7% [-18.8 to -31.8], NS) (Figure 1A). Rosiglitazone had no effect on vascular 
permeability measured with TERalb (+ 0.27 %/hr [-1.21 to 1.75] P = 0.71) 
(Figure 1B)
Insulin infusion reduced systemic vascular resistance during placebo 
treatment (-6.2% [95% CI -9.1 to -3.2], P < 0.001) and not during rosiglitazone 
treatment (-4.5% [-10.2 to 1.6], P = 0.14), but these changes did not differ 
significantly between treatments (0.4% [-5.5 to 6.7], P = 0.68). Similarly, insulin 
increased cardiac output, but again these changes were not different between 
both treatments.
Effect of rosiglitazone on blood pressure
DBP was reduced during rosiglitazone treatment whether measured via 
ausculatory or intra-arterial methods (ausculatory -5 mmHg [95% CI -6.87 to 
-2.35], P = 0.0005; intra-arterially – 2 mmHg  [-3.6 to -1.6], P = 0.03) (Figure 1C). 
Rosiglitazone seemed to reduce the calculated systemic vascular resistance, but 
the difference in this measure failed to reach statistical significance (-3.2% [-9.6 
to 3.7], P = 0.28).
Effect of rosiglitazone on fluid compartments
During rosiglitazone, plasma volume increased by 255 ml/1.73m2 (95% CI 80-
430) (P = 0.007) compared with placebo (Figure 1D). Haematocrit decreased 
accordingly (–0.019 l/l [-0.03 to -0.01], P = 0.002). We observed an increase in 
plasma ANP with rosiglitazone, (12.1 pg/mL [0.7-23.4] P = 0.039; rosiglitazone vs. 
placebo). Rosiglitazone did not induce an increase in foot volume over placebo 
(0.37% [-0.80 to 1.50], NS). However, a period effect was detected, with greater 
relative differences from baseline during the second period, probably related to a 
seasonal increase in outside temperature throughout the study. Post hoc analyses 
revealed a significant correlation between changes in foot volume and GIR 
(Figure 2) (R2 = 0.53, P = 0.001) and trends between changes in GIR and TERalb 
and between changes in GIR and DBP (R2 = 0.23, P = 0.07 and R2 = 0.15, P = 0.11, 
respective).
Characterization of subject with thiazolidinedione-induced oedema
One subject developed moderate oedema and showed an increase in body weight 
of 3.7 kg, in plasma volume of 544 ml/1.73 m2, and in of foot volume 4.6% during 
rosiglitazone treatment. Compared to the whole study population this subject had 
an equivalent treatment response with regard to insulin-mediated vasodilation 
(-9% vs. –7.6% [95% CI -21.4 to+8.7], but a more pronounced response in insulin 
sensitivity (15.8% vs. 5.3 [1.7-8.8].
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Figure 1:  
A) Mean percentage change in FBF (experimental arm [mean  and CI] during hyperinsulinaemia 
clamp and during subsequent infusion of L-NMMA into the brachial artery. There was no difference in 
response between placebo and rosiglitazone. 
B) Intra-subject changes in transcapillary escape rate of albumin (means ± SE). There was no difference 
in vascular permeability between the two treatments (9.14 ± 0.52 vs. 9.41 ± 0.51%).
C) Absolute change in diastolic blood pressure (means ± SE) from the start of each treatment period. 
Rosiglitazone clearly reduced diastolic blood pressure. 
D) Intrasubject changes in plasma volume adjusted for body surface (means ± SE). During rosiglitazone 
treatment the mean increase was 255 ml/1.73m2 compared to placebo.
 [n=14: Four subjects were excluded for this analysis. In one patient, no 125I-albumin was available; in 
two cases the correlation between (ln)plasma radioactivity and time did not exceed 0.85; and in one 
case, we derived a nonphysiologic high plasma volume.] 
Figure 2: Plot of correlation between differences in foot volume and glucose infusion rate between 
rosiglitazone and placebo treatment. This correlation is not driven only by the subject with oedema (☐), 
n = 18. 
Conclusions
The first principal observation of the present study is that rosiglitazone, 
while improving the metabolic action of insulin, did neither affect vascular 
permeability nor the NO-dependent vascular responses to insulin. The second 
is that rosiglitazone significantly increased plasma volume and lowered diastolic 
blood pressure. Taken together, these findings do not support the hypothesis 
that potentiation of the vascular effects of insulin, being either vasodilation or 
increased vascular permeability, are the specific mechanism of thiazolidinedione-
induced fluid retention. Nevertheless, since the change in insulin-induced 
glucose uptake appeared to be related to the change in foot volume, our study 
does support some relationship between the effects of rosiglitazone on glucose 
uptake and interstitial fluid content.
In this study, rosiglitazone did not affect the vascular actions of insulin. In 
contrast, Paradisi et al. found that troglitazone was able to reverse the blunted 
insulin-mediated vasodilation in subjects with polycystic ovary syndrome(29). 
There are two important differences between Paradisi’s study and ours, 1) the 
investigated population and 2) measurement of leg blood flow, while we measured 
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FBF. Since previous studies have shown that the vasodilator response to acute 
hyperinsulinaemia did not differ between the leg and the forearm vascular 
bed, our data may be extrapolated to the leg(30). Someone might still argue that 
rosiglitazone could exert a different effect on the response to insulin in forearm 
versus leg. However, in agreement with our forearm observations, we did not 
find any treatment effect of rosiglitazone on calculated total peripheral vascular 
resistance during hyperinsulinaemia. 
Two other studies are in complete agreement with our present findings. In 
a previous study, we did not find an effect of troglitazone on insulin-induced 
changes in FBF in obese subjects(23), neither did Natali et al. in patients with type 
2 diabetes(31). In both studies a lower insulin dose (60 and 40 mU/m2/min) was 
used. As such, the results of the present study confirm previous reports in obese 
or diabetic subjects using forearm measurements and extend it to high insulin 
infusion rates. Since our data are in contrast with observations in the polycystic 
ovary syndrome, the vascular mechanism of action of rosiglitazone may be 
different in this particular form of insulin resistance. 
Our observation that rosiglitazone did not reverse insulin-mediated 
vasodilation seems to conflict with published reports showing a beneficial 
effect of rosiglitazone on NO-dependent vasodilation (and hence on endothelial 
function) measured with acetylcholine infusion. For example, Pistrosch et 
al. reported an increased vasodilator response to either acetylcholine alone or 
acetylcholine combined with locally infused insulin in rosiglitazone-treated 
patients compared to nateglinide-treated patients(32). Likewise, Natali et al., found 
that rosiglitazone improved the vasodilator responses to acetylcholine but not to 
insulin in patients with type 2 diabetes(31). Of note, Natali did not find any effect 
of rosiglitazone on the response to L-NMMA infusion, which is perfectly in line 
with our observations. It appears that insulin’s activation of the NO-pathway is 
not strong enough to disclose rosiglitazone’s favourable effects on endothelium 
and on insulin-mediated vasodilation and that either a large improvement of 
insulin sensitivity (Pistrosch et al. 85%) or additional infusion of acetylcholine 
is needed. 
This was the first human in vivo study investigating the influence of 
rosiglitazone-treatment on TERalb. The finding that rosiglitazone did not change 
TERalb seems in contrast with an in vitro study with human pulmonary artery 
endothelial cells(9), but the discrepancy can be explained by clear differences in 
design and methodology. The absolute rate of TERalb in our population appeared 
to be rather high(33), although Pedrinelli et al. reported a similar rate (9.6%) in 
subjects with essential hypertension(34), and Hilsted et al. found TERalb rate of 
9.9% in normal individuals during an hyperinsulinaemia-euglycaemic clamp(13,34). 
Therefore, the observed high TERalb could either be the resultant of features of 
the metabolic syndrome such as hypertension or be due to the hyperinsulinaemia 
state. Please note that TERalb is a measure of total body protein permeability. As 
such, we cannot exclude from these data that rosiglitazone affects total body fluid 
filtration.
In the present study, rosiglitazone resulted in a decrease in DBP (but not 
SBP) when measured intra-arterially or ausculatory, which is in agreement with 
another study(31). As DBP is primarily determined by peripheral resistance, the 
reduction in blood pressure during rosiglitazone treatment could be caused by 
systemic vasodilation. In support of this notion is our finding that the systemic 
vascular resistance was lower during rosiglitazone treatment before the start of 
the clamp. Interestingly, Shargorodsky et al. did report that rosiglitazone lowers 
systemic vascular resistance(35). Apart from a potentiation of insulin effect, 
rosiglitazone may induce vasodilation by inhibition of calcium currents(36,37), 
reduction of endothelin-1 secretion(38), or down regulation of the sympathetic 
nervous system(39).
Several studies have reported a decrease in haematocrit in response to 
thiazolidinedione treatment, which has been interpreted as the result of an increase 
in plasma volume(40), but so far only one other study combined haematocrit with 
directly derived plasma volume measurements(41). Indeed haematocrit decreased 
and plasma volume increased in our study, but, interestingly, we did not find 
a correlation between changes in haematocrit and changes in plasma volume. 
Also the observed elevation of plasma ANP levels during rosiglitazone treatment 
is consistent with plasma volume expansion. In healthy subjects, rosiglitazone 
increased plasma volume by only 1.8 ml/kg after 8 weeks treatment(42). Apparently, 
the fluid-retaining effect of rosiglitazone is more pronounced in insulin-resistant 
subjects. 
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As there was no association between changes in metabolic and vascular actions 
of insulin, our results do not support the view that insulin-induced glucose 
disposal is the consequence of enhanced total muscle blood flow(18). However, 
it should be acknowledged that opposing views exist in the literature, whether 
or not the vasodilator effects of (physiological levels of) insulin contribute 
to the effect of insulin on tissue glucose uptake(17). The emerging view is that 
insulin may increase capillary recruitment and increase tissue perfusion, without 
necessarily increasing total blood flow(43). This view could be the explanation 
for the correlation between change in foot volume and the metabolic but not 
vascular action of insulin, as found by post hoc analysis. Capillary recruitment 
will reduce systemic vascular resistance, and increase glucose transport and fluid 
filtration. Therefore, capillary recruitment couples oedema formation, reduced 
blood pressure and insulin sensitization. In line with this reasoning, Bakris et al. 
reported a correlation between the reduction of diastolic blood pressure and the 
improvement in insulin sensitivity during rosiglitazone treatment(44). 
Altogether, our findings do not support the hypothesis that changes in the 
vascular effect of insulin, being either vasodilation measured in the forearm or 
increased vascular permeability, are the specific mechanism of thiazolidinedione-
induced fluid retention. Although this conclusion is valid at the level of the whole 
study population, it also appears to be true for the single case with oedema. 
This study included an insulin-resistant nondiabetic population, which 
enabled us to investigate whether rosiglitazone can reverse the blunted vascular 
response of insulin, without any interference from changes in glycaemic control. 
For example hyperglycaemia in itself could additionally impair endothelial 
function(45). The main outcome of the present study, being no correlation between 
fluid retention (plasma volume) and changes in the vascular action of insulin, 
probably holds true for a diabetic population as well. The incidence of oedema 
may be expected to be higher in a diabetic population, for example because of 
autonomic neuropathy (sympathetic nervous system dysfunction) or because of 
heart failure. As such, in a diabetic population the correlation between improved 
insulin sensitivity and oedema formation could be less strong due to potential 
confounders.  
The hypothetical framework of the present study lends heavily on capillary 
recruitment being the primary cause of oedema formation, but the pathogenesis of 
fluid retention is probably multifactorial(2). At the moment, there are controversial 
reports about the potential of PPAR-γ agonists to stimulate the epithelial sodium 
channel (ENaC), which could play an important role in thiazolidinedione-related 
fluid retention(46-48).
In summary, this study provides no support for the view that thiazolidinediones 
increase transcapillary leakage of fluid as a result of either the augmentation of 
the NO-mediated vasodilator response to insulin or an increase of capillary 
permeability. The correlation between metabolic insulin sensitivity and oedema 
formation may point to an alternative mechanism of thiazolidinedione-related 
oedema formation, possibly increased capillary recruitment.
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Abstract
Aims/hypothesis: The mechanism of fluid-related complications caused 
by thiazolidinedione-derivatives is unclear. One potential mechanism is 
thiazolidinedione-induced arterial vasodilation, which results in vascular leakage 
and a fall in blood pressure, normally counterbalanced by sympathetic activation 
and subsequent renal fluid retention. We hypothesized that thiazolidinedione-
induced vascular leakage will be particularly prominent in patients with 
autonomic neuropathy.
 
Methods: We conducted a randomized, double-blind, placebo-controlled, 
parallel study in 40 patients with type 2 diabetes on insulin-treatment recruited 
from a university medical centre. The randomization was performed by a central 
office using a randomization schedule. Both treatment groups, placebo (n = 21) 
and rosiglitazone (n = 19), were stratified for sex and level of autonomic neuropathy 
as assessed by Ewing score (<2.5 or 2.5). We investigated the effects of 16-week 
treatment with rosiglitazone 4 mg twice daily on vascular leakage (transcapillary 
escape rate of albumin, TERalb), body weight, extracellular volume and plasma 
volume. 
Results: Thirty-nine patients were included in the analysis. In the patients 
with high Ewing scores (n = 16), rosiglitazone increased TERalb significantly 
(DTERalb: rosiglitazone +2.43±0.45%/hr vs. placebo -0.11±0.15%/hr, P = 0.002), 
while rosiglitazone had no effect in the patients with low Ewing scores (n = 23). 
Rosiglitazone-induced increase in TERalb and Ewing score at baseline were 
correlated (r = 0.65, P = 0.02). There was no correlation between Ewing score 
and rosiglitazone-induced changes in fluid variables. One subject was withdrawn 
from the study because of atrial fibrillation. 
Conclusions/interpretation: Rosiglitazone may increase vascular leakage 
in insulin-treated patients with type 2 diabetes with autonomic neuropathy. 
Autonomic neuropathy did not exaggerate rosiglitazone-induced fluid retention. 
Therefore, autonomic neuropathy should be considered as a risk factor for 
thiazolidinedione-induced oedema, not for thiazolidinedione-induced fluid 
retention. 
Introduction
Thiazolidinedione-derivatives are used in the treatment of type 2 diabetes 
as they improve insulin sensitivity and reduce blood glucose concentration(1,2). 
Besides their effect on glycaemia, thiazolidinediones appear to have favourable 
effects on plasma lipids, blood pressure, fibrinolysis and inflammation, which 
might offer additional beneficial effects beyond glucose lowering with respect 
to the prevention of cardiovascular disease(3). There is  intense scientific dispute 
about whether thiazolidinediones, particularly rosiglitazone protect against 
cardiovascular disease or may even increase the risk of ischaemic cardiovascular 
events(4-7). Part of the beneficial effects of thiazolidinediones may be outbalanced 
by side effects, especially fluid retention. For example, the PROspective 
pioglitAzone Clinical Trial In macroVascular Events (PROActive) study showed 
a trend towards a reduced risk of cardiovascular events with pioglitazone 
compared to placebo in subjects with type 2 diabetes, but this benefit was largely 
offset by fluid-related adverse events, oedema formation and heart failure(8). The 
mechanism of fluid retention is unclear(9), but unraveling the mechanism would 
identify risk factors for the use of thiazolidinediones and enable prescribing 
thiazolidinedione therapy only to patients with a favourable benefit/risk ratio. 
Based on the demonstration in preclinical studies that thiazolidinediones 
stimulate epithelial sodium channels in the renal collecting duct(10,11), it has been 
suggested that thiazolidinedione-related fluid retention in humans is caused by 
primary renal mechanisms, although a recent preclinical study showed opposing 
results(12) and human experimental data are lacking. Primary renal sodium 
retention would also increase blood pressure which is at odds with the observed 
blood pressure lowering effect of thiazolidinediones(13,14). As the initiating key 
mechanism, thiazolidinediones-induced arterial vasodilation(9) explains both 
blood pressure reduction and fluid retention. The local microvascular consequence 
of arterial vasodilation is increased hydrostatic capillary pressure with more 
vascular leakage and formation of interstitial fluid. The systemic consequence is 
reduction in peripheral vascular resistance(15) and blood pressure, which is the 
driving force for secondary renal sodium retention. Meanwhile, the sympathetic 
nervous system counteracts the vasodilator effect(16), reducing the increment 
in vascular leakage and preventing an exaggerated fall in blood pressure and 
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consecutive increment in sodium retention. Sympathetic activation also directly 
stimulates rennin production which induces sodium retention. Therefore, the net 
effect of the increased sympathetic tone on renal sodium retention is unclear 
(Figure 1).
Patients with autonomic failure are not able to counterbalance haemodynamic 
changes effectively, which will result in an unopposed change in capillary 
hydrostatic force. Indeed, some case reports suggest that the haemodynamic 
effects of insulin are exaggerated in subjects with autonomic neuropathy(17,18), 
while blockade of the autonomic nervous system may increase insulin-induced 
vascular leakage(19). 
Epidemiological data support this mechanistic line of reasoning. It has been 
reported that the incidence of oedema is higher when thiazolidinediones are 
combined with insulin(9). This may be due to a combined effect of thiazolidinediones 
and insulin or to complications accompanying longstanding diabetes(9). In a 
previous study in insulin-resistant people without diabetes, we found no evidence 
for adverse vascular effects of the combined use of rosiglitazone and insulin(20), 
suggesting that it is not insulin itself, but probably complications associated 
with longstanding diabetes that render patients prone to oedema formation. 
Autonomic neuropathy is a typical complication of longstanding diabetes(21,22). 
In the present study in insulin-treated patients with type 2 diabetes, we 
investigated whether thiazolidinedione-induced microvascular leakage is more 
pronounced in patients with autonomic neuropathy. We also investigated whether 
autonomic neuropathy affects thiazolidinedione-induced  fluid retention.  
Methods
The study population consisted of 40 participants with type 2 diabetes, who 
had received  insulin treatment for at least 6 months. Further inclusion criteria 
were age between 30 and 75 years, body mass index below 40 kg/m2, and fasting 
plasma glucose (FPG) between 7.0 and 15 mmol/l. Participants were not eligible 
for inclusion if HbA1c was higher than 12%, if they used over 200 units insulin 
a day, if they used oral hypoglycaemic drugs other than metformin, if they 
used any investigational drug or had used a peroxisome proliferator activated-
receptor gamma (PPAR-γ ) agonist within 4 months before the start of the study, 
or had a significant history of hypersensitivity to a PPAR-γ agonist. Additional 
exclusion criteria were blood pressure exceeding 160/90 mmHg, symptomatic 
postural hypotension, diuretic therapy for oedema, unstable or severe angina or 
congestive heart failure, any cardiovascular event in the last six months before 
entry to the study, presence of clinically significant hepatic disease or anaemia, 
calculated creatinine clearance below 40 ml/min, pregnancy, lactation, women 
of childbearing potential without appropriate contraception, and alcohol or 
drug abuse. To overcome confounding in the interpretation of the Ewing score, 
all participants using alpha or beta-blockers were excluded. Study participants 
were either selected by advertisement or invited by their own physician at the 
outpatient clinics of the Radboud University Nijmegen Medical Centre, Rijnstate 
Figure 1:  Schematic representation of hypothesis
The local consequence of rosiglitazone-induced vasodilation will be increased hydrostatic pressure 
leading to an elevation in capillary filtration (vascular leakage), which predisposes to oedema 
formation (top). An intact sympathetic nervous system counteracts the vasodilator effect which will 
prevent increased vascular leakage.
The systemic consequence of vasodilation is reduction of blood pressure (bottom), leading to renin 
production and sodium retention. An intact sympathetic nervous system on the one hand prevents 
reduction in blood pressure immediately, on the other sympathetic activation directly stimulates renin 
production, the result is diminished and elevated sodium retention respectively. 
RAAS: Renin-Angiotensin-Aldosterone-System
Local effect Vascular leakage Oedema 
Sympathetic tone
Blood pressure
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or Catharina Hospital. The participants received a payment and gave written 
informed consent. The study was approved by the hospital ethics committee, 
registered at clinical trials.gov (NCT00422955) and performed according to 
Good Clinical Practice guidelines.
Procedure
This was a randomized, placebo-controlled, double-blind, single-centre, parallel 
study with 4 weeks of single-blind run-in. At screening, the Ewing score was 
determined to quantify autonomic neuropathy(22). In short, continuous finger 
arterial pressure and cardiac cycle duration  (R-R interval) were recorded on a PC-
based data-acquisition system during 5 standardized tests. Heart rate responses 
to the Valsalva maneuver (longest R-R interval after the manoeuvre divided 
by the shortest R-R interval during the maneuver; normal values are >1.21), 
to deep breathing (maximum-minimum heart rate during a breathing cycle; 
normal ≥15 bpm) and to standing up (ratio: longest R-R interval (±30th beat) 
divided by the shortest R-R interval (±15th beat); normal values are ≥1.04) were 
measured to determine parasympathetic function, and blood pressure response 
to standing up (fall in systolic blood pressure (SBP): normal values ≤10mmHg) 
and to sustained hand grip (increase in diastolic blood pressure (DBP): normal 
values ≥16mmHg) were determined as a measure of sympathetic function.  Each 
result was compared with the normal response and scored as normal, borderline 
or abnormal which were allocated 0, ½ or 1 point respectively. The total score 
ranges from 0 to 5. The participants were divided into two groups, with either 
Ewing scores ≥2.5 or <2.5. Throughout this article the groups are referred high 
versus low Ewing scores or established autonomic neuropathy versus mild 
or no autonomic neuropathy. Four weeks after screening (week –4), eligible 
participants were randomized to either rosiglitazone 4mg twice daily or placebo 
for 16 weeks in a 1:1 ratio (week 0) and balanced for the two Ewing score groups 
within 40-60% boundaries. The participants were assigned to study treatment in 
accordance with the randomisation schedule via the automatic GlaxoSmithKline 
Registration and Medication Ordering System, which could be reached by phone. 
At week 0 and week 16, primary endpoint experiments were performed. Vascular 
leakage was assessed as the transcapillary escape rate of albumin (TERalb). 
During all visits, including the control visits in week 4, 8 and 12, adverse events 
and pill compliance were recorded and blood glucose lowering pharmacotherapy 
was adjusted. If a participant repeatedly had measurements below 4 mmol/L, the 
metformin dose was decreased, as it was our intention to keep the insulin dose 
as constant as possible during the study. In addition, we performed a physical 
examination, measured body composition using bio-impedance and foot volume, 
and chemical, haematological, and glycaemic safety profiles were determined. 
There was a final follow-up visit in week 18. Participants were strictly advised to 
maintain their diet and not to change lifestyle throughout the study. 
Experimental day 
Each participant attended the hospital after an overnight fast without taking 
insulin or oral blood glucose lowering pharmacotherapy in the morning. The 
procedure started at 8.00a.m. in a quiet temperature-controlled room (23-24oC) 
with the participant in supine position. A venous catheter (Venflon, 20G, 32mm, 
Becton Dickinson, Sandy, Utah, USA) was inserted for the infusion of either 
insulin or glucose to keep the glucose level between 5 and 12 mmol/l. During 
the experiment, plasma glucose was measured every twenty minutes (Glucocard 
memory 2, Menarini, Florence). The participant was asked to inject his or her 
normal morning insulin dose. Then, a 20-gauge catheter (Angiocath, Becton 
Dickinson) was inserted into the left brachial artery under local anaesthesia (0.3-
0.4 ml lidocaine HCl 20mg/ml, Braun AG, Melsungen, Germany), connected to 
an arterial pressure monitoring line and kept patent with heparin in saline 0.9% 
(2 U/ml; 3 ml/h) (NaCl 0.9%, Baxter, Utrecht; heparin, Leo Pharma, Ballerup, 
Denmark). This catheter was used for blood sampling and blood pressure 
measurement. After 30 minutes of supine rest, blood was drawn for hormone 
analysis (atrial natriuretic peptide (ANP), aldosterone and renin) and for baseline 
TERalb measurement. An additional venous needle (BD Valu-set, 0.6 x 20 mm, 
Becton Dickinson) was inserted and 7.4x104-14.8x104 Bq 125I-albumin (Shering 
Nederland BV, Weesp, the Netherlands) was given as an i.v. bolus injection at 0 
min. Over the next 60 min, seven plasma samples were collected from the arterial 
line for radioactivity measurements.
Bioimpedance
During all visits, total body water (TBW) and extracellular volume (ECV) were 
assessed using an Akern 2000 bioelectrical impedance analyser(23) (Akern, 
Florence, Italy).
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Foot volume
Foot volume was assessed by the water displacement method using an electronic 
balance (coefficient of variation: 0.30%)(24). The balance recorded the force 
necessary for a standardized immersion of the foot, which depends solely on the 
volume of the foot (Archimedes’ principle). 
Analytical methods
Plasma ANP was analyzed by radioimmunoassay after cartridge extraction 
(Phoenix Pharmaceuticals, Inc., Burlingame, California, USA). Plasma renin 
was determined with a two-site immunochemiluminometric assay (Diagnostic 
System Laboratories (DSL), Webster, Texas, USA). Plasma aldosterone was 
analyzed using antibody-coated tubes and competing radiolabeled aldosterone 
(Diagnostic Products Corp., Los Angeles, California, USA). 
Calculations
For each TERalb test the measured radioactivity was plotted over time. An 
extinction curve was drawn assuming first-order kinetics. Slope and the 
extrapolated peak plasma concentration at t=0 were calculated using Microsoft 
Excel. Plasma volume and TERalb were calculated using the following 
formulas(20,25):
Plasma volume (ml)/1.73m2 = [cpm injected/cpm t=0/ml] /surface(m2)/1.73m2
TERalb = [1- e 3600 x slope]x100(%/h).
To ensure reliable results, calculated plasma volume and TERalb were excluded 
from primary endpoint analysis when the correlation coefficient between the 
extinction curve and the actual measured time points was below 80%. Creatinine 
clearance was calculated with the Cockcroft formula(26).
Statistical analysis
The groups were balanced for sex and Ewing score. For variables measured at 
baseline and in week 16, only participants with paired observations were included. 
For variables with additional assessments, intention-to-treat populations both 
with and without last observation carried forward were analyzed. The difference 
between the two treatment groups in either the total population or in one of the 
Ewing score subgroups was estimated by analysis of covariance with terms for 
treatment, sex, baseline measurement, and, if applicable, Ewing score. Similarly, 
the difference in treatment effect between participants from different Ewing 
score subgroups was estimated with an analysis of covariance with terms for sex, 
baseline, and Ewing score. For the assessment of various relationships, the partial 
correlation coefficient was estimated adjusted for sex. All significance tests were 
two-sided and the overall type I error was 5%. Descriptive statistics are presented 
as mean and standard deviation or as percentage. Treatment effects are presented 
as mean with standard error. All statistical analyses were performed using the 
SAS software package (SAS Institute, Cary, NC, USA).
Results
A total of 40 subjects were included in the study; 21 participants received 
placebo and 19 rosiglitazone (Figure 2). One participant in the rosiglitazone group 
was withdrawn after 8 weeks because of atrial fibrillation and heart failure. Thirteen 
participants in the rosiglitazone-treated group and seventeen participants in the 
placebo-treated group met the reliability criteria for TERalb-measurements and 
were included in the analysis of the primary endpoint.
There were no clinically significant differences in baseline characteristics 
between the treatment groups in the total population, nor were there differences 
between the randomised subgroups, except for Ewing score (Table 1). Sixteen 
participants were classified with Ewing scores ≥2.5. 
Drug compliance was excellent. The 39 participants who finished the study 
reported only mild side effects. Oedema was more prevalent in the rosiglitazone 
group compared to placebo (63% vs. 24%, P<0.05), but always mild, and not 
different between participants with high or low Ewing scores. 
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Figure 2: Enrolment of study participants and distribution among subgroups and flow of participants 
through the study. aTo assure reliable results, calculated transcapillary escape rate of albumin (TERalb) 
with correlation coefficients below 80% between the extinction curve and the actual measured time 
points were excluded from this analysis. FPG: fasting plasma glucose. BP: blood pressure.
Excluded (n = 21):
• BP > 160/90 mmHg (n = 5)
• FPG < 7 mmol/l (n = 3)
• Diabetes type 1 (n = 2)
• Hepatic disease (n = 2)
• Renal insufficiency (n = 1)
• Beta-blocker use (n = 2)
• Alcohol abuse (n = 1)
• No autonomic neuropathy,
 while for balancing purpose  
 neuropathy was required 
 (n = 5)
Recruitment
Assessed for eligibility
(n = 61)
placebo (n = 21)
Low Ewing score = 13,
High Ewing score = 8
rosiglitazone (n = 19)
Low Ewing score = 11,
High Ewing score = 8
Withdrawal due to atrial 
fibrillation (n = 1),
discontinued  
rosiglitazone
Analysis (n = 21)
Excluded from TERalb 
analysis (n = 4) for 
quality reasonsa
Low Ewing score = 9,
High Ewing score = 8
Analysis (n = 18)
Excluded from TERalb 
analysis (n = 5) [for 
quality reasonsa (n = 4) 
and cannulation failure 
(n = 1)]
Low Ewing score = 6,
High Ewing score = 7
Randomized
(n = 40)
Total Population Ewing score < 2.5 Ewing score ≥ 2.5
Rosiglita-
zone
Placebo Ewing 
score < 2.5
Ewing  
score ≥ 2.5
Rosiglita-
zone
Placebo Rosiglita-
zone
Placebo
(n=19) (n=21) (n=24) (n=16) (n=11) (n=13) (n=8) (n=8)
Age (years) 58 ± 8 59 ± 10 59 ± 8 58 ± 10 58 ± 9 60 ± 8 59 ± 6 57 ± 13
Male (%) 58 57 63 50 64 62 50 50
BMI (kg/m2) 29 ± 4 29 ± 6 28 ± 4 31 ± 6d 28 ± 4 27 ± 5 30 ± 3 32 ± 8
Waist (cm) 101 ± 10 101 ± 17 97 ± 13 105 ± 14 98 ± 10 97 ± 15 104 ± 9 107 ± 19
SBP (mmHg) 132 ± 15 132 ± 15 132 ± 12 132 ± 18 131 ± 13 133 ± 13 133 ± 19 131 ± 19
DBP (mmHg) 80 ± 6 80 ± 7 80 ± 6 80 ± 7 80 ± 4 80 ± 8 79 ± 8 80 ± 6
Heart rate  
(1/min)
73 ± 10 75 ± 11 73 ± 12 76 ± 7 70 ± 10 75 ± 13 77 ± 7 75 ± 8
Calculated  
creatinine 
clearance  
(ml/min)
89 ± 16 85 ± 30 86 ± 19 88 ± 32 92 ± 15 81 ± 21 84 ± 17 92 ± 42
Urinary albumin/
creatinine ratio
(mg/mmol creat)
0.9 ± 1.4 3.9 ± 13.3 0.9 ± 1.3 5.1 ± 15.5 1.0 ± 1.9 0.8 ± 0.8 0.9 ± 0.5 10.7 ± 23.5
Duration of
diabetes (years)
12.8 ± 7.8 14.1 ± 5.7 13.1 ± 6.9 14.0 ± 6.5 11.2 ± 8.0 14.6 ± 5.8 14.9 ± 7.4 13.1 ± 5.9
HbA1c (%) 7.7 ± 1.4 8.1 ± 1.1 7.7 ± 1.2 8.3 ± 1.3 7.5 ± 1.3 7.8 ± 1.0 8.0 ± 1.4 8.6 ± 1.1
Insulin dose  
(U/day)
60 ± 40 64 ± 33 58 ± 28 69 ± 45 57 ± 24 58 ± 32 64 ± 56 74 ± 34
Metformin (%) 32 43 29 50 18 38 50 50
Ewing score 2.1 ± 1.3 1.7 ± 0.9 1.2 ± 0.6 3.0 ± 0.8c 1.2 ± 0.6 1.1 ± 0.6 3.3 ± 0.9 a 2.7 ± 0.5b
Data are mean ±  SD 
a P < 0.05 vs. rosiglitazone, Ewing score < 2.5
b P < 0.05 vs. placebo, Ewing score < 2.5
c P < 0.001 vs. Ewing score < 2.5
d P < 0.05 vs. Ewing score < 2.5
Total population
In this section the model-adjusted treatment effects of rosiglitazone and placebo 
are given. A summary of  the raw endpoint data at baseline and after treatment 
for the total population is provided in Table 2. 
Table 1: Baseline characteristics. 
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Rosiglitazone Placebo
Rosiglitazone 
vs 
placebo
n Before After Adjusted effect n Before After
Adjusted 
effect P-value
TERalb  
(%/hr) 13 6.75 ± 0.51 8.36 ± 0.48 1.38 ± 0.46 17 7.38 ± 0.38 7.46 ± 0.40 0.29 ± 0.40 0.09
Plasma 
volume 
(ml)
13 2663 ± 108 2912 ± 109 220 ± 71 16 2746 ± 84 2706 ± 83 -21 ± 64 <0.05
Body 
weight
 (kg)
18 85.5 ± 1.9 87.8 ± 2.0 2.4 ± 0.5 21 88.5 ± 5.1 88.8 ± 5.0 0.5 ± 0.4 <0.01
TBW (l) 18 43.7 ± 1.4 44.8 ± 1.5 1.0 ± 0.3 21 45.1 ± 2.1 45.4 ± 2.0 0.4 ± 0.3 0.12
ECV (l) 18 19.3 ± 0.6 20.1 ± 0.6 0.8 ± 0.2 21 19.7 ± 0.9 20.0 ± 0.8 0.4 ± 0.2 0.18
Haemato-
crit 17 0.39 ± 0.01 0.36 ± 0.01 -0.02 ± 0.00 20 0.39 ± 0.01 0.38 ±0.01 -0.00 ± 0.00 <0.01
ANP (ng/l) 17 121 ± 14 180 ± 27 64 ± 20 21 108 ± 13 108 ±13 -1 ± 18 <0.05
DBP  
intra-
arterial 
(mmHg)
17 74.3 ± 2.5 72.1 ±2.0 -2.3 ± 1.1 17 73.2 ±1.8 74.9 ±1.9 1.4 ± 1.1 <0.05
SBP intra-
arterial 
(mmHg)
17 149.5 ± 5.1 150.8 ± 4.5 1.0 ± 2.3 17 147.4 ±3.9 152.1 ±3.8 4.1 ± 2.3 0.34
Insulin 
dose 
(units/day)
18 61 ± 10 50 ± 8 -11 ± 2 21 64 ± 7 66 ± 7 2 ± 2 <0.001
HbA1c (%) 17 7.79 ± 0.34 7.22 ± 0.22 -0.67 ± 0.15 21 8.12 ± 0.24 7.83 ± 0.20 -0.24 ± 0.14 <0.05
Data are mean ±SE
Table 2: Endpoint variables at baseline and after treatment in the total population (mean±SE).
Effect of rosiglitazone on glycaemic control
Rosiglitazone improved glycaemic control (HbA1c; rosiglitazone: -0.67±0.15% 
vs. placebo: -0.24 ±0.14%,   P<0.05) despite a significant reduction in the daily 
insulin dose (rosiglitazone: -11±2 U/day vs. placebo: +2±2 U/day, P<0.0001) and 
a slight decrease of background metformin treatment. 
Effect of rosiglitazone on vascular leakage and diastolic blood pressure
There was a trend for rosiglitazone to increase vascular leakage (TERalb; 
rosiglitazone: +1.38± 0.46%/hr vs. placebo: +0.29±0.40%/hr, P=0.09). Rosiglitazone 
decreased the intra-arterially measured diastolic blood pressure (rosiglitazone: 
-2.3 ± 1.1mmHg vs. placebo: +1.4±1.1mmHg, P = 0.02) 
Effect of  rosiglitazone on fluid parameters and vascular hormones
During rosiglitazone treatment, plasma volume (rosiglitazone: 220±71 ml/1.73m2 
vs. placebo: -21 ± 64 ml/1.73m2, P = 0.02) and body weight (rosiglitazone: +2.4 kg 
± 0.5 vs. placebo: +0.5 ± 0.4 kg, P = 0.004) increased, while haematocrit decreased 
(rosiglitazone: -0.024 ± 0.005 vs. placebo: -0.005 ± 0.005, P = 0.007). Rosiglitazone 
did not increase ECV (rosiglitazone: +0.8 ± 0.2 l vs. placebo: +0.4±0.2 l, P = 
0.18) and TBW (rosiglitazone: +1.0 ± 0.3 l vs. placebo: +0.4±0.3 l, P = 0.12), 
and had no effect on foot volume. In addition, rosiglitazone increased plasma 
ANP (rosiglitazone: +64 ± 20 ng/l vs. placebo: -1 ± 18 ng/l, P = 0.02) but did not 
influence plasma renin and aldosterone levels.
Low and High Ewing score subgroups
A summary of  raw endpoint data and model-adjusted treatment effects of 
rosiglitazone and placebo within these Ewing score subgroups is provided in 
Table 3.
Effect of rosiglitazone on glycaemic control
The changes in glycaemic control and insulin requirements did not differ between 
the two Ewing score subgroups. 
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Variable
Ewing Score < 2.5 Ewing Score ≥ 2.5
Rosiglitazone Placebo
Rosigli-
tazone vs 
placebo
Rosiglitazone Placebo
Rosigli-
tazone vs 
placebo
n Before After
aAdjusted 
effect n Before After
aAdjusted 
effect P-value n Before After
aAdjusted 
effect n Before After
aAdjusted 
effect P-value
TERalb (%/hr) 6 6.41 ± 0.48 7.15 ± 0.66 -0.44 ± 0.72 9 7.94 ±0.42 8.11 ± 0.49 1.04 ± 0.56 0.16 7 7.04 ± 0.88 9.41 ± 0.40 2.43 ± 0.45 8 6.75 ± 0.61 6.73 ± 0.56 -0.11 ± 0.42 <0.01
Plasma volume  
(ml)
6 2681 ± 210 2989 ± 201 287 ± 82 9 2716 ± 131 2617 ±61 -98 ± 66 <0.01 7 2648 ± 108 2845 ± 116 171 ± 110 7 2786 ± 103 2821 ± 172 132 ± 117 0.82
Body weight 
(kg)
10 84.8 ± 2.9 87.1 ± 3.1 2.5 ± 0.6 13 82.0 ± 4.7 82.0 ± 4.6 0.0 ± 0.5 <0.01 8 86.3 ± 2.5 88.6 ± 2.6 2.1 ± 0.7 8 99.0 ± 10.4 99.8 ± 10.1 1.0 ± 0.7 0.33
TBW (l) 10 44.9 ± 1.8 46.2 ± 2.0 1.3 ± 0.4 13 43.6 ± 2.2 43.8 ± 2.2 0.3 ± 0.3 0.04 8 42.2 ± 2.3 43.1 ± 2.2 0.7 ± 0.6 8 47.5 ± 4.3 48.0 ± 4.0 0.8 ± 0.6 0.92
ECV (l) 10 19.5 ± 0.7 20.3 ± 0.7 0.9 ± 0.3 13 19.0 ± 0.9 19.1 ± 0.8 0.2 ± 0.3 0.12 8 19.2 ± 1.1 19.9 ± 0.9 0.7 ± 0.3 8 20.8 ± 1.8 21.4 ± 1.7 0.7 ± 0.3 1.00
Haematocrit 10 0.39 ± 0.01 0.37 ± 0.02 -0.02 ± 0.01 13 0.39 ± 0.01 0.39 ± 0.01 0.00 ± 0.00 <0.01 7 0.38 ± 0.01 0.35 ± 0.01 -0.02
±0.01
7 0.38 ±0.02 0.37 ± 0.01 -0.01 ± 0.01 0.40
DBP intra-
arterial (mmHg)
10 73.5 ± 2.5 72.2 ± 1.8 -2.2 ± 1.7 11 73.5  ±2.2 75.2 ± 2.7 1.6 ± 1.5 0.11 7 75.3 ± 5.1 71.9 ± 4.2 -3.1 ± 1.2 6 72.6 ± 3.4 74.1 ± 2.7 1.2 ± 1.3 0.03
SBP intra- 
arterial (mmHg)
10 147.7 ± 4.6 150.2 ± 4.5 1.4 ± 3.3 11 149.9 ±3.8 155.0 ± 3.6 5.2 ± 3.0 0.39 7 152.2 ± 10.9 151.7 ± 9.2 0.7 ± 3.7 6 142.9 ± 9.0 146.9 ± 8.7 3.0 ± 4.0 0.68
ANP (ng/l) 10 109 ± 16 152 ± 24 37 ± 22 13 117 ± 17 125 ± 17 9 ± 19 0.35 7 138 ± 26 220 ± 55 81 ± 45 8 95 ± 18 79 ± 17 -20 ± 29 <0.05
Aldosterone b
(nmol/l)
5 0.161 ± 
0.022
0.144 ± 
0.028
-0.014 ± 
0.016
4 0.125 ± 
0.018
0.083 ± 
0.011
-0.058 ± 
0.021
0.18 3 0.296 ± 
0.098
0.139 ± 
0.028
-0.059 ± 
0.039
6 0.203 ± 
0.083
0.129 ± 
0.028
-0.085 ± 
0.024
0.57
Reninb (mU/l) 10 103 ± 64 76 ± 46 -15 ± 37 9 27 ± 12 38 ± 14 -14 ± 37 0.99 5 44 ± 20 27 ± 8 -10 ± 3 6 27 ± 11 20 ± 7 -12 ± 2 0.56
Insulin dose 
(units/day)
10 58 ± 8 45 ± 8 -13 ± 3 13 58 ± 9 60 ± 9 2 ± 3 <0.01 8 64 ± 20 55 ± 15 -10 ± 2 8 74 ± 12 75 ± 11 2 ± 2 <0.01
HbA1c(%) 10 7.59 ± 0.43 7.17 ± 0.35 -0.45 ± 0.17 13 7.83 ± 0.28 7.68 ± 0.22 -0.11 ± 
0.15
0.15 7 8.09 ± 0.59 7.29 ± 0.23 -0.97 ± 0.31 8 8.60 ± 0.40 8.09 ± 0.40 -0.37 ± 0.28 0.19
Data are mean±SE
aAdjusted effect is raw value after treatment minus raw value before treatment using model-adjustments (see Me-
thods). The data in this Table are model-adjusted for the comparison between rosiglitazone and placebo within the 
same Ewing score subgroup. Therefore, we cannot derive the model-adjusted difference in TERalb change (+1.96%/
hr) due to treatment with rosiglitazone between the participants with high (2.54±0.49%/hr) and low Ewing score 
(0.58±0.53%/hr) from this Table.
bThe number of valid observations is low because many participants had aldosterone and renin levels below the 
detection level.
Table 3A: Endpoint variables at baseline and after treatment in the subgroups with either high or low Ewing score. Table 3B: Endpoint variables at baseline and after treatment in the subgroups with either high or low Ewing score.
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Effect of rosiglitazone on vascular leakage and blood pressure
In the subgroup of patients with high Ewing scores, rosiglitazone significantly 
increased TERalb (rosiglitazone: 2.43 ± 0.45%/hr vs. placebo: -0.11 ± 0.42%/hr, 
P = 0.002), while rosiglitazone had no effect in the subgroup of patients with low 
Ewing scores (rosiglitazone: -0.44 ± 0.72%/hr vs. placebo: 1.04 ± 0.56%/hr, P = not 
significant, Figure 3A). As a result, rosiglitazone significantly increased TERalb in 
patients with high Ewing scores compared to those with low Ewing scores (high 
Ewing score: 2.54 ± 0.49%/hr vs. Low Ewing score: 0.58±0.53%/hr P = 0.03). 
In the rosiglitazone-treated patients the reduction in intra-arterial diastolic 
blood pressure tended to be more pronounced in participants with high Ewing 
scores (rosiglitazone: -3.1 ± 1.2 mmHg vs. placebo: +1.2 ± 1.3 mmHg, P = 0.03) 
than with low Ewing scores (rosiglitazone: -2.2 ± 1.7 mmHg vs. placebo: +1.6 ± 
1.5 mmHg, P = 0.11).
Figure 3: Rosiglitazone induced vascular leakage in 
the autonomic neuropathy subgroups.
A) (top): Mean model-adjusted change in transca-
pillary escape rate of albumin (TERalb)(SE) during  
treatment with either rosiglitazone or placebo wit-
hin the subgroup of participants with a high Ewing 
score (left) and with a low Ewing score (right) (di-
chotomous). Values are means with SE. The data in 
this Figure are model-adjusted for the comparison 
between rosiglitazone and placebo within a Ewing 
score subgroup. Therefore, we cannot derive the 
exact model-adjusted difference in TERalb change 
(+1.96%/hr) due to the treatment with rosiglitazone 
between the participants with high and low Ewing 
score from this Figure (see Methods). Black bars: 
rosiglitazone; white bar: placebo. aP=0.002;bP=0.03; c 
not significant  
B) (bottom): Correlation (r =0.65,  P=0.02) between 
baseline Ewing score (continuous) and change in 
TERalb (individual raw data, therefore not model-
adjusted) during treatment with rosiglitazone.
Effect of rosiglitazone on fluid parameters and vascular hormones
In the subgroup of patients with a high Ewing score, rosiglitazone did not increase 
fluid parameters and decrease haematocrit significantly, while in the patients 
with low Ewing scores rosiglitazone seemed to increase plasma volume, TBW, 
body weight, and did decrease haematocrit (Table 3). The difference in effect of 
rosiglitazone over placebo in both subgroups was partly driven by the different 
response to placebo in these subgroups. 
Correlations
Baseline Ewing score and change in vascular leakage or fluid parameters
In patients randomized to rosiglitazone, the increase in TERalb was highly 
correlated with the Ewing score at baseline (r = 0.65, P = 0.02, Figure 3B), while 
the change in TERalb during placebo treatment was not (r = 0.12, P = 0.66). 
The correlation between the increase in TERalb during rosiglitazone treatment 
and baseline Ewing score was even more robust after inclusion of all the TERalb 
results (r = 0.72, P = 0.002), showing that the exclusion of qualitative weak 
TERalb measurements neither biased nor caused the relationship. As participants 
with a high Ewing score had a significantly higher BMI we also evaluated  the 
correlation between the change in TERalb during rosiglitazone treatment and 
baseline BMI (r = 0.11) but this correlation was not significant. Furthermore, the 
changes in intra-arterial DBP while taking rosiglitazone were not significantly 
correlated with baseline Ewing score (r = -0.28). In addition, also the changes in 
body weight, haematocrit, plasma volume, TBW and ECV during rosiglitazone 
treatment were not correlated with the Ewing score at baseline.
Correlation between change in vascular leakage, and change in diastolic 
blood pressure or fluid parameters
As expected from the vascular hypothesis, changes in diastolic blood pressure 
in patients receiving rosiglitazone were strongly inversely correlated to changes 
in vascular leakage in participants with high Ewing scores (r = -0.96, P = 0.002, 
Figure 4A), indicating that participants with a large blood pressure drop had 
a large increase in vascular leakage. This correlation was not significant in 
participants with low Ewing scores. 
In patients taking rosiglitazone, the changes in vascular leakage were inversely 
correlated to changes in TBW (r = -0.76, P = 0.004, Figure 4B) and ECV (r = 
-0.65, P = 0.02).
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Figure 4: Relationships between vascular leakage 
and either diastolic blood pressure or total body 
water.
A) Inverse correlation (r = -0.96, P = 0.002) between 
rosiglitazone-induced changes in diastolic blood 
pressure (DBP) and transcapillary escape rate of 
albumin (TERalb) in participants on rosiglitazone 
with established autonomic neuropathy (n = 7; two 
participants had almost exactly the same readings 
for both change in DBP and change in TERalb) 
B) Inverse relationship (r = -0.76, P = 0.004) between 
rosiglitazone-induced changes in TERalb and  
changes in total body water (TBW) in all 
participants treated with rosiglitazone with reliable 
TERalb measurements (n = 13).
Discussion
There are two main clinically relevant findings in the present study. First, in 
the presence of autonomic neuropathy, rosiglitazone induces vascular leakage 
in insulin-treated patients with type 2 diabetes. Second, neither autonomic 
neuropathy nor the increase in vascular leakage in itself led to increased fluid 
retention. Together these findings suggest that, in established autonomic 
neuropathy, thiazolidinediones will lead to exaggerated vascular leakage, but 
not necessarily to more pronounced fluid retention. Nevertheless, an increased 
vascular leak will render these patients more susceptible to oedema formation.
We postulate that thiazolidinediones have a vasodilator action, which 
subsequently promotes vascular leakage into interstitial tissues. In the present 
study, vascular leakage indeed tended to increase during treatment with 
rosiglitazone, although not statistically significant. Predefined subgroup analyses, 
however, showed a clear increase in vascular leak following treatment with 
rosiglitazone in participants with established autonomic neuropathy but not in 
participants with absent or mild autonomic neuropathy. This was confirmed by 
the positive correlation between Ewing score and change in TERalb. The findings 
suggest that autonomic nerve damage in diabetic participants prevents sympathetic 
nerve stimulation from counteracting the vasodilator effects of rosiglitazone. This 
concept (Figure 1) is supported by the strong inverse correlation between changes 
in diastolic blood pressure and TERalb in participants with established autonomic 
neuropathy (Figure 4A). All in all, the findings fit with the concept that defective 
counter regulation of haemodynamic changes caused by autonomic neuropathy 
exaggerates vascular leakage induced by thiazolidinediones. In persons with none 
or mild autonomic neuropathy, rosiglitazone did not increase vascular leakage, 
which is in accordance with previous human(20) and with preclinical(27) findings. 
The notion that autonomic neuropathy results in a defective counterbalance 
towards rosiglitazone-induced vasodilation and subsequent vascular leakage, 
has two consequences. First, people prone to vascular leak should be protected 
against excessive plasma volume expansion, because excess fluid would leak out 
of the plasma compartment. Indeed, we did not observe either a disproportional 
increase in plasma volume or decrease in haematocrit during rosiglitazone 
treatment in participants with established autonomic neuropathy. Second, the 
excessive leakage should result in an increase in TBW and ECV. This, however, 
was not observed in the present study: if anything changes in TBW an ECV 
were lower in the established autonomic neuropathy group. This apparent 
discrepancy can be explained by the complicated relation between sympathetic 
counter regulation and renal sodium retention. The sympathetic nervous system 
responds to systemic hypoperfusion, both by direct renal sodium retention and 
by activation of the Renin-Angiotensin-Aldosterone-System(28). In fact, after 
drug-induced vasodilation an intact sympathetic nervous system protects the 
body against local vascular leak by reflex vasoconstriction and against systemic 
hypoperfusion by sodium retention. Consequently, a defective sympathetic 
nervous system will lead to vascular leak without much sodium retention (Figure 
1). In both situations there should be an inverse correlation between vascular leak 
and ECV and TBW, and this indeed is in complete agreement with our findings 
(Figure 4B). The clinical implication of our observations is that insulin-treated 
Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients 
with type 2 diabetes: a randomized-controlled trial on thiazolidinedione-induced vascular leakage
73
3
72
3
patients with diabetic autonomic neuropathy may be partly protected from fluid 
overload by sodium retention induced by thiazolidnediones, but on the other 
hand will be more prone to vascular oedema, as a consequence of microvascular 
imbalance.
The prevalence of oedema was much higher in our study than in another 
study in insulin-treated patients performed by Raskin et al.(13), both during 
placebo treatment (present study: 24%, Raskin et al.: 4%) and during rosiglitazone 
treatment (present study: 64%, Raskin et al.: 17%). A potential explanation for 
this difference is that we were more focused on the development of oedema 
because oedema was a main outcome in our study. Another explanation could be 
the high prevalence of autonomic neuropathy in our population, although there 
was no correlation between Ewing score and the clinical finding of oedema. The 
reason we found differences in vascular leakage but not in oedema formation 
between the autonomic neuropathy subgroups during rosiglitazone treatment 
seems to be the absence of a reliable clinical test to quantitatively assess changes 
in total body interstitial fluid (oedema) in a chronic setting. Vascular leakage was 
measured as mean of total body capillary leakage while oedema was measured 
only locally in the foot. For instance, changes in visceral vascular leakage will not 
influence foot volume.
In the present study, the glycaemic effect of rosiglitazone was moderate (a 
decrease in HbA1c of 0.42%) and seemingly less than expected. For example, Raskin 
et al. reported a treatment effect of -1.3%(13). This difference may be explained by 
the shorter treatment period, the lower baseline HbA1c, the reduction in insulin 
dose, the slight decrease of background metformin use during rosiglitazone, and 
the marked glycaemic improvements in the placebo group.
The participant who was withdrawn from this study with atrial fibrillation had 
used beta blocker therapy for subjective palpitations in the past. She discontinued 
this therapy one month before entry into the study. Atrial fibrillation and oedema 
resolved quickly after re-institution of beta blocker therapy and discontinuation 
of rosiglitazone. Despite correction of the rhythm, the participant was withdrawn 
as beta blocker therapy would have been a confounder in the final analyses.
To assess the degree of autonomic neuropathy, different methods each 
with important limitations, are being used. We have used the Ewing score, as 
it is well validated, widely accepted, non-invasive, and suitable for screening. A 
disadvantage of the Ewing score is that there is no international consensus how 
to adjust the tests for aging. We have our own age-adjusted reference tables but 
these have not been published. Therefore, we used in this study the internationally 
accepted Ewing tests without age adjustment. We did perform a post-hoc analysis 
after adjusting Ewing score for age, but this did not result in any change in study 
outcome (data not shown).
We have also measured baseline arterial plasma noradrenaline, adrenaline and 
calculated the noradrenaline appearance rate (data not shown), which tended to 
be lower in the group with established autonomic neuropathy, suggesting that the 
higher Ewing score did indeed reflect autonomic neuropathy.
While sympathetic dysfunction is most relevant for our hypothesis, the 
Ewing score contains parasympathetic as well as sympathetic tests(22). In most 
patients the initial manifestation of autonomic disease is an abnormal response 
to the parasympathetic tests, followed by abnormal sympathetic tests in more 
severe autonomic neuropathy(21). The increased frequency of abnormalities 
found with the parasympathetic tests may reflect both an earlier involvement 
of parasympathetic damage and a better sensitivity of the parasympathetic 
tests. To maximize the separation of participants with and without sympathetic 
neuropathy, we divided our population on the basis of the Ewing score in two 
categories with a cut off value of 2.5, in slight deviation with the original four 
categories described by Ewing (normal, early, definite and severe). Indeed, more 
participants in the ≥2.5 group had abnormalities in the sympathetic nerve tests 
than in the <2.5 group (data not shown). In line with the concept of sympathetic 
counterbalance, rosiglitazone increased vascular leakage in participants with 
the combination of a high Ewing score and sympathetic disturbances in a post 
hoc analysis. On the contrary, rosiglitazone did not influence vascular leakage 
in participants with the combination of a low Ewing score and no sympathetic 
disturbances.
In conclusion, in insulin-treated type 2 diabetes patients who have autonomic 
neuropathy, thiazolidinediones increase vascular leakage and render the patient 
susceptible to development of oedema. Autonomic neuropathy in itself does 
not exaggerate thiazolidinedione-induced fluid retention. Therefore, autonomic 
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neuropathy should be considered as a risk factor for thiazolidinedione-induced 
oedema, not for fluid retention. 
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Abstract
Thiazolidinediones are associated with fluid retention, that has been suggested 
to be resistant to treatment with loop diuretics. This resistance is thought to be 
caused by upregulation of renal epithelial sodium channels (ENaCs). In this 
study, we tested whether these mechanisms are of clinical significance. 
We conducted a well-controlled study in 12 insulin-resistant nondiabetic 
participants, who received treatment for 9 weeks with either rosiglitazone at a 
dosage of 4 mg b.i.d. or placebo The aim of the study was to investigate whether 
upregulation of ENaCs by rosiglitazone reduces furosemide’s natriuretic response 
and enhances the response to the ENaC inhibitor amiloride. The natriuretic 
response to furosemide and amiloride, and the amount of α-ENaC in urinary 
exosomes were quantified. Rosiglitazone neither reduced furosemide-induced 
natriuresis nor changed furosemide’s concentration-effect curve. Furthermore, 
rosiglitazone did not change either amiloride-induced natriuresis nor the amount 
of urinary α-ENaC. 
This study challenges previous findings regarding thiazolidinedione-related 
ENaC upregulation and suggests that thiazolidinedione-induced fluid retention 
should respond normally to loop diuretics.
Introduction
Thiazolidinedione derivatives (TZDs) are used in the treatment of type 2 
diabetes because they improve insulin sensitivity and reduce plasma glucose 
levels(1,2). Besides their effect on glycaemia, thiazolidinediones appear to have 
favourable effects on plasma lipids, blood pressure, fibrinolysis, and inflammation 
that are thought to offer additional cardiovascular benefit(3,4). However, there is 
controversy about the use of thiazolidinediones, particularly rosiglitazone, as 
possibly being associated with higher risks of ischaemic cardiovascular events(5-8). 
Such concerns recently resulted in the suspension of marketing authorization 
for rosiglitazone in Europe. The well-documented side effect of fluid retention 
associated with the use of thiazolidinediones, which doubles the incidence 
of heart failure, significantly contributes to the vigorous discussion about the 
benefit-to-risk ratio of this class of drugs. The incidence of oedema formation 
during rosiglitazone treatment ranges from -4.8% when given as monotherapy 
to almost 15% during concomitant use of insulin(9). For example, the PROActive 
(Prospective Pioglitazone Clinical Trial in Macrovascular Events) study showed a 
trend towards a reduced risk of cardiovascular events with the use of pioglitazone 
as compared with placebo in subjects with type 2 diabetes, but this benefit was 
largely offset by fluid retention-related adverse events, namely, oedema formation 
and heart failure(10). 
The findings from experiments in animals and in vitro cell experiments 
suggest that thiazolidinediones upregulate epithelial sodium channels (ENaCs) 
in the renal collecting duct(11,12). Consequently, thiazolidinedione-related fluid 
retention in humans may be caused by primary renal mechanisms. ENaC is 
a membrane-bound channel that specializes in the reabsorption of sodium, 
regulated by aldosterone and insulin(13) and pharmacologically inhibited by the 
diuretic drug amiloride(14). The concept that thiazolidinediones upregulate ENaC 
is appealing and explains the following two observations.
First, despite furosemide’s higher natriuretic potential, spironolactone, an 
aldosterone receptor antagonist and indirect inhibitor of ENaC, was superior 
in the treatment of rosiglitazone-induced fluid retention(15). This is similar to 
observations in cirrhotic patients with ascites, in whom hyperaldosteronism(16) and 
subsequent ENaC upregulation results in increased distal sodium reabsorption. 
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Using this line of reasoning, the direct ENaC-inhibitor amiloride might be the 
drug of choice to treat thiazolidinedione-induced fluid overload(17). In healthy 
individuals, amiloride is not a potent natriuretic drug, but upregulation of ENaCs 
may lead to an increased natriuretic potential similar to what has been observed 
in patients with a gain-of-function mutation of ENaC, the so called Liddle’s 
syndrome(18). 
Second, thiazolidinedione-induced oedema is reported to be resistant 
to loop diuretic therapy. Several case studies on thiazolidinedione-related 
pulmonary oedema observed resistance to loop diuretics(19,20). Niemeyer et al. 
presented a clinical cohort study showing that up to 30% of thiazolidinedione-
induced oedema was refractory to furosemide treatment(21). Resistance to loop 
diuretics has been studied extensively in the past, but not specifically with 
thiazolidinediones. Loop diuretics specifically inhibit the apical Na-K-2Cl-
cotransporter in the ascending limb of the loop of Henle(22). Extensive distal renal 
sodium reabsorption, for example as a result of ENaC upregulation, is one of the 
potential pharmacodynamic causes of resistance to loop diuretics(23).
This concept is of great interest and needs clinical proof. Therefore, we 
addressed the hypothesis that treatment of insulin-resistant subjects with 
rosiglitazone upregulates ENaCs in the renal collecting duct, thereby reducing 
the diuretic response to furosemide while stimulating the diuretic response to 
amiloride. To this end, we measured the effect of rosiglitazone on furosemide- and 
amiloride-induced natriuresis and the amount of ENaC in urinary exosomes in 
humans in vivo in a double-blind, placebo-controlled, randomized clinical trial.  
Results
Thirteen participants with insulin resustance were enrolled in the study 
(Figure 1). One participant decided to withdraw two weeks after randomization 
because of personal reasons. Therefore, the final statistical analysis was performed 
on end-point data for 12 participants (6 participants in each treatment sequence) 
(Table 1). 
Adherence to the study drug (as measured by tablet counting) was excellent 
during both treatment regimens (rosiglitazone: 96%, range 80-102%; placebo: 
97%, range 92-101%). The participants reported slightly more adverse events 
during rosiglitazone treatment (total 32 events, 92% of subjects) as compared with 
placebo (total: 25 events, 100% of subjects). All events were mild including oedema 
(ankle oedema that did not interference with daily activities) (rosiglitazone: 42%; 
placebo: 25%, P = 0.32) and anaemia (defined as haemoglobin levels of < 8.1 
mmol/L for men and < 7.3 mmol/L for women) (rosiglitazone: haemoglobin: 8.2 
± 0.2 mmol/L; placebo: haemoglobin 8.5 ± 0.2 mmol/L, P = 0.08). There was 
no difference in natriuretic responses between period 1 and 2 either in the total 
population or in placebo treatment. Therefore, it seems unlikely that either a 
carryover or a period effect confounded the primary outcome data.
Figure 1: Enrolment of study participants
Excluded (n= 3):
• Holiday (n = 1)
• ś 2 characteristics of 
 the metabolic syndrome
 (n = 2)
Recruitment
Assessed for eligibility
(n = 16)
Withdrawal (n = 1),
for personal reasons
Primary analysis (n = 12)
Randomized
(n = 13)
Placebo - Rosiglitazone 
(n=6)
Rosiglitazone - Placebo 
(n = 7)
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The effect of rosiglitazone on metabolic, haemodynamic and fluid  
variables
Relative to placebo rosiglitazone reduced insulin levels (rosiglitazone: 8.0 ± 
1.0 mU/l versus placebo: 11.3 ± 1.5 mU/l, P < 0.05) and insulin resistance 
(Homeostasis model assessment index (HOMA): rosiglitazone: 1.67 ± 0.22 versus 
placebo: 2.41 ± 0.34, P < 0.05). As expected, given that the participants were not 
diabetic, rosiglitazone did not lower fasting plasma glucose (rosiglitazone: 4.6 ± 
0.1 mmol/l versus placebo: 4.7 ± 0.1 mmol/l, P=NS) or glycosylated haemoglobin 
(HbA1c) (rosiglitazone: 5.5 ± 0.1 % versus placebo: 5.4 ± 0.1 %, P = NS). In 
addition, rosiglitazone tended to lower alanine transaminase levels (rosiglitazone: 
26 ± 34 U/l versus placebo: 32 ± 4 U/l, P = 0.07).
As compared with placebo, rosiglitazone tended to decrease systolic blood 
pressure (rosiglitazone: 121 ±2 mmHg versus placebo: 126 ± 3 mmHg, P = 0.09) 
as well as diastolic blood pressure 
(rosiglitazone: 82 ± 2 mmHg versus 
placebo: 85 ± 2 mmHg, P = 0.04) 
after 8 weeks of treatment.
As compared with placebo, 
rosiglitazone treatment did not 
result in an increase in body 
weight, foot volume, extracellular 
water concentration or total body 
water concentration or a decrease 
in haematocrit level. After 8 weeks 
of rosiglitazone treatment, we did 
not find differences in plasma 
concentrations of  atrial natriuretic 
peptide, brain natriuretic peptide, 
vascular endothelial growth factor, 
aldosterone, or renin in plasma 
samples. 
Table 1: Baseline characteristics of the 12 evaluable subjects
Variable Mean±SD 
Age (year) 51 ± 8
Male (%) 58
Body Mass Index (kg/m2) 32.6 ± 3.5
Systolic blood pressure (mmHg) 143±8
Diastolic blood pressure (mmHg) 92 ± 7
Waist circumference (cm) 109 ± 9
Plasma Triglycerides (mmol/L) 1.91 ± 1.24
HDL-cholesterol (mmol/L) 1.20 ± 0.31
Fasting Plasma Glucose (mmol/L) 5.0 ± 0.4
HOMA-index (mU.mmol/L2) 3.2 ± 1.7
Cockcroft (ml/min) 108 ± 26
Criteria metabolic syndrome
2 criteria (n)
3 criteria (n)
4 criteria (n)
5
4
3
Medication
Statin (%) 17
Antihypertensive medication (%) 17
HDL, High Density Lipoprotein 
HOMA, Homeostasis model assessment index
Figure 2: 
A) Total natriuresis during the first 8 hours after  
the furosemide bolus injection (40mg).
B) Rosiglitazone treatment period. Furosemide 
excretion rate-response curve. The individual 
circles are the readings of all the voidings of the 
participants minus one (excluded participant). The 
solid line represents the sigmoidal curve calculated 
according to the average dose-response parameters 
(Table 2)(24). 
C) The same as B but now representing the placebo 
period. 
Emax, calculated maximal furosemide-induced 
sodium excretion rate; LogER50, the logarithm of the 
furosemide concentration at which a half maximal 
response was observed; PLAC, placebo; RSG, 
rosiglitazone.
Natriuretic effects of furosemide
Furosemide induced a clear natriuretic response, but sodium excretion over 8 
hours was not different between rosiglitazone and placebo (257 ± 13 mmol and 
251 ± 18 mmol respectively, P = 0.66; Figure 2A) nor were there differences 
in the natriuretic response as assessed by comparing the furosemide excretion 
rate-response curves (Table 2; Figure 2B,C). The analyses of these furosemide 
excretion rate-response curves were performed after exclusion of one participant, 
for whom nonlinear regression analysis resulted in an unrealistically maximum 
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sodium excretion rate. Post-hoc, we reanalyzed the data without excluding this 
particiapant’s data, but this did not change the conclusion that there was no 
difference in natriuretic effect of furosemide.
Furosemide concentrations, in both plasma and urine, were similar for both 
treatment periods (Table 3). The peak value obtained for  furosemide concentration 
was consistent with previous studies by our group(24). In addition, the value for 
area under the curve was in line with observations of Beermann et al.(25). Except 
for blood pressure, which was slightly lower during rosiglitazone, the baseline 
values before the furosemide experiments were  similar during both treatment 
periods (Table 4).
 
Parameter Rosiglitazone Placebo P-value
Urine 8 hours sodium output (mmol) 257 ± 13 251 ± 18 NS
Urine 24 hours sodium output (mmol) 297 ± 12 296 ± 26 NS
Baseline sodium excretion rate (μmol/min) 46.9 ± 8 44.6 ± 12 NS
Sodium Emax (μmol/min) 3299 ± 490 3480 ± 300 NS
Furosemide ER50 (μg/min) 127 ± 5 133 ± 4 NS
Hill slope 1.98 ± 0.2 1.71 ± 0.2 NS
Data are mean ± SE; n = 12
Emax: Calculated maximal furosemide-induced sodium excretion rate. ER50: calculated from the analysis of the  
furosemide excretion rate-response curves. The ER50 is the furosemide excretion rate at which a half-maximal 
response was observed. NS, nonsignificant
Natriuretic effects of amiloride
Amiloride induced a clear natriuretic response, but sodium excretion over 24 
hours was not different between rosiglitazone and placebo (313 ± 21 mmol and 
315 ± 20 mmol, respectively; P = 0.90, Figure 3A). 
Amiloride concentrations in both plasma and the urine were similar 
for rosiglitazone and placebo treatment periods (Table 3). The steady-state 
concentration of amiloride (42 ng/ml) was within the chosen range. In addition, 
the baseline parameter valueprior to commencing amiloride experiments were 
similar for the rosiglitazone and placebo treatment periods,  except for the blood 
pressure readings, which were slightly lower during rosiglitazone treatment 
(Table 4).
 
Parameter Amiloride Furosemide
rosiglitazone placebo rosiglitazone placebo
Peak plasma level (ng/ml; μg/ml) 96 ± 7 103 ± 8 2.9 ± 0.3 3.2 ± 0.2
Plasma steady state (ng/ml) 42 ± 2 43 ± 2 NA NA
AUC plasma concentration (μg.ml-1.min1) 22.5 ± 1.1 22.5 ± 1.3 166 ± 13 166 ± 13 
Peak urinary concentration (μg/ml) 18.4 ± 2.9 18.5 ± 2.7 453 ± 52 482 ± 59
Mean urinary concentration (μg/ml)a 7.8 ± 1.6 6.8 ± 0.6 NA NA
Data are mean ± SE; n = 12; No significant differences observed
aTotal amount of amiloride divided by total volume of urine during the first 8 hours. 
AUC, Area under curve; NA, not applicable
Parameter Amiloride Furosemide
rosiglitazone placebo rosiglitazone placebo
Baseline 24-hours sodium output (mmol) 204±40 184±29 151±12 139±19
Plasma creatinin (μmol/L) 73±3 73±3 73±4 71±3
Systolic blood pressure (mmHg) 123±3a 129±2 121±2 126±3
Diastolic blood pressure (mmHg) 80±2a 85±2 82±2a 85±2
Aldosterone (nmol/L) 0.11±0.02 0.13±0.03 0.14±0.03 0.22±0.08
Renin (mE/L) 10±2 9±2 10±2 12±2
Atrial natriuretic peptide (pmol/L) 16±2 16±2 15±2 12±1
Data are mean ± SE; n = 12; 
aP < 0.05
Table 2:  Indexes of the natriuretic and diuretic response to furosemide
Table 3: Exposition to furosemide and amiloride during the diuretic experiments.
Table 4: Baseline conditions before the diuretic experiments. 
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α-ENaC abundance in exosomes
When normalized for the total amount of urinary exosome protein and for the 
individual placebo-treated α-ENaC exosome abundance, rosiglitazone did not 
increase α-ENaC exosome abundance (rosiglitazone: 83 ± 12%; placebo: 100%; 
P = 0.15) (see Figure 3B for the individual data). Also, there was no influence 
of rosiglitazone on α-ENaC abundance normalized for the individual urinary 
creatinine concentration (rosiglitazone: 282±123%; placebo: 100%; P = 0.40). We 
were able to measure α-ENaC abundance in 7 out of the 12 participants. In two 
participants the urine was too dilute to isolate enough protein for immunoblotting, 
and in three others we were unable to detect α-ENaC even though sufficient 
protein was avaiable. 
Discussion
The most important observation in this study was the lack of any alteration 
in the diuretic response to furosemide and amiloride in insulin-resistant subjects 
treated with rosiglitazone. This observation is robust because the natriuretic 
responses to furosemide and amiloride were quantified and analyzed with high 
accuracy in this trial. Moreover, the findings are relevant, because the outcome 
parameters (natriuresis and diuresis) are of obvious clinical significance. 
Altogether, the results convincingly show that treatment with rosiglitazone does 
not reduce the diuretic response to furosemide in subjects with insulin resistance. 
Interestingly, the hypothesis of our study was also addressed by an elegant 
clinical study of Karalliedde et al.(15). Their conclusion was that spironolactone was 
superior to furosemide in the treatment of rosiglitazone-induced oedema in diabetic 
patients. This suggests, at the minimum, that furosemide was less effective than 
expected. The authors viewed their finding as compatible with the upregulation 
of ENaCs in the renal collecting ducts. However, their study did not compare 
the diuretic responses during rosiglitazone and placebo; instead, it investigated 
the diuretic responses to spironolactone, furosemide and hydrochlorothiazide 
separately in an open-label parallel study. Therefore, differences in the dose of 
these three diuretic drugs chosen could have been responsible for the observed 
differences in outcome. 
There are also a few case reports or case series suggestive for resistance to loop 
diuretics during thiazolidinedione treatment(19-21). Obviously, these case reports 
were not placebo-controlled , and leave ample room for alternative explanations 
for the described resistance to loop diuretics. For instance, the subjects had 
established diabetes, with more insulin resistance and overt fluid retention in 
comparison with our study population. In order to support the clinical relevance 
of our data we performed a post hoc analysis whether oedema formation or 
degree of insulin resistance influences the natriuretic response to furosemide 
during rosiglitazone treatment. Within our population we could not detect such 
an influence. However, in actual practice, subjects may have additional problems 
(e.g., autonomic neuropathy) in addition to  their original metabolic disease, 
which may influence the water and sodium homeostasis(26). This makes us careful 
with the extrapolation of our results to the clinic. 
Figure 3: 
A) Total natriuresis during 24 hours after the start of 
the amiloride infusion in the individual participant 
during both periods.
B) An equal amount of urinary exosome proteins 
from the individual participants (depicted by treat-
ment number), was blotted for α-ENaC both during 
rosiglitazone (black bars) and placebo treatment 
(broken line). Signals were quantified by densitome-
try and individually normalized for placebo-treated 
α-ENaC levels (100%). ENaC: epithelial sodium 
channel.
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In the present study, we thoroughly investigated the pharmacodynamic 
properties of furosemide during placebo and rosiglitazone phases under similar 
baseline conditions (Table 4). Therefore, pharmacodynamic mechanisms of 
thiazolidinedione-induced furosemide resistance, such as ENaC upregulation, 
increments in renin-angiotensin-aldosterone system (RAAS) activity or atrial 
natriuretic peptide secretion, including decreased tubular furosemide secretion 
(pharmacokinetic) are more or less excluded by our study. However, other 
differences in pharmacokinetics, such as changes in bioavailability of the orally 
administered drug, were not investigated and are beyond the scope of this study.
As mentioned, Karalliedde et al.(15) suggested superiority of spironolactone 
over furosemide in the treatment of thiazolidinedione-induced oedema. On the 
basis of the concept of ENaC upregulation we hypothesized that the optimal 
treatment for thiazolidinedione-induced oedema would be the ENaC-inhibitor 
amiloride(17). It is important to stress that our study was not designed to address 
whether amiloride is superior to furosemide in the treatment of thiazolidinedione-
induced oedema. The higher 24-hours natriuresis during amiloride is the result of 
the dosing schedules chosen. The clinical message that emerges from our study 
regarding diuretic therapy in thiazolidinedione-induced oedema is that we found 
no thiazolidinedione-induced furosemide resistance. 
Apart from the lack of any effect of rosiglitazone on the response to furosemide, 
we also observed that the response was unaffected by the ENaC-inhibitor amiloride. 
This argues against a relevant upregulation of ENaCs in the renal collecting ducts 
in rosiglitazone-treated subjects. This clinical observation is further supported by 
direct measurements of ENaC expression in urinary exosomes. 
To date, the relationship between rosiglitazone and ENaCs has been studied 
only in animals. Guan et al.(11) provided in vivo evidence for upregulation of 
ENaC in a mouse model with pioglitazone, and Hong et al.(12) had previously 
shown comparable results for both rosiglitazone and pioglitazone. Therefore, 
it is not likely that our negative findings are compound-related. This is in line 
with the joined consensus statement by the American Heart Association  and 
the American Diabetes Association that considered fluid retention to be a class 
effect of thiazolidinediones rather than an effect of the individual compound(27). 
Interspecies differences could be responsible for the discrepancy between the 
animal experiments and those of the present study. 
Three elegant animal in vivo studies have thoroughly investigated whether 
inhibition of ENaC could reduce oedema formation. Guan et al.(11) provided 
evidence for the primary role of ENaC upregulation, by using amiloride in mice 
without peroxisome proliferator activated-receptor gamma (PPAR-γ) in their 
collecting duct cells. On the other hand, neither Chen et al.(28) using amiloride for 
direct ENaC inhibition, nor Vallon et al.(29), using a collecting-duct-specific gene 
inactivation of ENaCs, were able to reduce thiazolidinedione-induced oedema. 
Our clinical results related to the response to amiloride and furosemide, as well as 
our data on ENaC exosome abundance are in line with the latter two studies and 
a subsequent editorial(30) and challenge the concept of thiazolidinedione-induced 
ENaC upregulation with subsequent oedema formation. It could be argued that 
the findings in our mildly insulin-resistant non-diabetic population without fluid 
retention, are not representative of patients in actual practise. Although our post 
hoc analysis did not detect ane effect of insulin resistance and oedema formation 
on the response to amiloride, we admit that there are still some limitations to the 
extrapolation of our findings to daily practice. 
Our data on α-ENaC exosome abundance must be interpreted with caution 
for a number of reasons. First, we were able to measure α-ENaC in only seven 
participants. Second, we assume that α-ENaC exosome abundance provides a 
measure of the ENaC expression in the kidney. Although data from studies in 
animals data showed a correlation between exosome abundance and kidney 
expression with respect to other transporters,(31) proof that such a correlation exists 
with respect to ENaCs is lacking. In addition, we did not measure independent 
confounders of this correlation, such as production and degradation rate of 
ENaCs(32). In contrast, our observations on the diuretic response to furosemide 
and amiloride during rosiglitazone compared with placebo were very accurate 
and complete, and can be interpreted without any caution. Therefore, our 
complete data set argues against upregulation of renal ENaCs after rosiglitazone 
treatment in these mildly insulin-resistant nondiabetic subjects. An alternative 
hypothesis for thiazolidinedione-induced fluid retention is vasodilation(27), and 
this could unify our observations with the clinical observations on furosemide-
resistant thiazolidinedione-induced oedema. Oedema related to microvascular 
imbalance will not resolve adequately by furosemide treatment even despite 
normal natriuresis could be obtained after a single dose. An illustrative example 
is oedema associated with nifedipine treatment, which is thought to be due to 
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microvascular imbalance. It develops despite the natriuretic characteristics of 
nifedipine and is resistant to additional diuretic treatment(33, 34). 
The result of the tablet counts suggests that there was optimal compliance with 
rosiglitazone treatment. This is supported by the fact that rosiglitazone treatment 
ameliorated insulin sensitivity and lowered systolic and diastolic blood pressure, 
which is in line with our previous findings in such a population(35) and argues 
against primary renal fluid retention. As expected in this nondiabetic population, 
plasma glucose concentrations and HbA1c levels did not change after rosiglitazone 
treatment. Consequently, our data on natriuresis have not been confounded 
by diuretic effects of changes in glucosuria as a result of the intervention with 
rosiglitazone. In theory, the slightly lower blood pressure during rosiglitazone 
treatment could have affected the natriuretic response to furosemide and 
amiloride. However, the lowering in blood pressure was mild, and well within the 
range of autoregulation; we therefore assume this did not influence our results. 
Finally, anaemia was more common in rosiglitazone-treated subjects, which may 
be compatible with the presence of some fluid retention in these individuals. 
In conclusion, the results of this study in insulin-resistant nondiabetic subjects 
challenge the concept that, in humans, thiazolidinediones by themselves reduce 
the diuretic response to furosemide. The lack of any effect of rosiglitazone on the 
diuretic response to amiloride and on the ENaC abundance in urinary exosomes, 
argues against an effect of thiazolidinediones on ENaCs in the renal collecting 
duct.
Methods
Subjects
The study population consisted of 13 nondiabetic subjects and was characterized 
by two features of the metabolic syndrome (American Heart Association/National 
Heart, Lung, and Blood Institute (AHA/NHLBI) criteria)(36). Their age ranged 
from 30 to 70 years. Diabetes was excluded because the expected reduction of 
glucosuria as a result of rosiglitazone would have seriously confounded our results 
on natriuresis and diuresis. Nonetheless, we tried to get as close as possible to 
the target population for thiazolidinedione treatment, and therefore we selected 
insulin-resistant subjects who had not developed diabetes.
Subjects were not eligible for inclusion if fasting glucose was >7.0 mmol/L, 
they used hypoglycaemic agents, had a documented significant hypersensitivity 
to a peroxisome proliferator-activated receptor-g agonist, or were simultaneously 
participating in another study. Additional exclusion criteria were clinically 
significant liver disease or anaemia, angina or heart failure (New York Heart 
Association classification I-IV); calculated creatinine clearance below 40 ml/min; 
abuse of alcohol, liquorice or drugs; and pregnancy or lactation. Study participants 
were selected by advertisement, and each gave written informed consent. Subjects 
who participated in this study received  financial compensation. The study 
protocol was approved by the hospital ethics committee, was in accordance with 
the declaration of Helsinki, was registered at clinical trials.gov (NCT00285805) 
and performed according to Good Clinical Practice guidelines.
Study design
This was a randomized, placebo-controlled, double-blind, single-centre, 
crossover study  comparing rosiglitazone 4 mg b.i.d. with placebo for 9-week 
treatment periods (washout period, 4 weeks). The medication used in the study 
was provided by GlaxoSmithKline (Brentford, United Kingdom). Randomization 
of the treatment sequence was computer-generated, with a sequentially driven 
allocation. Randomization and blinding were performed at the department of 
Clinical Pharmacy of Radboud University Nijmegen Medical Centre. In both 
treatment periods, the end-point experiments were performed with furosemide 
and amiloride at the end of weeks 8 and 9, respectively. During all the visits (week 
0, 4, 8, 9) of each period, adverse events and compliance with treatment regimen 
(assessed by counting tablets) were recorded. In addition, physical examination, 
foot-volume and bioimpedance measurements were performed and safety-
related biochemical and hematological profiles were determined. Only at start 
and at 8 weeks in each period, glucose, insulin and HbA1c levels measured. All 
visits and interventions were performed at the Clinical Research Centre of the 
Radboud University Nijmegen Medical Centre. 
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Furosemide end-point experiment 
Each participant visited the hospital at 8 a.m. after an overnight fast and having 
abstained from consumption of alcohol and caffeine for 20 hours, for 24-hour 
urine collection and the morning urine collection. On the three previous days 
each participant had to adhere to an individualized diet containing 150 mmol of 
sodium and 80 mmol of potassium prescribed by a dietician(24). First, blood was 
collected to measure fasting glucose and insulin concentrations. Next, each subject 
was given an individualized breakfast along with one cup of water. Afterward, a 
brachial vein was cannulated and connected to a Braun infusion pump (B. Braun 
Medical, Sheffield, UK)(10 ml/hr NaCl 0.9%), and blood samples were drawn 
for safety and vascular hormone measurements (levels of aldosterone, atrial 
natriuretic peptide, brain natriuretic peptide, vascular endothelial growth factor 
and renin).
A bolus of 40 mg furosemide (Centrafarm, Etten-Leur, the Netherlands) was 
injected through a small cannule in a vein of the contra-lateral arm, immediately 
after emptying of the bladder. Venous blood samples were drawn at 0, 15, 30, 
45, 60, 90,120, 150, 180, 240, 300, 360, 420 and 480 minutes after bolus injection 
to measure  furosemide concentrations in plasma. The participants were asked 
to urinate regularly, at least once every hour. The exact time of voiding and the 
urine volume passed were recorded. After each voiding, the urine was separated 
into two samples. In one sample, sodium and creatinine concentrations were 
measured while the other sample was light-protected and immediately frozen 
for measurement of furosemide concentrations later on. To prevent dehydration 
each participant had to drink tap water equal in volume of diuresis in the 
previous hour(24). During the test, the participant was in a sitting position on a 
bed. At noon, the participant was offered an individualized lunch. After 8 hours, 
each participant left the hospital with instructions regarding adherence to the 
prescribed diet but without restrictions on fluid intake. They were asked to collect 
their urine for up to 24 hours after the start of the experiment. 
Amiloride end-point experiment 
The initial setup for the amiloride experiment resembled the furosemide 
experiment. Until amiloride infusion, the procedures were similar. At time 
point 0, venous infusion of a loading dose of amiloride was started (150 μg/kg 
in 60 minutes) followed by maintenance infusion (0.20 μg/kg/min) for 4 hours. 
Amiloride (Duchefa pharma BV, Haarlem, The Netherlands) was obtained as 
a sterile powder which was dissolved directly before use in NaCl 0.9% up to a 
concentration of 1 mg/ml. The solution was filtered through a 0.22 μm Millipore 
filter (Millipore, Billerica, MA). For measuring  the concentration levels of 
amiloride in plasma, venous blood samples were drawn  at 60, 180, 300 and 
420 minutes. All the other procedures were similar to those in the furosemide 
experiment. 
Pharmacokinetic considerations related to amiloride dosage
According to the literature, after the oral intake of 10 or 20 mg amiloride, peak 
concentration levels in plasma are reached after 3 to 4 hours and measure 20 
μg/L(37) and 38-40 μg/L, respectively(38). These concentrations are well below the 
half-maximal inhibitory concentration (IC50) of amiloride for Na+/H+ and Na+/
Ca2+-transporters and for the α1-adrenergic receptor, but well above the IC50 for 
ENaC(39). Using the pharmacokinetic characteristics of amiloride(37), we calculated 
the required dosing schedule of amiloride infusion required to reach a steady-
state concentration between 30-45 μg/L.
Exosome extraction and quantification of α-ENaC
Urinary exosomes originate as the internal vesicles of multivesicular bodies and 
are delivered to the urine from all renal epithelial cell types. Exosomes contain a 
collection of cytosolic and apical plasma membrane proteins, including ENaCs 
from renal cortical collecting duct cells(32). ENaC is a heteromultimeric protein 
containing three homologous subunits (α, β, and γ)(14). Urinary exosomes 
were isolated by ultracentrifugation and α-ENaC abundance was measured by 
immunoblotting, as previously described(40, 41) and normalized to urine creatinine 
levels. Next, four µg of protein lysed in Laemmli buffer was loaded on 8% SDS-
PAGE. Gel electrophoresis, blotting, and blocking of the polyvinylidene difluoride 
membranes were carried out as previously described(40). The membrane was 
incubated with 1:4000-diluted affinity-purified rabbit α-ENaC antibody (kindly 
provided by BC Rossier, Lausanne, Switzerland), followed by 1:5,000-diluted goat 
anti-rabbit immunoglobulin G as secondary antibody coupled to horseradish 
peroxidase. Blotting signals were visualized using enhanced chemiluminescence 
(ECL, Pierce, Rockford, IL). The results were normalized for the expression level 
of α-ENaC during placebo treatment and calculated as percentages.
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Analytical methods
The concentration levels of furosemide and amiloride concentration in plasma 
and urine were measured using high-performance liquid chromatography(42,43). 
Plasma insulin was measured by a radioimmunoassay. HOMA was used to 
determine insulin resistance with the following formula: fasting plasma insulin 
(μU/ml) x fasting plasma glucose  (mmol/l)/22.5(44).
Plasma atrial natriuretic peptide was analyzed by radioimmunoassay (Euro 
diagnostica BV, Arnhem, The Netherlands), brain natriuretic peptide using a 
fluorescence method with a Triage Meter Plus (Biosite, San Diego, CA), renin 
by means of an immunoradiometric assay (Cis Bio International, Gif-sur-Yvette, 
France), aldosterone by radioimmunoassay, and vascular endothelial growth 
factor by enzyme-linked immunosorbent assay.
Bioimpedance and foot volume
During each visit, total body water and extracellular volume were assessed in 
all the participants using the Akern 2000 bioelectrical impedance analyzer(45) 
(Akern, Florence, Italy). Foot volume was assessed using the water-displacement 
method(46).
Data analysis
The study was powered (80%) to detect a rosiglitazone-induced increase in 
natriuretic response of 40 mmol/24hours during amiloride, or a rosiglitazone-
induced reduction of the half maximal response (ER50) in the furosemide 
excretion rate of 20 µgram/min. All statistical tests and confidence intervals were 
two-sided and the overall type I error was 5%. Descriptive statistics of population 
characteristics are presented as mean with standard deviation. Treatment effects 
are presented as mean with standard error; these were statistically analyzed by the 
paired Student’s t-test. The response was measured at the end of each treatment 
period, with the assumption that any carry-over effects from the previous 
treatment period would have been washed out. Responses to furosemide were 
evaluated by plotting the natriuretic response against the furosemide excretion 
rate. These furosemide excretion rate–response curves were analyzed according 
to a sigmoidal curve with variable slope by nonlinear regression using GraphPad 
Prism5.03 (GraphPad Software, San Diego, CA)(24). All statistical analyses were 
performed using the SPSS personal computer software package16.0 (SPSS, 
Chicago, IL).
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Abstract
Thiazolidinediones (TZDs) expand plasma volume, which can cause oedema 
and heart failure. The current assumption is that the increase in plasma volume is 
reflected by a decrease in haematocrit. However, this is only valid when the total red 
blood cell volume is constant and thiazolidinediones can influence erythropoiesis. 
We used data from two double-blind placebo-controlled randomized trials with 
insulin-resistant subjects and diabetic subjects treated with rosiglitazone for 12-
16 weeks to test this relationship. Plasma volume was measured directly by the 
dilution of 125I-labelled human albumin. Rosiglitazone increased plasma volume 
by approximately 9% (ratio: 1.09 ± 0.02; P < 0.001), and decreased haematocrit 
by approximately 5% (ratio: 0.95 ± 0.01; P < 0.001), but there was no correlation 
at all between the change in plasma volume and the change in haematocrit 
(r = 0.009; P = 0.96). Thus, the observed change in haematocrit during treatment 
with rosiglitazone does not reflect changes in plasma volume and implicates that 
the reduction in haematocrit observed during thiazolidinedione treatment is, 
at least partly, explained by a decrease in red blood cell volume. It also shows 
that measurement of haematocrit cannot be used to monitor plasma volume 
expansion in individuals on thiazolidinedione treatment.
Introduction
Treatment with thiazolidinediones (TZDs) is associated with fluid retention 
and plasma volume expansion(1-3). This important side effect can lead to oedema 
and heart failure and is one of the reasons for the limited risk benefit ratio for 
this class of drugs. The observed drop in haematocrit during thiazolidinedione 
treatment(4) is often attributed to plasma volume expansion and reported as 
a marker for fluid retention(5,6), but this has never undergone direct testing. 
Changes in haematocrit and plasma volume will only be correlated if total red 
blood cell volume remains constant(7). This may not necessarily be the case, 
as an in-vitro human cell study has shown suppression of erythroid-colony 
forming cells by troglitazone and pioglitazone(8). This notion is supported by a 
case report describing hypoerythropoetinemia due to rosiglitazone(9). Also, it 
has recently become clear that thiazolidinediones induce osteopenia, which is 
partly explained by bone marrow fat hyperplasia(10,11). So, the drop in haematocrit 
during thiazolidinedione treatment may be explained by a decreased red blood 
cell volume. This possibility is further supported by small drops in white blood 
cell counts observed during thiazolidinedione treatment(12) and by findings in 
older reports that gradual changes in plasma volume are not reflected at all by 
changes in haematocrit(7,13).
Plasma volume can be measured directly by dilutional methods, like 
measurement of the volume of distribution of radioactive iodinated 
albumin(2,3,14,15). The advantage of this technique is that the measurements are not 
confounded by changes in red blood cell production and/or degradation.
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Characteristics Study 1 Study 2
Rosiglitazone
n = 15
Rosiglitazone
n = 13
Placebo
n = 16
Male (%) 60 54 50
Age (year) 46 ± 8 57 ± 8 59 ± 10
BMI (kg/m2) 32 ± 3 29 ± 4 30 ± 7
Waist (cm) 109 ± 8 98 ± 10 103 ± 18
Systolic blood pressure (mmHg) 137 ± 10 129 ± 14 131 ± 16
Diastolic blood pressure (mmHg) 94 ± 4 79 ± 7 80 ± 8
Calculated creatinin clearance 96 ± 30 90 ± 16 85 ± 33
Duration of diabetes (years) 14.2 ± 7 14.2 ± 6
HbA1c (%) 5.5 ± 0.3 8.0 ± 1.3 8.2 ± 1.2
Insulin dose (U/day) 62 ± 46 72 ± 33
BMI: Body Mass Index
HDL: High Density Lipoprotein
HbA1c: Glycosylated haemoglobin
Endpoint Study 1 Study 2 Pooled analysis
Rosiglitazone Rosiglitazone Placebo Rosiglitazone
Plasma volume 1.09±0.03* 1.10± 0.02** 0.99±0.03 1.09±0.02#
Haematocrit 0.96±0.01* 0.94±0.02** 0.99±0.01 0.95±0.01#
Plasma albumin 0.99±0.01 0.98± 0.02 0.99±0.01 0.98±0.01
TBW 1.00 ±0.01 1.02± 0.01 1.01±0.01 1.01±0.01
* P < 0.05; **P < 0.01; #P < 0.001
MCV: Mean Corpuscular Volume
TBW: Total Body Water
 
Results
In this study we investigate whether changes in plasma haematocrit correlate 
to changes in directly measured plasma volume (125I-labelled human albumin) 
in individuals who were treated with rosiglitazone for at least 3 months in the 
context of two previously reported trials. In the first study, overweight, insulin-
resistant subjects with obvious features of the metabolic syndrome were included. 
Fifteen subjects had paired plasma volume measurements. One subject in this 
study developed moderate oedema during rosiglitazone treatment(2).
The second study consisted of 
insulin-treated patients with type 
2 diabetes who were additionally 
treated with rosiglitazone or placebo. 
In this study paired plasma volume 
measurements were obtained in 
thirteen patients in the rosiglitazone-
treated group and sixteen patients 
in the placebo-treated group. Here, 
oedema was more prevalent in the 
rosiglitazone group compared to 
placebo (63% vs. 24%, P < 0.05), but 
always mild(3). Baseline characteristics 
of the study populations are depicted in 
Table 1. Drug adherence, measured by 
tablet counting, was excellent in both 
studies and supported by expected 
effects of rosiglitazone on glycaemic 
control and blood pressure.
In both trials rosiglitazone increased 
plasma volume (Study 1: 223 ± 83 
ml/1.73 m2; Study 2: 248 ± 51 ml/1.73 
m2) and reduced haematocrit (Study 1: 
0.019 ± 0.006; Study 2: 0.021 ± 0.006), 
while placebo had no effect (Table 2). 
Rosiglitazone had no effect on plasma 
albumin concentration, total body 
water (TBW) or mean corpuscular 
volume (MCV) of the red blood cells. 
There was no correlation between the 
Table 1: Baseline characteristics of evaluable subjects and patients (means±SD)
Table 2: Treatment effect on endpoints in ratio (mean±SE)
Figure 1: Plots of correlation between change in 
plasma volume and either haematocrit (Panel A) or 
plasma albumin (Panel B) during treatment with 
rosiglitazone. Panel C: correlation between plasma 
volume and haematocrit in patients using placebo only. 
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change in plasma volume and haematocrit, neither in the pooled population of 
participants treated with rosiglitazone (r = 0.009; P = 0.96; Figure 1, panel A), nor 
in the split populations (insulin-resistant subjects: r = 0.14; P =0.61; diabetes: r 
= –0.008; P = 0.98). Interestingly, in patients treated with placebo, changes in 
haematocrit and plasma volume did seem to correlate (r = –0.46; P = 0.08. Figure 
1, panel C).
Discussion
The main finding of this pooled post-hoc analysis is that there is no correlation 
whatsoever between change in haematocrit and change in plasma volume during 
chronic treatment with rosiglitazone neither in subjects with insulin resistance 
nor in patients with diabetes. From a scientific point of view the uncoupling of 
haematocrit and plasma volume changes is important, as it suggests rosiglitazone 
has additional effects on top of plasma volume expansion, probably a reduction 
in total red blood cell volume. From a clinical point of view these findings suggest 
that changes in haematocrit, do not reflect fluid-related complications in an 
individual patient on chronic thiazolidinedione treatment.
The direct measurement of plasma volume by using 125I-labelled human 
albumin in combination with measurements of haematocrit in subjects on 
chronic treatment with rosiglitazone are rather unique features of this study. 
Only one other study has measured plasma volume with a direct method during 
thiazolidinedione treatment in human subjects. Young et al. used 131I-labelled 
human albumin to calculate plasma volume in 16 healthy subjects either 
treated with troglitazone 600 mg or placebo for 6 weeks in a parallel design(16). 
Troglitazone non-significantly expanded the plasma volume by 8% and did 
not change haematocrit. The study has, however, a relatively short treatment 
interval and a small sample size. Two other human studies, both from Berria et 
al., investigated the correlation between changes in haematocrit and body fluid 
compartments. In the first study, 50 patients with diabetes type 2 were treated 
with either placebo or pioglitazone (45 mg a day) for 16 weeks(17). Total body 
water and extracellular water but not plasma volume were measured using 3H20 
dilution and bio-impedance. Pioglitazone induced a significant weight increase 
mainly driven by an increase in fat mass. These authors did not observe an 
increase in TBW, decrease in haematocrit, nor a correlation (0.01) between both 
endpoints which is in agreement with our data. In the second study, subjects with 
the polycystic ovary syndrome were treated with pioglitazone which resulted in 
a fall in haematocrit without an increase in TBW, again suggesting that it is not 
haemodilution that drives the reduction in haematocrit(18). In these studies plasma 
volume was not directly measured and there was no reduction in haematocrit 
in the diabetes study. Recently, Li et. al. observed that in patients with type 2 
diabetes after interruption of pioglitazone treatment body weight decreased 
while haematocrit level did not change(19). Thus, a number of earlier observations 
support our current findings.
Theoretically, at least on the short run, one would expect that an increase in 
plasma volume would result in a decrease in haematocrit. Interestingly, there was 
a strong indication for such a relationship in the placebo-treated group. Therefore 
our data suggest that it is rosiglitazone in itself that disrupts this relationship in 
the individual patient. A potential explanation is that rosiglitazone changes either 
the total number of red blood cells or the mean size of the individual erythrocyte. 
This last suggestion can be rejected as MCV did not change. As mentioned before, 
thiazolidinediones have been found to suppress erythroid-colony forming cells 
in human in-vitro cell experiments(8), but in short clinical trials they did not alter 
erythrocyte production nor destruction(16, 20). To overcome potential confounding 
by influences on the red blood cell life cycle we analyzed in the present study 
whether changes in plasma albumin can be used as indirect marker for change in 
plasma volume. However, we did not find a correlation between these endpoints. 
The present study has weaknesses. Because the plasma volume calculations 
assume first order kinetics for injected human albumin, we excluded 
measurements in which there was a correlation coefficient of less than 0.8 
between extinction curve and time. However, also when all measurements 
were included, the results were unchanged. Second, this is a post-hoc analysis, 
although performed on predefined important endpoints. Finally, the present 
study only included rosiglitazone, but for a number of reasons, our results can 
be extrapolated to pioglitazone, as the effects on red blood cell production in 
in-vitro cell experiments have been described for pioglitazone(8). Furthermore, a 
previous joined consensus statement considered fluid retention to be a class effect 
of thiazolidinediones(21).
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In conclusion, we find no relationship between changes in haematocrit and 
changes in directly measured plasma volume in patients on thiazolidinedione 
treatment. These results implicate that haematocrit measurements are not useful 
for monitoring fluid-related complications during chronic thiazolidinedione 
treatment in an individual patient. They also suggest that thiazolidinediones have 
additional haematocrit lowering effects by interference with total red blood cell 
volume. 
Concise methods
Study design and population
The current analysis merged data from two randomized placebo-controlled 
trials, investigating the mechanism and risk factors of fluid retention during 
treatment with rosiglitazone. The first trial was a crossover study in which 18 
insulin-resistant subjects were treated with rosiglitazone 4 mg bd and placebo 
during 12 weeks(2) (No clinical trial registration as it was performed in 2003). 
The second, more recently published trial(3) (NCT00422955) had a parallel design 
and included 40 patients with diabetes type 2 treated with either rosiglitazone 
4 mg bd or placebo for 16 weeks. As per inclusion, 16 subjects in this trial had 
autonomic neuropathy. Both study protocols were approved by the hospital 
ethics committee, in accordance with the declaration of Helsinki, and performed 
according to Good Clinical Practice.
Endpoint procedures
Plasma volume, haematocrit and Total Body Water (TBW) were measured in the 
morning, starting at 8.00 a.m. in a quiet temperature-controlled room (23-24oC). 
TBW was assessed using the Akern 2000 bioelectrical impedance analyzer(22) 
(Akern, Florence, Italy) with the patient in supine position. A 20-gauge catheter 
(Angiocath, Becton Dickinson) was inserted into the left brachial artery under 
local anaesthesia (0.3-0.4 ml lidocaine HCl 20mg/ml, Braun AG, Melsungen, 
Germany), and connected with an arterial pressure monitoring line and kept 
patent with heparin in saline 0.9% (2 U/ml; 3 ml/h) (NaCl 0.9%, Baxter, Utrecht; 
heparin, Leo Pharma, Ballerup, Denmark). Blood was drawn for measurement of 
haematocrit, parameters of glycaemic control and safety parameters. 
An additional venous needle (BD Valu-set, 0.6 x 20 mm, Becton Dickinson) 
was inserted and 2-4 μCi 125I-albumin (Shering Nederland BV, Weesp, the 
Netherlands) was given as an intravenous bolus injection. Over the next 
60 minutes, seven plasma samples were collected from the arterial line for 
radioactivity measurements.
Calculations
To assess plasma volume the measured radioactivity (counts per minute, cpm) was 
plotted over time. An extinction curve was drawn assuming first order kinetics. 
Slope and the extrapolated peak plasma concentration at t = 0 were calculated 
using Excel. Plasma volume was calculated using the following formula(2, 3, 23): 
Plasma volume (ml)/1.73m2 = [cpm injected/cpm t=0/ml] /surface(m2)/1.73m2
To assure reliable results, calculated plasma volume was excluded from 
analysis when the correlation coefficient between the extinction curve and the 
actual measured time points was below 80%.
Statistical analysis
We used the paired student t-test or Wilcoxon rank test, if appropriate, to 
calculate statistical significances. Correlations were calculated using Pearson’s or 
Spearman’s correlation tests. Descriptive statistics of population characteristics 
are presented as mean with standard deviation. Treatment effects are presented as 
mean with standard error. All significance tests are two-sided with a Type I error 
of 5%. All statistical analyses were performed using the SPSS personal computer 
software package.
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Abstract
Aim/background: Autonomic neuropathy is a common complication of 
longstanding diabetes and leads to clinical manifestations in a variety of organ 
systems. Cardiovascular autonomic neuropathy (CAN) is an important form of 
diabetic autonomic neuropathy in clinical practice.  In this study we investigated 
whether the baseline sympathetic tone is changed in CAN and whether 
rosiglitazone can restore the expected blunted  response to orthostatic stress. 
Methods: We investigated  the forearm vasodilator response to infusion of the 
α -adrenergic receptor antagonist phentolamine into the brachial artery (baseline 
α -adrenergic tone) and the forearm vasoconstrictor response to sympathetic 
stimulation (Lower Body Negative Pressure,  LBNP) after either rosiglitazone 
4 mg twice daily or placebo. Data were derived from a previously performed 
randomized, double-blind, placebo-controlled study in 40 patients with type 2 
diabetes who were treated with insulin.
Results: In patients with CAN baseline phentolamine-induced flow, ie 
α-adrenergic tone, appeared to be intact (forearm blood flow  in CAN: 6.7 ± 
1.6 ml/dl/min; no CAN: 5.4 ± 0.7 ml/dl/min; P = 0.46), but the sympathetic 
responsiveness to LBNP was blunted (Change in diastolic blood pressure: no 
CAN: +2.1 ± 0.8 mmHg; CAN: -1.9 ± 1.8 mmHg, P < 0.05). Rosiglitazone did 
not affect baseline α-adrenergic tone, but improved the sympathetic response to 
LBNP (LBNP-induced change in forearm blood flow (P = 0.02): placebo week 0:
-0.95 ± 0.25 ml/dl/min, week 16: -0.25 ± 0.14 ml/dl/min; rosiglitazone week 
0:-0.41 ± 0.15 ml/dl/min, week 16: -0.51 ± 0.21 ml/dl/min).
Conclusion: The α-adrenergic tone is preserved in diabetic CAN. However, 
the sympathetic response to LBNP is blunted, but seems to improve after 16 
weeks treatment with rosiglitazone.
Introduction
Autonomic neuropathy is a frequent complication of longstanding diabetes and 
can result in dysfunction of several organ systems(1). Cardiovascular autonomic 
neuropathy (CAN) is probably the best studied entity of diabetic autonomic 
neuropathy. When assessed by noninvasive (Ewing) tests(2), the prevalence of 
CAN was over 20% in a referral population of type 2 diabetic patients in Europe(3). 
The clinical impact of CAN is high as it is associated with major cardiovascular 
events(4). In the ACCORD cardiovascular outcome study, the presence of CAN 
strongly predicted all-cause (hazard ratio 2.14) and cardiovascular disease (CVD) 
mortality (hazard ratio 2.62) independently of baseline CVD, diabetes duration, 
multiple traditional CVD risk factors and medication(5).
CAN is characterized by two main abnormalities: cardiac denervation and 
decreased efferent sympathetic nervous system response to orthostatic stress. 
Cardiac denervation results in resting tachycardia and exercise intolerance. 
The decreased efferent sympathetic nervous system response results in 
decreased vasoconstriction in the peripheral vascular bed leading to orthostatic 
hypotension(5). Although clinically important, CAN is a frequently overlooked 
complication of diabetes mellitus, and as a consequence many questions are 
unresolved. In this article we focus on two issues.
First, opposing results have been reported on the basal vascular sympathetic 
tone in patients with diabetes in general(6, 7). Baseline vascular sympathetic tone is 
relevant for understanding the potential consequences of CAN. 
Second, a blunted response to orthostatic stress is characteristic for autonomic 
neuropathy and trials have shown that tight glycaemic control induced by 
pancreas transplantation(8) or multifactorial intervention(9) is capable to 
improve autonomic neuropathy. Whether specific glucose lowering compounds 
can restore the blunted response to orthostatic stress is unknown. There is 
some evidence that PPAR-γ agonists may restore the autonomic imbalance in 
diabetes(10,11).
Recently, we studied rosiglitazone-induced vascular leakage in the context of 
autonomic neuropathy in patients with type 2 diabetes on insulin treatment(12). In 
a substudy, we assessed the responsiveness of the sympathetic nervous system in 
patients with and without autonomic neuropathy. This enabled us to investigate 
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whether baseline sympathetic tone (α-adrenergic tone) in patients with clinical 
diabetic autonomic neuropathy is decreased and whether rosiglitazone restores 
the expected blunted response to orthostatic stress.
 
Methods
Protocol
The study was a randomized, placebo-controlled, double-blind, single-centre, 
parallel study with 4 weeks of single-blind run-in (NCT00422955)(12). At 
screening, the Ewing score was determined in patients with type 2 diabetes to 
quantify cardiac autonomic neuropathy. The participants were divided into 
two groups, with either Ewing scores ≥2.5 (CAN) or <2.5 (no CAN). Details 
regarding general study protocol, study population and experimental day have 
been reported previously(12). In short: the study population consisted of 40 
insulin treated subjects with type 2 diabetes, who were treated with rosiglitazone 
or placebo for 16 weeks. Based on Ewing scores, 40% of the study population 
had autonomic neuropathy. At baseline and at the end of treatment sympathetic 
responsiveness was measured. The study was approved by the ethics committee 
and all participants gave written consent. The data presented here result from a 
substudy and have not been included in the earlier publication.
 
Experimental procedures
The procedures started at the clinical research center at 8.00 am with the subject 
in supine position after an overnight fast without taking insulin or oral blood 
glucose lowering pharmacotherapy in the morning. A venous catheter and 
subsequently an arterial catheter were inserted. After 30 minutes of equilibration 
time, baseline forearm blood flow (FBF) was measured simultaneously in the 
experimental and control arm by mercury-in-silastic strain-gauge venous 
occlusion plethysmography(13). The experimental forearm was subsequently used 
to assess the maximal forearm vasodilator response to intra-artrial infusion of 
the α-adrenergic receptor antagonist phentolamine into the brachial artery. This 
vasodilator response is considered to reflect the baseline α-adrenergic tone of 
the forearm vascular bed(14). Phentolamine infusion was started in a dose of 15 
μg/min per 100 ml of forearm volume during 10 minutes (dose based on pilot 
experiments, data not shown ). FBF of the contra-lateral arm was used as a time-
control value so that systemic effects could be observed and vasoactive effects of 
intra arterial phentolamine could be expressed as a quotient of the experimental 
and control arm(15). FBF was expressed in ml/minute per 100 ml of forearm 
tissue. In addition, forearm vascular resistance (FVR) was calculated. These data 
are not shown but always resemble the results derived by using FBF. Arterial 
and venous blood samples were drawn for measurement of catecholamines 
levels. Subsequently, an equilibration period was included to allow FBF to return 
towards baseline levels. Then, the sympathetic nervous system was stimulated 
with orthostatic stress applied by Lower Body Negative Pressure (LBNP) (25 
mmHg)(16) for 15 minutes. Before and after LBNP, FBF was measured to quantify 
the forearm vasoconstrictor response to sympathetic stimulation (LBNP). 
Arterial and venous blood sampling was repeated to quantify the catecholamine 
response to LBNP.
Analytical methods
The samples were collected in pre-cooled 5ml lithium-heparin tubes on melting 
ice. Immediately after collection, the blood was centrifuged (10 minutes at 
1500g, 4oC) and plasma was stored at -70oC. Noradrenaline and adrenaline 
were analyzed with high performance liquid chromatography (HPLC) with 
fluorometric detection(17). 
Circulating noradrenaline is a function of the amount of adrenergic 
neurotransmitter that is released from nerve terminals with a small contribution 
of the adrenal medulla, clearance in the sympathetic cleft and in the plasma 
compartment(18). Noradrenaline appearance rate can be calculated from arterial 
(a) and venous (v) noradrenaline concentrations and reflects the changes in 
noradrenaline release in the sympathetic cleft(19), especially during LBNP(16). 
Noradrenaline appearance rate can be estimated by infusion of titriated 
noradrenaline to assess local noradrenaline clearance. Under the assumption 
that the extraction of noradrenaline is similar to that of adrenaline, we used 
the extraction of adrenaline as a substitute for noradrenaline extraction(20). We 
calculated forearm noradrenaline (NA) appearance rate (AR) as follows:
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AR=NA spillover/ 1-FEA
NAspillover = (1-Ht) x FBF x ([NA]v-[NA]a+[NA]a x FEA)
FEA=[A]a-[A]v/[A]a
FEA: fractional extraction of adrenaline. Ht: haematocrit. A: adrenaline
Statistical analysis
The groups were balanced for gender and Ewing score and all patients with 
paired-observations were included in the analyses. The difference between both 
Ewing score groups and treatment was estimated with t-tests for independent 
samples or nonparametric tests where applicable. The effect of sympathetic 
stimuli in the total population was estimated with paired t-tests or where 
applicable nonparametric tests. All statistical tests were two-sided and the overall 
Type I error was 5%. Treatment effects are presented as mean ± standard error. 
All statistical analyses were performed using the SPSS software package.
 
Results
Characteristics of study participants 
A total of 40 insulin-treated patients with diabetes participated in the study. 
Sixteen participants were classified with Ewing scores ≥ 2.5, while 24 participants 
had a Ewing score <2.5. Participants classified having CAN appeared to have a 
higher BMI (Table 1). 
In 36 participants we were able to assess baseline activity of the sympathetic 
nervous system (Figure 1). In total 39 participants (placebo: 21; rosiglitazone: 
18) finished the treatment period of the study. Some reported mild side effects, 
including oedema. One patient in the rosiglitazone group was withdrawn after 
8 weeks because of atrial fibrillation and heart failure. Drug adherence was 
measured by tablet counting and appeared to be excellent(12).
 
Total Population No CAN CAN
Rosiglitazone Placebo No CAN CAN Rosiglitazone Placebo Rosiglitazone Placebo
n = 19 n = 21 n = 24 n = 16 n = 11 n = 13 n = 8 n = 8
Age (years) 58 (8) 59 (10) 59 (8) 58 (10) 58  (9) 60 (8) 59 (6) 57 (13)
Male (%) 58 57 63 50 64 62 50 50
BMI (kg/m2) 29 (4) 29 (6) 28 (4) 31 (6)a 28 (4) 27 (5) 30 (3) 32 (8)
Waist (cm) 101 (10) 101 (17) 97 (13) 105 (14) 98 (10) 97 (15) 104 (9) 107 (19)
SBP (mmHg) 132 (15) 132 (15) 132(12) 132 (18) 131 (13) 133 (13) 133(19) 131 (19)
DBP (mmHg) 80 (6) 80 (7) 80 (6) 80 (7) 80 (4) 80 (8) 79 (8) 80 (6)
Heart rate 
(1/min) 73 (10) 75 (11)
73 (12) 76 (7) 70 (10) 75 (13) 77 (7) 75 (8)
Duration of 
DM (years) 12.8 (7.8) 14.1 (5.7)
13.1 (6.9) 14.0 (6.5) 11.2(8.0) 14.6 (5.8) 14.9 (7.4) 13.1 (5.9)
HbA1c (%) 7.7 (1.4) 8.1 (1.1) 7.7 (1.2) 8.3 (1.3) 7.5(1.3) 7.8 (1.0) 8.0  (1.4) 8.6 (1.1)
Insulin dose 
(U/day) 60 (40) 64 (33)
58 (28) 69 (45) 57 (24) 58 (32) 64 (56) 74 (34)
Ewing score 2.1 (1.3) 1.7 (0.9) 1.2(0.6) 3.0 (0.8)b 1.2 (0.6) 1.1 (0.6) 3.3 (0.9)c 2.7(0.5)d
CAN  Cardiovascular Autonomic Neuropathy
BP:  Diastolic Blood Pressure
SBP: Systolic Blood Pressure
a P < 0.05 vs. no CAN
b P < 0.001 vs. no CAN
c P < 0.05 vs. Rosiglitazone, no CAN
d P < 0.05 vs. Placebo, no CAN
 
Table 1: Baseline characteristics, mean (SD).
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Baseline sympathetic nervous system activity
At baseline, sympathetic nervous system activity, expressed as noradrenaline 
appearance rate, was significantly higher in patients with CAN (see Figure 2. Left 
top panel). In response to phentolamine, FBF ratio (experimental arm/control 
arm), representing baseline α-adrenergic tone, increased significantly (from 
1.02 ± 0.05, to 3.60 ± 0.37, P < 0.001). While numerically higher, the vasodilator 
response to intra-arterial infusion of phentolamine was not significantly different 
in patients with and without CAN either when expressed in relative or in absolute 
numbers (ratio FBF experimental/ control arm: CAN 3.87 ± 0.38; no CAN 3.25 
± 0.33; absolute increase in flow in the experimental arm: CAN: 6.7 ± 1.6 ml/dl/
min; no CAN: 5.4 ± 0.7 ml/dl/min; Table 2; Figure 2).
Parameter No CAN CAN P-value
Baseline Noradrenaline Appearance rate 
(pmol/min/dl forearm tissue)
6.83 ± 2.66 6.90 ± 0.78 0.008
Phentolamine FBF ratio (E/C) 3.25 ± 0.33 3.87 ± 0.38 0.23 
Phentolamine FBF (absolute increase) 5.38 ± 0.72 6.69 ± 1.57 0.46 
LBNP Δ Noradrenaline Appearance rate 
(pmol/min/dl forearm tissue)
6.05 ± 1.39 2.17 ± 1.33 0.07 
LBNP Δ DBP (mmHg) 2.2 ± 0.7 -1.4 ± 1.6 0.03
LBNP Δ FBF (ml/dl/min) -0.89 ± 0.20 -0.37 ± 0.20 0.08 
CAN: Cardiovascular Autonomic Neuropathy
DBP: Diastolic Blood Pressure
E/C: experimental arm/control arm
FBF: Forearm Blood Flow
LBNP: Lower Body Negative Pressure
Sympathetic response to LBNP
As expected, sympathetic nervous system stimulation by LBNP induced a 
significant increase in the global sympathetic response (noradrenaline appearance 
rate increased from 7.0 ± 1.8 to 11.6 ± 2.4 pmol/min/dl forearm tissue; P < 0.001) 
Figure 1: Enrolment of study participants.
* The response to phentolamine was not measured due to mastectomy with lymph node dissection 
in their history (n = 3) and because of a backache-induced haemodynamic collapse just before 
phentolamine-infusion (n = 1).
**The response to LBNP was not measured due to a mild haemodynamic collapse (n = 3) during LBNP  
and because of a backache-induced haemodynamic collapse just before LBNP (n = 1).
***During rosiglitazone-treatment the response to phentolamine could not be measured in one 
additional subject due to cannulation failure.
****During placebo-treatment the response to LBNP could not be measured in one additional subject 
again due to backache-induced haemodynamic collapse during LBNP.
Excluded (n = 21):
• BP > 160/90 mmHg (n = 5)
• FPG < 7 mmol/l (n = 3)
• Diabetes type 1 (n = 2)
• Hepatic disease (n = 2)
• Renal insufficiency (n = 1)
• Beta-blocker use (n = 2)
• Alcohol abuse (n = 1)
• No autonomic neuropathy,
 while for balancing purpose  
 neuropathy was required 
 (n = 5)
Recruitment
Assessed for eligibility
(n = 61)
Withdrawal due to atrial 
fibrillation (n = 1),
discontinued  
rosiglitazone
Analysis: 
Phentolamine 
n = 18****
LBNP n = 18
Analysis: 
Phentolamine 
n = 15***
LBNP n = 16
Randomized
(n = 40)
Invasive neuropahy 
assessment:
phentolamine (n = 36)*
LBNP (n = 36)**
Table 2: Comparison of invasive autonomic function tests between subpopulations of autonomic 
function
Placebo: 
Phentolamine n = 19
LBNP n = 19
Rosiglitazone: 
Phentolamine n = 17
LBNP n = 17
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and a significant decrease in the forearm blood flow (FBF in the experimental 
arm before LBNP: 2.81 ± 0.24 ml/dl/min; after LBNP: 2.13 ± 0.16 ml/dl/min, P < 
0.001). LBNP did not change diastolic blood pressure.
In the subset of patients with CAN, the sympathetic response to LBNP was 
diminished as documented by a reversal of the diastolic blood pressure response. 
Furthermore, we observed a trend towards a blunted response in forearm 
vasoconstriction and noradrenaline appearance rate (Table 2; Figure 2).
Effects of rosiglitazone
Compared to placebo, the forearm vasoconstrictor response to LBNP was 
stronger during rosiglitazone treatment (LBNP-induced change in FBF (P = 
0.02): placebo week 0: –0.95 ± 0.25 ml/dl/min, week 16: -0.25 ± 0.14 ml/dl/min; 
rosiglitazone week 0: -0.41 ± 0.15 ml/dl/min, week 16: -0.51 ± 0.21 ml/dl/min), 
but did not affect baseline activity of the sympathetic nervous system, neither at 
the hormonal nor at the functional level of the forearm vascular bed (Figure 3).
Discussion
There are two main findings in this study. First, in patients with cardiovascular 
autonomic neuropathy,  the baseline activity of the sympathetic nervous system 
is preserved while the response to orthostatic stress is diminished. Second, 
sympathetic responsiveness in this group was improved by rosiglitazone treatment.
The first conclusion is based on the preserved response to phentolamine and on 
the fact that the baseline noradrenaline appearance rate is not reduced, but even 
increased in patients with CAN. The finding of an increased baseline activity is a 
new finding in the vascular bed, but to some extend in accordance with findings 
of Pop-Busui et al. who reported an increase in cardiac sympathetic tone in the 
early phase of CAN(21).
Figure 2:  Invasive autonomic neuropathy assessment with phentolamine-infusion disclosing 
the α-adrenergic tone and with lower body negative pressure (LBNP) measuring sympathetic 
responsiveness.
A) Baseline noradrenaline (NA) appearance rate (AR) in patients with cardiovascular autonomic 
neuropathy (CAN) is higher than in patients without CAN.
B) Phentolamine-infusion induced a clear increase in forearm blood flow (FBF) in the total population. 
There was no decreased response in subjects with CAN. 
C) Patients with CAN had an impaired increase in noradrenaline appearance rate during LBNP 
compared to those without CAN.
D) Change in diastolic blood pressure as a response to LBNP in the total population. There was no 
change in the total population, but a clear difference between patients with CAN and those without  
CAN. 
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Earlier reports from Hogikyan et al.(7) suggest that the response to 
phentolamine infusion in patients with type 2 diabetic without clinical signs of 
autonomic neuropathy is higher compared to non diabetic subjects which is 
consistent with an increase in α-adrenergic tone in patients with diabetes. As 
we only studied patients with diabetes, our results cannot be compared to this 
study. The finding of a preserved α-adrenergic tone in autonomic neuropathy 
seems to be paradoxical, but is in line with earlier observations from our group 
found in a population of individuals with autonomic failure due to spinal cord-
injury(22). A number of mechanisms may explain such a preserved α-adrenergic 
tone, including upregulation of α-adrenergic receptors.
The combination of a preserved baseline noradrenaline appearance rates and 
α-adrenergic tone and an impaired response to LBNP, suggests that at baseline, 
the sympathetic nervous system is intact, but at the cost of an increased basal 
α-adrenergic tone. In response to sympathetic stress, however, the responsiveness 
is decreased.
The second main finding of our study is the suggestion that rosiglitazone 
compared to placebo enhances the forearm vasoconstrictor response to LBNP. 
This effect may theoretically be explained by improved glycaemic control. Indeed 
rosiglitazone decreased HbA1c compared to placebo, but there was no significant 
correlation between the change in HbA1c and the vasoconstrictor response to 
LBNP. Alternatively, rosiglitazone may affect CAN by influencing factors that are 
crucial in the pathophysiology of autonomic dysfunction such as reduction in 
leptin and/or TNF-α(23,24). The observed effect could be a class effect as also from 
pioglitazone a beneficial effect has been reported on cardiac autonomic regulation 
as quantified by heart rate variability(25).
A limitation of our study is that the sympathetic nervous system endpoints 
in the present study were not primary endpoints and hence the study was not 
powered on these. However,  they were originally prespecified secondary 
endpoints. We used a Ewing score without correction for age as there is no 
internationally accepted standard age correction for the Ewing score. In addition, 
we used a binominal division of the Ewing score instead of  the original division. 
Our study also has strengths, it provides a detailed quantification of 
sympathetic nervous system responsiveness in a clinically relevant population 
and tests the effect of a glucose lowering therapy.
In conclusion, in a population of insulin treated patients with type 2 diabetes 
and cardiac autonomic neuropathy, α-adrenergic tone is preserved, probably 
at the cost of maximal compensatory mechanisms with the consequence that 
the sympathetic responsiveness to an orthostatic stimulus fails. Rosiglitazone 
may have a beneficial effect on sympathetic responsiveness both in patients 
with and without autonomic neuropathy, which seems to be independent from 
improvements in glycaemic control.
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Figure 3:  
A) The influence of rosiglitazone compared to placebo on the phentolamine-induced change in forearm 
blood flow.
B) Individual forearm blood flow (FBF) response during LBNP (Lower Body Negative Pressure) before 
and after treatment with either rosiglitazone or placebo. Mean and standard error at each time point.
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Abstract
Aims: Cardiovascular disease is the leading cause of death in patients with 
type 2 diabetes due to both a high event rate and a worse outcome. Rosiglitazone 
and pioglitazone are registered for the treatment of hyperglycaemia. Animal 
data suggest that these drugs can protect against ischaemia-reperfusion injury 
by improving insulin responsiveness. A meta-analysis of clinical trials suggests 
that rosiglitazone increases the incidence of myocardial infarction. However, 
no human data on a possible benefit on infarct size are available. Therefore, 
we investigated whether rosiglitazone reduces ischaemia-reperfusion injury in 
humans with insulin resistance.
Methods and results: This is a randomized, double-blind, placebo-controlled 
crossover study with a washout period of 6 weeks comparing 8 weeks of treatment 
with rosiglitazone 4mg bd with placebo. We included 10 evaluable subjects with 
the metabolic syndrome. At the end of each treatment period, volunteers were 
subjected to 10 minutes of forearm ischaemia, combined with standardized 
intermittent handgripping. At reperfusion, 500MBq 99mTc-Annexin A5 was 
administered intravenously in the control arm. Annexin A5 uptake in the thenar 
muscle was quantified 1 and 4 hours post-reperfusion using a gamma camera to 
quantify ischaemia-reperfusion injury.
 
Results: Rosiglitazone reduced annexin targeting from 8.4% (median; range 
0.6-49%) to 4.7% (0.7-20%) at 1hour after reperfusion (P = 0.037) and from 7.4% 
(0.5-50%) to 4.8%  (-0.1-13%) at 4 hours of reperfusion (P = 0.06). There was no 
correlation between changes in glycaemic regulation and the changes in annexin 
targeting.
Conclusion: We present the first human in vivo data on the beneficial effects 
of rosiglitazone on ischaemia-reperfusion injury.
Introduction
Cardiovascular disease is one of the leading causes of death in patients with 
diabetes(1). This increased cardiovascular risk is the result of both an increased 
incidence of events(2), and a worse outcome of these events(3). In type 2 diabetes, 
there is evidence that ischaemic preconditioning is reduced(4) and ischaemia-
reperfusion (I/R) injury exaggerated(5). As such, a pharmacological intervention 
to reduce  I/R injury would be a valuable strategy to improve survival in diabetes. 
The thiazolidinedione derivative rosiglitazone activates the peroxisome 
proliferator-activated receptor-γ (PPAR-γ) thereby sensitizing insulin effects in 
type 2 diabetes. Recent data suggest that the therapeutic effects of PPAR-γ ligands 
reach beyond their use as insulin sensitizers(6). In the present study we will focus 
on the effect of rosiglitazone on I/R injury. 
Beneficial effects of rosiglitazone on I/R injury were observed in in vitro and 
in vivo preclinical studies, both after acute(7) or chronic(8) use. With respect to 
rosiglitazone’s insulin sensitizing effects, it is well known that insulin itself has 
anti-apoptotic properties in myocardial ischaemia-reperfusion(9). Therefore, 
the protective effects of rosiglitazone on I/R injury may be coupled to its insulin 
sensitizer properties. Indeed, in one study, the protective effect of rosiglitazone 
was more pronounced in insulin-resistant animals and was positively correlated 
with the improvement in insulin sensitization(10). 
Despite this mechanistic preclinical evidence for a beneficial effect of 
rosiglitazone on I/R injury, several epidemiological meta-analyses(11,12) showed an 
increase in myocardial events in patients treated with rosiglitazone, challenging 
whether the improvements in I/R injury could be translated to humans. In 
addition, it is obvious that an experimental approach to investigate ischaemia-
reperfusion injury in the human heart in vivo is limited by ethical and 
methodological restrictions. Therefore, we developed and validated a human in 
vivo model to quantify I/R injury in forearm skeletal muscle using annexin-A5 
scintigraphy(13). This forearm ischaemia-reperfusion model detects the loss of 
membrane asymmetry which results from increased phosphatidylserine (PS) 
exposure on the outer membrane leaflet. Phosphatidylserine exposition occurs 
shortly after an ischaemic insult. In addition to its diagnostic properties to 
detect early, reversible, signs of cell injury(14,15), annexin A5  may be a potential 
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therapeutic tool to reduce injury(16). By labeling recombinant annexin-A5 with 
Tc-99m, it is possible to visualize PS exposure by gamma camera imaging.  We 
have validated this model thoroughly by showing that well-known protective 
strategies like ischaemic preconditioning and adenosine are also protective in 
this model(13). 
In the present study, we used this human in vivo model of I/R injury to assess 
the effect of rosiglitazone treatment during 8 weeks on I/R injury in subjects 
with the metabolic syndrome, who by definition are characterized by insulin 
resistance. 
Methods
Subjects
A group of 13 non-diabetic subjects, characterized with the metabolic 
syndrome(17), aged between 30 and 70 years, was selected. Subjects were not 
eligible for inclusion if fasting glucose was higher than 7.0 mmol/L or if they 
used  hypoglycaemic agents, if they had exposure to a PPAR-γ agonist during 
the last 4 months or a documented significant hypersensitivity to a PPAR-γ 
agonist, if they were participant in another study, or if they were premenopausal. 
Additional exclusion criteria were clinical significant liver disease, anaemia, 
angina or heart failure, abnormal renal function, alcohol or drug abuse, physical 
inability to perform the exercise protocol and administration of any radiotracer 
for research purposes during the previous 5 years. Study participants were 
selected by advertisement, and gave written informed consent. Subjects who 
participated in this study received a financial compensation. The study complies 
with the Declaration of Helsinki and was performed according to Good Clinical 
Practice guidelines. Furthermore, this study was approved by the hospital ethics 
committee and registered at clinical trials.gov (NCT00405015).
Study design
This was a randomized, placebo-controlled, double-blind, single-centre, 
crossover study  with 6 weeks of wash out comparing placebo (GlaxoSmithKline, 
Brentford, United Kingdom) with rosiglitazone 4 mg (GlaxoSmithKline) twice 
daily during 8 weeks, which was chosen to be able to detect both acute and 
chronic effects of rosiglitazone. At randomization eligible subjects received a 
specific treatment sequence, either rosiglitazone-placebo or placebo-rosiglitazone. 
Block randomization and blinding was performed at the department of Clinical 
Pharmacy. At the end of each period, the primary end-point experiments were 
performed in the morning after a 24-hour abstinence from caffeine containing 
beverages and an overnight fast. All interventions and the scintigraphic imaging 
were performed at the Clinical Research Center Nijmegen (CRCN). 
One hour after ingestion of the last trial medication, injury in response to 
ischaemic hand gripping was measured using previously described experimental 
procedures(13,18). Immediately on reperfusion recombinant human annexin-A5 
labeled with Tc-99m (0.1mg; 400MBq) was administered intravenously. Both 
hands were imaged at 1 and 4 hours of reperfusion by using a gamma camera 
(Orbiter, Siemens Healthcare, Hoffman Estates, IL, USA) connected to a Hermes 
Gold image processing system (Hermes, Stockholm, Sweden). Recombinant 
human annexin-A5 was obtained from Theseus Imaging Corporation (Houston, 
Texas) and labeled with Tc-99m as described in detail previously(18). 
During all visits adverse events and pill compliance were recorded. In addition, 
physical examination was performed and safety chemical, haematological, and 
glycaemic profiles were determined. Participants were strictly advised to maintain 
their diet and not to change lifestyle throughout the study. 
Statistical analysis
A predefined region of interest was identified for each hand representing the 
thenar muscle. Within this region of interest radioactivity was expressed as counts 
per pixel. Annexin-A5 targeting after ischaemic exercise was calculated as the 
percentage difference in radioactivity between the experimental and control hand. 
To allow detection of at least 40% reduction in annexin targeting by rosiglitazone 
treatment with confidence on 5% level and power of 90% we calculated the 
sample size to be 9 subjects. A group of 13 subjects was selected to allow for some 
dropouts. Statistical analysis was performed with SPSS software. Descriptive 
statistics are presented as mean ±SD or median with the range for variables 
which were not distributed normally (Shapiro Wilk test <0.05). For the primary 
analysis we compared rosiglitazone with placebo using a distribution free analysis 
for paired observations (Wilcoxon) between the scintigraphic measurements at 
one and four hours after the ischaemic insult. The HOMA-index was used to 
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assess insulin resistance and calculated according to Matthews formula(19). For 
vital signs, safety parameters and parameters of glucose regulation the change 
during a treatment period was calculated. Treatment effect of rosiglitazone was 
defined as the difference between the changes in each period. 
 
Results
Subjects’ enrolment and flow through the study are represented in Figure 
1. The final statistical analysis on the primary endpoint was performed on 10 
subjects in whom a complete data set was obtained. Indeed, the selected subjects 
showed characteristics of the metabolic syndrome with insulin resistance as 
shown in Table 1. 
Adherence to the study drug was excellent during both treatment regimens 
(placebo: 98%, range 92-100%; rosiglitazone: 95%, range 88-100%). The subjects 
reported slightly more adverse events during rosiglitazone treatment (total 19 
events, 75% of subjects) in comparison with placebo (total: 13 events, 75% of 
subjects). All adverse events were mild and included headache, common cold, 
nausea and oedema. Two subjects reported oedema while using rosiglitazone, one 
during placebo treatment.
Ischaemia-reperfusion injury
Rosiglitazone reduced annexin-A5 targeting at 1 hour after the ischaemic exercise 
by 43% (median 8.4% (range 0.6-49%) versus 4.7% (range 0.7-20%); P = 0.037). 
At 4 hours after reperfusion, targeting was reduced by 35% (median: 7.4% (range 
0.5-50%) versus 4.8% (range -0.1-13%); P = 0.059) (Figure 2). There was no 
difference in workload (product of force (kg) and duration of exercise (seconds)) 
between the two ischaemic-exercise tests (rosiglitazone: 4049 ± 1981, placebo: 
3693 ± 1450 kg∙sec, P = 0.323). Annexin targeting during placebo treatment did 
not differ whether performed in period 1 or 2 (period 1:  median 11% (range 
(range 0.5-22%); period 2: median 8.3 % (range 1.3-49%); P = 0.91). 
Clinical effects of rosiglitazone
As expected rosiglitazone decreased haematocrit (Table 2) compared to placebo 
(rosiglitazone: -0.02 ± 0.01; placebo: 0.001 ± 0.02; P = 0.03). In addition, 
rosiglitazone tended to decrease diastolic blood pressure, fasting glucose and waist 
circumference, but none was statistically significant. Rosiglitazone did not change 
systolic blood pressure, body mass, Homeostasis Model Assessment (HOMA) 
index and plasma insulin (Table 3).
Figure 1: Enrolment of study participants.
Flow of subjects through the study.
Excluded (n = 20):
• Not reaching criteria 
 Metabolic Syndrome 
 (n = 16)
• FPG < 7 mmol/l (n = 2)
• Alcohol abuse (n = 1)
• Participant’s personal
 reason (n = 1)
Recruitment
Assessed for eligibility
(n = 33)
Withdrawal without 
complaints, on the 
advice of the general 
practitioner (n = 1)
Randomized
(n = 13)
Placebo - Rosiglitazone 
(n = 7)
Rosiglitazone - placebo 
(n = 6)
Primary analysis (n = 10)
One subject in each treatment group was excluded from the 
primary analysis due to petechia after the ischaemic insult in 
the second period
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Screening characteristics Mean (SD)
N=10 
Age (year) 56 (7)
Male (%) 60
BMI (kg/m2) 30.7 (4.6)
Systolic blood pressure (mmHg) 136 (17)
Diastolic blood pressure (mmHg) 84 (8)
Waist circumference (cm) 108 (12)
Plasma Triglycerides (mmol/L) 2.12 (0.59)
HDL-cholesterol (mmol/L) 1.25 (0.22)
Fasting plasma glucose (mmol/L) 5.2 (0.5)
HOMA-index 4.10 (2.14)
Medication
Statin 50%
SSRI 20%
BMI: Body Mass Index
HDL:  High Density Lipoprotein
HOMA:  Homeostasis Model Assessment
SSRI: Selective Serotonin Reuptake Inhibitors
Parameters of glycaemic regulation Baseline Mean (SD) Rosiglitazone Mean (SE)
Fasting plasma glucose (mmol/L) 5.5 (0.5) -0.3 (0.17)
Plasma insulin (mU/L) 16 (7) -1.3 (2.5)
HOMA index 4.10 (2.14) -0.52 (0.66)
The treatment effect of rosiglitazone was defined as the difference between the change during the rosiglitazone-
period minus the change during the placebo-period.
HOMA: Homeostasis Model Assessment
Discussion
The main finding of this study is that rosiglitazone is able to reduce annexin 
targeting after ischaemic exercise. As annexin targeting is considered to be 
an early marker of I/R injury, this study supports the view that the previously 
observed protective influence of rosiglitazone in animal models also holds for 
human in vivo conditions. 
This study was designed to translate preclinical animal data to humans. In 
comparison with the animal studies the daily dose in the present study was lower 
than was used in the rat (8mg/day versus up to 3 mg/kg/dag). The oral route of 
administration was also used by Yue et al. in the rat. In contrast to the animal study 
the endpoint in the present study was measured in skeletal muscle of the forearm 
and not in the heart for ethical reasons. Despite these differences in design, our 
results provide evidence in humans for the concept as developed in animals 
that rosiglitazone protects against the deleterious sequelae of ischaemia and 
reperfusion. The observed rosiglitazone-related reduction in annexin targeting 
was 43%. Differences in ischaemic challenge cannot explain this observations 
since workload did not differ between placebo and rosiglitazone treated 
individuals. In addition, our data are in line with the effect of other interventions 
in previous human studies with this model. Ischaemic preconditioning, and 
treatment with rosuvastatin, dipyridamole, or adenosine resulted in reductions 
Vital signs and  
safety parameters
Baseline
Mean (SD)
Rosiglitazone
Mean (SE)
Body mass (kg) 90 (17) 0.61 (0.74)
Systolic blood 
pressure (mmHg) 130 (12) -2.7 (4.4)
Diastolic blood 
pressure (mmHg) 82 (5) -5.0 (2.0)
Waist circumference 
(cm) 104 (12) 0.9 (1.6)
ALAT (U/L) 33 (19) -1.2 (3.6)
Haematocrit (1/L) 0.40  (0.03) -0.02  (0.01)
The treatment effect of rosiglitazone was defined 
as the difference between the change during 
rosiglitazone minus the change during placebo.
ALAT: Alanine aminotransferase
Table 1: Screening characteristics of 10 
evaluable subjects
Table 2: Therapeutic effect of rosiglitazone 
on vital signs en safety parameters. 
Table 3: Therapeutic effect of rosiglitazone on parameters of glycaemic regulation.
Figure 2: Therapeutic effect of rosiglitazone on annexin targeting.
Annexin-A5 targeting (expressed as percentage difference between experimental and control hand) 
in the thenar muscle at 1h (A) and 4h (B) after reperfusion at the end of either the rosiglitazone (o) or 
placebo (n) period).
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of annexin targeting of around 50%(13, 20,21). Since half of the participants of the 
present study were already on statin treatment, the additional protective effect 
of rosiglitazone is remarkable, and may suggest that the mechanism of action of 
the protective effects of rosiglitazone and statins do not interfere with each other.
After the meta-analysis performed by Nissen et al.(11) an intense scientific 
dispute started whether thiazolidinediones and particularly rosiglitazone, can 
protect against cardiovascular disease or are associated with an increased risk of 
ischaemic cardiovascular events accumulating with the recent publication of the 
final results of the RECORD study(22,23). Our results are not favouring any side in 
this dispute as we did not investigate the frequency of an ischaemic event but the 
size of injury after a standardized ischaemic insult. Extrapolating our observation 
to clinical practice would suggest that rosiglitazone reduces the infarct size at the 
moment of an event. Interestingly, this could be one of the mechanisms behind 
the finding that rosiglitazone did not increase mortality in conjunction with the 
elevation in myocardial ischaemic events seen in the meta-analyses by Nissen 
et al. and Singh et al. In addition, the RECORD study showed numerically less 
cardiovascular deaths in the group treated with rosiglitazone.
The main therapeutic objective of rosiglitazone treatment in type 2 diabetes 
is insulin sensitization. It is well known that insulin itself has anti-apoptotic 
properties in myocardial ischaemia-reperfusion(9) and in one animal study the 
improvement in insulin sensitivity was associated with the beneficial effect on 
I/R injury(10). However, with the current data we cannot proof this association. 
Our study was not powered for the endpoint “insulin sensitivity” and we did not 
measure this endpoint with the gold standard, a hyperinsulinaemia euglycaemic 
clamp procedure. Nevertheless, our data suggest that rosiglitazone has direct 
effects on I/R injury. Potential alternative mechanisms not directly affecting 
insulin sensitivity, could be upregulation of haem-oxygenase or NO-synthase. 
Recently, the protective effect of haem-oxygenase 1 upregulation in recurrent 
myocardial injury was shown(24). Furthermore, expression of haem-oxygenase 1 
in human vascular cells was shown to be regulated by PPAR-γ(25). With respect 
to NO-synthase, pioglitazone did not induce upregulation of NO-synthase in an 
animal I/R injury model(26). In line with this preclinical study we were not able 
to show increased insulin-induced NO-related vasodilation after treatment with 
rosiglitazone in a previous clinical study(27).
The reason we did not find significant changes in diastolic blood pressure, 
waist circumference and body weight was that this study was underpowered for 
these endpoints and the duration of the intervention was probably too short for 
significant changes in body composition. The rosiglitazone-related reduction 
of  haematocrit is a well known side effect of rosiglitazone therapy and supports 
adequate  compliance to  their study treatment.
Inherent drawbacks of the crossover design are carry-over effects. In this 
study there were two potential candidates for inducing carry-over: treatment 
with rosiglitazone and the ischaemic exercise test with annexin-A5 injection. We 
did not observe any difference in annexin targeting during placebo treatment in 
both periods making a carry-over unlikely. 
In this study we did not include subjects with diabetes to overcome 
confounding by a rosiglitazone-mediated improvement of glycaemic control. 
Since the beneficial effect of rosiglitazone on I/R injury was supposed to be more 
pronounced in insulin-resistant than in healthy subjects we decided to include 
non-diabetic subjects with the metabolic syndrome without glucose intolerance. 
Insulin resistance is a mainstay of this syndrome and the clinical criteria for 
the metabolic syndrome are better defined than for insulin resistance. Indeed, 
the HOMA-index of these subjects at baseline indicated that they were insulin-
resistant. In addition, we included only male and postmenopausal female subjects 
because potential formation of antibodies against annexin-A5 could in theory 
interfere with placental function.
In conclusion, we present the first human in vivo data on the beneficial effects 
of rosiglitazone on ischaemia-reperfusion injury.
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Appendix: published version in the European Heart Journal
In animals, thiazolidinediones reduce ischaemia-reperfusion injury. A 
clinical meta-analysis  raised suspicion that rosiglitazone increases the incidence 
of myocardial infarction (Nissen et al. N Engl J Med 2007). However, human 
data on a possible benefit on infarct size (i.e. ischaemia-reperfusion injury) are 
not available. Therefore, we investigated the effect of rosiglitazone on ischaemia-
reperfusion injury in 10 insulin-resistant participants without hyperglycaemia. 
We used a thoroughly validated human in vivo model to quantify ischaemia-
reperfusion injury in skeletal muscle by annexin-A5-scintigraphy (Rongen et al. 
Circulation 2005). At the end of each treatment period (rosiglitazone 4mg b.d. 
vs. placebo), the participants were subjected to 10 minutes of forearm ischaemia, 
combined with standardized intermittent handgripping. At reperfusion, 500MBq 
99mTc-annexin-A5 was administered intravenously. Annexin-uptake (counts 
per pixel) was measured in thenar muscle one hour post-reperfusion using a 
gamma camera. Ischaemia-reperfusion injury was quantified as the percentage 
difference in uptake between experimental and control side (annexin-targeting). 
Rosiglitazone reduced annexin-targeting from 8.4% (median; range 0.6-
49%) to 4.7% (0.7-20%) (P = 0.037). We present the first human in vivo data 
on the beneficial effects of rosiglitazone on ischaemia-reperfusion injury. This 
observation puts the disputed elevation in myocardial ischaemic events during 
rosiglitazone treatment  in perspective.
Panel A: Study design.
Panel B: Individual plots of the effects of 
rosiglitazone on 99mTc-annexin-targeting in 
insulin-resistant subjects.
Panel C: Typical 99mTc-annexin-uptake one 
hour after reperfusion at end of placebo 
period.  Left: control hand; right: post-
ischaemic hand. Counts increase from blue 
to yellow. 
Panel D: Same patient, but at the end of 
rosiglitazone treatment period.
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This thesis addresses important effects of the thiazolidinedione derivatives: 
negative effects on fluid retention and oedema formation, but also positive effects of 
thiazolidinediones on autonomic neuropathy and on ischaemic preconditioning. 
This chapter contains four parts. In the first part, the main findings of the 
performed studies are summarized. In part two an extensive updated literature 
review on the topic of thiazolidinedione-related fluid accumulation is presented, 
culminating in a proposed scheme, in which the results of the present studies 
are intertwined to data from the literature. During the years of this PhD project 
rosiglitazone became the subject of discussion, because of doubt around its 
cardiovascular safety. Therefore, rosiglitazone’s presumed cardiovascular unsafety 
is discussed in part three. Finally, future perspectives of PPAR-γ agonists and the 
importance of the presented studies with respect to newer hypoglycaemic agents 
are briefly outlined. 
Summary
Insulin induces vasodilation and increases capillary permeability. To determine 
whether thiazolidinedione-related fluid retention and oedema formation is based 
on amplification of these vascular effects of insulin (“insulin sensitization”), a 
randomized double-blind crossover study comparing rosiglitazone 4 mg b.i.d. and 
placebo was performed(1). The results are described in chapter 2. Rosiglitazone 
treatment increased insulin sensitivity, as measured by the hyperinsulinaemia 
euglycaemic clamp, but neither affected insulin-mediated vasodilation, nor 
the nitric oxide-dependent part of insulin-mediated vasodilation, nor vascular 
permeability. Nevertheless, thiazolidinediones may induce vasodilation as 
suggested by the fact that rosiglitazone caused a fall in diastolic blood pressure. 
As expected, rosiglitazone induced a rise in plasma volume of 255 ml/1.73 m2. 
The increase in foot volume during rosiglitazone treatment was correlated with 
the change in insulin-induced glucose uptake (insulin sensitivity). This implies 
that the stronger the effect on insulin sensitivity the more oedema was formed. 
These findings suggest that thiazolidinediones augment capillary recruitment, 
either structurally or functionally. This observation on capillary recruitment 
was recently confirmed by Gealekman et al. who found an increase in adipose 
capillary density during treatment with thiazolidinediones(2). In summary, our 
study suggests that the effects of thiazolidinediones are independent of insulin-
induced vasodilation and insulin-induced increases in capillary permeability. 
Assuming that vasodilation is at least one of the pathways leading to 
thiazolidinedione-related fluid retention, and with the notion that changes in 
vascular resistance would normally be counterbalanced by the autonomic nervous 
system, we explored whether autonomic neuropathy is a risk factor for oedema 
formation. This hypothesis was tested in a randomized double-blind parallel 
study comparing rosiglitazone 4 mg b.i.d. and placebo for 16 weeks in insulin-
treated patients with type 2 diabetes with and without autonomic neuropathy(3). 
As described in chapter 3, autonomic neuropathy indeed appeared to be a risk 
factor for thiazolidinedione-induced increases in vascular permeability, which 
may potentially lead to oedema formation. In contrast, autonomic neuropathy 
did not increase rosiglitazone-related fluid retention. We conclude that autonomic 
neuropathy should be considered a risk factor for thiazolidinedione-related 
oedema but not for fluid retention.
As described in chapter 1, thiazolidinedione-related fluid accumulation 
can be explained by primary renal sodium retention. The study described in 
chapter 4 was based on this renal hypothesis and aimed at determining whether 
thiazolidinediones induce resistance to the natriuretic response of loop diuretics. 
This hypothesis was tested in a double-blind placebo-controlled crossover 
study(4). The natriuretic response to amiloride and furosemide was measured, 
to detect rosiglitazone-induced upregulation of ENaC or furosemide resistance. 
We calculated furosemide excretion rate-response curves (analogous to dose-
response curves) for the individual subjects to compare furosemide’s natriuretic 
response during rosiglitazone and placebo in detail. We also measured the 
amount of ENaC excreted in exosomes in the urine as an assessment of renal 
ENaC expression. We did not find an increased natriuretic response to amiloride 
during rosiglitazone treatment and we did not find a higher amount of ENaC 
in the urine which argues against upregulation of ENaC both on a functional 
and molecular level. In addition, the furosemide dose response curves were not 
influenced by rosiglitazone treatment. We provide a number of explanations for 
the apparent discrepancy with the previous clinical observations of furosemide-
resistant oedema(5). Finally, the finding of normal pharmacodynamic responses to 
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furosemide combined with the previously observed furosemide-resistant oedema 
in clinical settings, may imply that thiazolidinedione-induced vasodilation is the 
key mechanism of thiazolidinedione-related oedema, analogously to oedema 
associated with calcium entry blocker treatment, in particular nifedipine(6,7), a drug 
which combines natriuresis and vasodilation. In conclusion, thiazolidinediones 
do not upregulate ENaC and do not induce resistance to loop diuretics and the 
clinical consequence of these findings is that thiazolidinedione-related fluid 
retention can be treated with diuretics.
It is clinically relevant to monitor for thiazolidinedione-related fluid 
accumulation. In chapter 5 we have described the relationship between changes in 
haematocrit and changes in plasma volume during rosiglitazone treatment, based 
on the studies described in chapter 2 and 3 where we measured plasma volume 
using a gold standard technique as well as haematocrit. In contrast to most views, 
we found no correlation whatsoever between change in haematocrit and change 
in plasma volume during chronic treatment with rosiglitazone neither in subjects 
with insulin resistance nor in patients with diabetes. From a pathophysiological 
point of view the nonrelationship between haematocrit and plasma volume 
changes suggests that thiazolidinediones, at least rosiglitazone, have additional 
effects on top of plasma volume expansion, such as lowering of total erythrocyte 
volume. The clinical implication of this uncoupling is that monitoring change in 
haematocrit cannot be used to detect fluid overload in an individual patient on 
chronic thiazolidinedione treatment.
An important topic in this thesis is diabetic autonomic neuropathy. In chapter 
6, we report on α-adrenergic tone and α-adrenergic responsiveness in insulin-
treated patients with type 2 diabetes with and without autonomic neuropathy. We 
found that in patients with cardiac autonomic neuropathy the α-adrenergic tone 
is preserved, while adrenergic responsiveness is diminished. The preservation of 
α-adrenergic tone in patients with cardiac autonomic neuropathy may be rather 
counter-intuitive, but is in line with previous findings from our group obtained in 
spinal cord-injured individuals(8). Moreover, we found that rosiglitazone enhanced 
the forearm vasoconstrictor response to lower body negative pressure, unrelated 
to the improvement in glycaemic control.
It had been hypothesized that thiazolidinediones were beneficial for ischaemic 
cardiovascular outcomes and that one of the hypothesized beneficial mechanisms 
was protection against ischaemia-reperfusion injury. Chapter 7 describes the 
results of a randomized double-blind placebo-controlled crossover study on the 
influence of rosiglitazone treatment on ischaemia-reperfusion injury, as measured 
with annexin A5 scintigraphy(9). Indeed, rosiglitazone reduced annexin targeting 
after ischaemic exercise, suggesting a protective effect on ischaemia-reperfusion 
injury in human in vivo conditions. 
Mechanisms of action of thiazolidinedione-related fluid  
accumulation
The previous section provides a summary of our findings on the mechanism 
of action, risk factors and treatment of thiazolidinedione-related fluid retention 
and oedema formation. In this part, these findings are put in perspective and 
integrated with the literature on this issue. This review follows the division by the 
potential mechanisms of action of fluid accumulation: cardiac, renal and vascular 
hypothesis. 
Cardiac hypothesis
Several clinical trials have studied echocardiographic changes in cardiac function 
during thiazolidinedione treatment. Compared to glibenclamide, rosiglitazone 
did not impair cardiac function in type 2 diabetic patients without heart failure 
(10). Neither pioglitazone(11,12) nor rosiglitazone(13) did reduce cardiac function in 
patients with pre-existing heart failure. Narang et al. found no differences in 
cardiac function as measured by cardiac Magnetic Resonance Imaging (MRI) 
between subjects, with and without rosiglitazone-related oedema(14). In one 
study, pioglitazone increased left ventricular end-diastolic volume and left–atrial 
end-systolic volumes, together with a borderline significant increase in ejection 
fraction(15). On the other hand pioglitazone has been shown to improve left 
ventricular diastolic function in subjects with essential hypertension(16). Taken 
together these results suggest that thiazolidinediones do not negatively influence 
cardiac function.
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Despite this, thiazolidinediones increase the risk of heart failure, as shown 
both in observational(17) and prospective clinical trials(18). The clinical trials 
were performed in a wide range of populations: pharmacotherapy-naïve type 
2 diabetic patients(21), patients inadequately controlled on sulfonylurea or 
metformin(22), patients without pre-existing evidence for cardiovascular disease 
or diabetes(20), and patients with established cardiovascular disease(19). In the last 
study the relative risk of heart failure events was 2.6. Additionally, an excess in 
heart failure deaths was found. Independent risk factors for thiazolidinedione-
associated heart failure were age, microalbuminuria, Body Mass Index (BMI) and 
systolic blood pressure(22). Thiazolidinedione-associated heart failure is suggested 
to be a milder form of heart failure as one retrospective cohort study reported 
lower mortality rates for patients with heart failure prescribed thiazolidinediones 
despite an increase in re-admissions for heart failure(23).
Following the introduction of rosiglitazone and pioglitazone, several case 
reports on weight gain and pulmonary oedema have been described(5,24-37). These 
reports provide a common profile of the subject prone to develop pulmonary 
oedema and the setting: roughly, thiazolidinediones can induce a sub-immediate 
(start of the adverse event, weeks to months after initiation of the drug), gradual 
volume overload, without haemodynamic compromise in patients on insulin 
treatment with either known renal failure or diastolic dysfunction(38).
Actually, all glucose-lowering therapies(39,40), but also poor glycaemic control(41) 
may increase the risk for heart failure. Of course, this notion complicates the 
exploration of the relation between thiazolidinediones and heart failure.
We did not investigate the cardiac hypothesis. Literature reports show that 
thiazolidinedione treatment is associated with a higher incidence of symptomatic 
heart failure with in general a milder clinical course, while thiazolidinediones 
have no negative influence on cardiac function and structure. An accepted 
explanation for this paradox is that heart failure becomes symptomatic due 
to thiazolidinedione-related fluid overload(14). There are cases of new onset 
heart failure in heart failure naïve patients and overt fluid overload after 
thiazolidinedione derivatives, but these are rare. 
Renal hypothesis
The fluid retaining properties of thiazolidinediones are found in many 
studies(1,42). Fluid accumulation in the body is always the consequence of either 
primary or secondary sodium retention in the kidney. In this paragraph, the 
literature on primary renal sodium retention is reviewed. Thiazolidinedione-
induced primary renal sodium retention could involve insulin-dependent en 
insulin-independent pathways.
Insulin has proven antinatriuretic properties both in diabetic patients(43) and in 
subjects without diabetes(44). As thiazolidinediones are insulin sensitizers, at least 
with regard to glucose regulation, one may hypothesize that thiazolidinediones 
also amplify the renal actions of insulin. The mechanism of insulin’s antinatriuretic 
effect seems to be a modulation of tubular sodium transport(45) but the exact 
anatomic location is not fully clear(45,46). Insulin binds to the basolateral renal 
cortical membrane and has the highest binding density in the distal convolute 
and the thick ascending limb(47).
Insulin-independent pathways of thiazolidinedione-related sodium 
retention could theoretically be related to alterations in renal haemodynamics 
or to modification of the tubular sodium transport. Preclinical(48) and human 
studies(49) have found neither changes in glomerular filtration rate nor in 
renal blood flow during thiazolidinedione treatment, despite clear sodium 
retention, together supporting an effect of thiazolidinediones on tubular sodium 
reabsorption. PPAR-γ is expressed in several parts of the kidney, especially in 
the medullary collecting duct, but also in the proximal tubules, glomeruli and 
microvasculature(50) and therefore both the proximal tubules and the distal 
nephron could be involved in thiazolidinedione-induced tubular sodium 
retention. Although several reports favour modification of proximal salt handling, 
such as reduction of lithium clearance(49), increments in protein levels of subunits 
of sodium channels and aquaporins from proximal sites(51), and elevation of 
bicarbonate-coupled proximal sodium transport(52), many studies have suggested 
that thiazolidinedione-related renal sodium retention is caused by epithelial 
sodium channel (ENaC) upregulation in the distal nephron. Key publications 
in this field were Zhang et al(53) and Guan et al.(54) demonstrating upregulation 
of ENaC by rosiglitazone and pioglitazone. Both groups showed that increases in 
weight, plasma volume, and urinary sodium excretion during thiazolidinedione 
treatment did not occur in PPAR-γ knockout mice. Guan et al. also showed that 
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amiloride was able to prevent weight and water increase in wild-type mice. On 
the other hand, neither Chen et al.(55) using amiloride for direct ENaC inhibition, 
nor Vallon et al.(56) using a collecting-duct specific gene inactivation of ENaC, 
were able to reduce thiazolidinedione-induced oedema. Furthermore, Chen did 
not find evidence for changes in renal expression of ENaC in vivo, and, in another 
report, PPAR-γ agonists failed to enhance sodium transport in collecting duct 
cell lines(57). Our human in vivo study(4) provided in vivo data on the importance 
of ENaC in thiazolidinedione-induced sodium retention in the human situation. 
As we observed neither functional nor molecular effects of rosiglitazone on renal 
ENaC, we in a way rehabilitated the view as hypothesized by Vallon that instead 
of ENaC, the amiloride-sensitive non-selective cation-channels in the medullary 
collecting duct may be critical in thiazolidinedione-induced sodium retention.
In summary, there is evidence that thiazolidinediones increase renal sodium 
reabsorption through direct pathways, but the exact mechanism and the site 
in the kidney and the exact transporter remains unclear. Moreover, the precise 
contribution of thiazolidinedione-related primary renal sodium reabsorption to 
body fluid retention and weight gain is probably limited, because a primary renal 
mechanism in itself is not compatible with the robust blood pressure lowering 
actions of thiazolidinediones(58). Therefore, direct thiazolidinedione-induced 
renal sodium retention is probably an additional mechanism.
Vascular hypothesis
The key mechanism in the vascular hypothesis is arterial vasodilation resulting in 
both blood pressure reduction and oedema formation. In this hypothesis, renal 
sodium retention is a secondary phenomenon. Direct evidence comes from a 
study by Shargorodsky  et al.(59) showing lower systemic vascular resistance in 
subjects using rosiglitazone. In line with these findings, we found a non-significant 
reduction in systemic vascular resistance during treatment with rosiglitazone(1). 
Zanchi et al.(49) observed an increased plasma renin activity, and a reduced 
urinary sodium excretion and lithium clearance during pioglitazone treatment, 
supporting secondary sodium retention. Basu et al.(42) found higher day time 
heart rate during pioglitazone treatment. The results of Zanchi and Basu  may 
point to  sympathetically driven activation of the renin-angiotensin-aldosterone 
system (RAAS). In line with these findings, we observed that diabetic patients 
with autonomic neuropathy treated with rosiglitazone seemed to be protected 
against fluid overload(3).
It is important to note that thiazolidinedione-related oedema formation is a 
common adverse event (up to 16%) and most prevalent when thiazolidinediones 
are combined with insulin therapy(60). PPAR-γ expression is common in the 
vascular system on several levels, for instance endothelial cells(61) and monocytes/
macrophages(62). Finally, thiazolidinediones are proposed to induce oedema both 
directly and indirectly (insulin) through several vascular mechanisms. In the next 
paragraph we summarize these mechanisms, starting with insulin-dependent 
pathways.
Insulin has vasodilator actions(63) which are diminished in case of insulin 
resistance(1,64). Several mechanisms to explain insulin-induced vasodilation have 
been proposed and proven, such as sympathetic activation(63, 65, 66), nitric oxide 
(NO) release(67,68), the activation of calcium-dependent potassium channels(69), 
and the stimulation of Na+-K+ ATP- ase(70). An argument for the role of the 
sympathetic nervous system in insulin-mediated oedema formation is the 
beneficial response to therapy with ephedrine, an α-adrenergic receptor agonist(71). 
Despite the strong evidence of insulin’s vasodilator actions, restoration of these 
vascular actions by thiazolidinediones is speculative. In our own study(1) we did 
not find proof for any effect of rosiglitazone on insulin-induced vasodilation or 
on the contribution of nitric oxide. In addition, there was also no evidence for 
upregulation of prostacycline mediated, calcium-activated potassium channel 
mediated or β-adrenergic mediated vasodilation (unpublished data). The absence 
of an effect on insulin-induced vasodilation are in agreement with findings with 
troglitazone in a previous report of our group(72). In some in vivo studies, insulin 
improved microvascular perfusion without evidence of increased total forearm 
blood flow, which is consistent with (functional) capillary recruitment(73,74) and 
was first observed in animals by Rattigan et al.(75). Recently, two reports showing a 
reduction in muscle insulin-induced glucose uptake in animals with a structural(76) 
or functional(77) reduction in capillary recruitment confirmed the concept of 
reduced capillary recruitment as a cause of muscle insulin resistance(78,79). In line 
with this concept it may be hypothesized that thiazolidinediones restore insulin’s 
ability to stimulate capillary recruitment. Circumstantial evidence for this view 
comes from our finding of a clear correlation between change in foot volume 
and glucose disposal during rosiglitazone treatment(1). Recently, another group 
observed that rosiglitazone increased adipose capillary density(2).
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In addition to insulin’s vasodilator actions, insulin also increases capillary 
permeability(80). Several mechanisms are proposed, including micropinocytosis(81) 
and activation of vascular endothelial growth factor (VEGF) production(82,83). In 
a situation of insulin-related oedema, leakage of albumin can lead to secondary 
hypoalbuminemia, which could potentiate oedema formation by reduction of 
the plasma oncotic pressure(84). Notwithstanding insulin’s actions on the capillary 
membrane, we could not find evidence for the hypothetical restoration of insulin’s 
capillary permeability during treatment with rosiglitazone(1).
Direct effects of thiazolidinediones have been described at several levels of the 
vascular system. With regard to vasodilation, Calnek et al. has observed increased 
NO production in endothelial cells after exposure to PPAR-γ ligands(85). In vivo 
studies, either preclinical(86) or clinical(87,88) have shown increased nitric oxide 
production during treatment with thiazolidinediones, but these studies do not 
prove that this effect is independent of insulin. Other proposed direct mechanisms 
to explain thiazolidinedione-induced vasodilation are decreased sympathetic 
activity(89), reduced endothelin-1 secretion(61), and anti-inflammatory effects 
reflected by lower levels of either plasma C-reactive protein(90) or tissue necrosis 
factor (TNF)-α(91).
Apart from haemodynamic actions, Idris et al. showed that rosiglitazone 
increases capillary permeability for macromolecules(92) in human endothelial 
cells. Some studies suggest that thiazolidinediones increase capillary permeability 
by elevation of VEGF(93,94). Conversely, several in vitro studies did show repression 
of VEGF production by thiazolidinediones(95,96). Another suggested explanation 
for thiazolidinedione-associated increase in permeability is activation of protein 
kinase C(97). Interestingly, in this study protein kinase C inhibition was able to 
prevent thiazolidinedione-induced oedema formation. Despite this mechanistic 
substantiation for thiazolidinedione-induced enhanced capillary permeability, 
our clinical study with insulin-treated diabetic patients found no effect of 
rosiglitazone itself on capillary permeability(3), which was in line with an animal 
study(98). Only in the subgroup of patients with autonomic neuropathy we found 
rosiglitazone to induce vascular leakage(3).
In summary, thiazolidinedione-induced vasodilation can explain the high 
incidence of oedema in combination with blood pressure reduction. There are 
data compatible with reflex activation of the sympathetic nervous and renin-
angiotensin-aldosterone system (RAAS) inducing renal sodium retention. Our 
own data could not confirm the hypothetical restoration of insulin-induced 
vasodilation or permeability by thiazolidinediones. Still, insulin sensitizing 
effects on capillary recruitment are likely to contribute to thiazolidinedione-
related oedema. 
Integrated framework of thiazolidinedione-related fluid accumulation
After having reviewed the literature and our own findings, we construct in this 
section our current view on the pathogenesis of thiazolidinedione-related fluid 
retention and oedema formation.
We think that the cause of thiazolidinedione-induced oedema formation, fluid 
retention and heart failure is multifactorial. This is a logical consequence of the 
notion that these clinical situations have some overlap but are not exchangeable. 
Figure 1 shows our hypothetical framework. The driving force for oedema 
formation, which is the most prevalent clinical outcome of thiazolidinedione-
related fluid accumulation, is of vascular origin. Either capillary recruitment, 
increments in vascular permeability or direct arterial vasodilation, could play 
a role. We refer arterial vasodilation sometimes as microvascular imbalance, 
since vasodilation will change the equilibrium of the Starling forces in favour 
of oedema formation. Primary renal sodium/fluid retention may contribute to 
some extent, but this is an additional mechanism. The fall in systemic blood 
pressure following arterial vasodilation will increase sympathetic tone and 
activate RAAS, which in turn induces secondary renal sodium/fluid retention. 
Sodium retention will sequentially increase plasma volume and microvascular 
perfusion pressure, fueling oedema formation. In a subset of patients, sodium 
retention and the sequential rise in plasma volume will unmask asymptomatic 
heart failure, that will subsequently increase sodium retention in the kidney and 
oedema formation.
We also include genetic predisposition for fluid retention in this scheme. 
About 8-20% of the population carries a polymorphism in the PPAR-γ protein 
(Pro12Ala) that reduces its ligand-induced activity(99). This polymorphism reduces 
the risk of thiazolidinedione-induced oedema(100) by pharmacodynamic and not 
physiological mechanisms. We did not include the finding that concomitant use 
of fenofibrate, a PPAR-α agonist, could protect against fluid retention(101), as this 
was only found in one small study, while several other studies with dual PPAR-
α/γ agonists(102,103) did not show a reduction in oedema formation.
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Implications for research and clinical care
At the time rosiglitazone and pioglitazone were approved for diabetes treatment 
it was expected that fluid accumulation was the Achilles heel of these drugs. 
Nowadays, there are two important arguments against this view. First, the 
primary pathway for fluid accumulation is from microvascular origin, leading to 
benign oedema formation. Second, other unwanted effects were finally the reason 
for restriction of prescription, namely doubt about cardiac safety and increased 
risk of bladder cancer in case of rosiglitazone(104) and pioglitazone(105) respectively. 
Regarding the mechanism of thiazolidinedione-related fluid accumulation 
Figure 1 provides a good starting point  to explain most clinical situations. We 
believe it is no longer appropriate to search for one pathway covering all cases of 
fluid accumulation. Indeed, this multifactorial scheme is the result of intensive 
research over the last decade. Obviously there remain areas of uncertainty, for 
instance, why some patients are more susceptible to develop serious pulmonary 
oedema. Perhaps, these cases can be explained by idiosyncratic drug-patient 
interactions. 
The recommendations for clinicians given in the 2003 consensus statement(106) 
of the American Heart Association in conjunction with the American Diabetes 
Association are still applicable, but based on the studies described in this thesis, 
three additional recommendations can be added. First, autonomic neuropathy 
is a risk factor for oedema formation(3). Second, monitoring haematocrit in 
the individual patient on thiazolidinedione treatment cannot detect fluid 
accumulation. Lastly, thiazolidinedione-treatment does not decrease the 
natriuretic response to loop diuretics and hence these agents can be used along 
with tapering of the thiazolidinedione dose to treat plasma volume overload(4).
While the exact pathogenesis and therapeutic approach towards 
thiazolidinedione-related fluid accumulation has not been solved, the studies 
described in this thesis have contributed to the knowledge regarding this clinical 
problem.
Rosiglitazone and cardiovascular safety
At the time of their introduction, the thiazolidinediones seemed promising 
regarding cardiovascular outcomes as they had beneficial effects on risk factors 
such as lipid profile, blood pressure, inflammatory markers and microalbuminuria. 
Meanwhile, cardiovascular outcome studies have provided more information. 
Pioglitazone seemed to redeem the expectations on cardiovascular benefit in 
the Proactive trial(14), and, although here the primary outcome parameter was 
not met, secondary outcomes were significantly better in patients treated with 
Figure 1: Proposed mechanisms leading to oedema formation, fluid retention and chronic heart failure 
during thiazolidinedione treatment. The shaded text in this Figure marks where this thesis adds new 
information.
The part of the scheme above the two braces represents the literature review of the effects of 
thiazolidinediones on renal and vascular processes. Thicker lines above the braces indicate more 
influence on fluid retention and oedema formation (at least in our view). The part under the braces 
visualizes the physiological consequences of the various factors that lead to the clinical conditions of 
fluid retention, oedema formation and heart failure. 
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pioglitazone instead of placebo. These results were confirmed in a meta-analysis 
a few years later(107). With  rosiglitazone, concerns regarding its cardiac safety, 
however, have eventual lead to withdrawal from the European market. In this 
paragraph the scientific proof for the cardiac (un)safety of rosiglitazone will be 
summarized.
The effect of rosiglitazone on cardiovascular outcomes has been debated 
extensively after the release of a meta-analysis by Nissen et al. in 2007(104). 
Following this publication, many reports have appeared on this topic: one 
randomized controlled trial (RCT), several meta-analyses, epidemiological 
studies, and post-hoc nonrandomized evaluations of RCTs. RECORD(22) was the 
only RCT that has investigated rosiglitazone’s safety on cardiovascular outcomes. 
While it met the non-inferior criteria for the combined cardiovascular endpoint, 
it could not proof that rosiglitazone did not increase myocardial infarction. The 
RECORD study also received severe criticisms regarding its open-label design 
and concerns about endpoint reporting(108).
The published meta-analyses show diverging results(109). In 2007 Nissen et 
al.(104) reported that rosiglitazone treatment was associated with a statistically 
significant increased risk for acute myocardial infarction (Hazard Ratio 1.43, 
p = 0.03) and a nonsignificant increased risk for cardiovascular death. Subsequently, 
Singh et al.(110) reported similar results. In contrast, 3 groups of independent 
researchers did not find a statistically significant increased risk for myocardial 
infarction with the use of rosiglitazone(111-113). In 2010 a second wave of meta-
analyses were published. The Federal Drug Agency (FDA), GlaxoSmithKline 
(GSK) and Nissen(114) updated their initial analyses. The updated FDA(115) and 
GSK(115) analyses were based on the same data sets, but used different statistical 
methods and reported a statistically significant increase in myocardial infarction 
(MI) of 80%, and a non-significant increase in MI of 41%, respectively.
Many epidemiological studies have tried to solve the dispute(116). The largest 
study included more than 200,000 Medicare beneficiaries over 65 years of age 
and compared rosiglitazone with pioglitazone(117). The results in this study were 
rather typical for the rest of the epidemiological data. Rosiglitazone yielded small 
increases in risk for chronic heart failure (25%) and death (14%) but did not 
increase the risk for acute myocardial infarction. In brief, the epidemiological 
studies showed weak associations, but are limited to their inherent limitations of 
potential confounding and bias(118).
Fueled by the scientific dispute, post-hoc analyses were performed on the data 
of 3 RCTs(119-121). These analyses did not disclose an increase in risk for ischaemic 
cardiovascular disease in patients using rosiglitazone, but the post-hoc nature 
with its nonrandomized comparisons diluted their scientific strength.
Recently, an independent reevaluation of the results of the RECORD study 
reported no increase in cardiovascular events, myocardial infarction or death 
during rosiglitazone treatment compared with metformin/sulfonylurea(122). As a 
consequence of this report the FDA relaxed some market restrictions and the 
scientific debate seemed to tilt again(123).
In summary, when all scientific evidence is taken together, there is no 
definite proof that rosiglitazone harms, but there is sufficient evidence to remain 
concerned about rosiglitazone’s cardiovascular safety. The fact that rosiglitazone 
does not have a unique health advantage over pioglitazone, justifies restriction of 
its use. 
Future perspectives
The thiazolidinediones combine adverse effects with unique properties, and 
interestingly, they are now off patent. In Europe, rosiglitazone has been withdrawn 
from the market, while in the USA and other parts of the world its use is 
restricted. Despite extended warning labels, due to non-cardiac health concerns, 
for instance increase in risk of bladder cancer(105,124), pioglitazone appears in many 
international guidelines(125,126) and is still widely used around the world with a 
market share of 10.8% in 2011(127). Strategies to optimize the risk/benefit ratio by 
using low dose thiazolidinedione in combination with metformin have received 
limited attention(128). Thiazolidinediones, especially pioglitazone, are also used 
for the treatment of non-alcoholic steatohepatitis (NASH)(129), polycystic ovary 
syndrome (PCO)(130) and lipodystrophy in human immunodeficiency virus 
(HIV) infected patients(131).
Newer PPAR-γ agonists may reach the diabetes market the coming years. They 
can be divided into the following four groups, thiazolidinediones (rivoglitazone), 
dual PPAR-α/γ agonists (aleglitazar), partial PPAR-γ agonists (balaglitazone) 
and the selective PPAR-γ modulators (SPPARM)(INT 131). Rivoglitazone(132), 
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and aleglitazar(133) appear fairly comparable with pioglitazone with respect to 
glycaemic control and oedema formation. In view of the previous members 
of these classes(134-136), expectations for these compounds need to be tempered. 
Recently, further development of aleglitazar has been interrupted due to side 
effects occurring in a cardiovascular outcome study (ALECARDIO). These 
side effects related to bone fractures, heart failure and gastrointestinal bleeding, 
mainly side effects already known from this class(137). Balaglitazone and INT 131 
are from a pharmacological point of view very interesting. Being a partial agonist, 
balaglitazone is supposed to have less adverse effects, which was shown in a phase 
III challenge against pioglitazone(138). INT 131 is designed to be selectively a full 
agonist for the beneficial insulin sensitizing properties of PPAR-γ. Indeed, in a 
phase II trial, INT 131 showed beneficial glycaemic action without the typical 
thiazolidinediones off-target adverse effects(139). If one of these drugs reaches the 
market and will have a role in diabetes management, knowledge of the mechanism 
of rosiglitazone-related fluid retention condensed in this thesis will contribute to 
monitoring potential fluid related side effects.
However, whether one of these new PPAR-γ agonists will actually reach 
the diabetes market is questionable as following the introduction of the 
thiazolidinediones other alternatives have become available. These are the 
incretins, represented by the Di Peptidyl Peptidase-4 inhibitors (DPP-4) and 
Glucagon-Like-Peptide-1 agonists (GLP-1)(140), and the Sodium-Glucose co-
transporter-2 inhibitors (SGLT2)(141), and are all approved for the treatment of type 
2 diabetes. As a consequence of the discussion about rosiglitazone’s cardiovascular 
safety, these new agents are monitored carefully for cardiovascular outcomes and 
as part of their registration, cardiovascular outcome safety trials are ongoing. 
Recently, the results of a cardiovascular outcome study with the DPP-4 inhibitor 
saxagliptin(40) have been reported. While the study showed that use of saxagliptin 
was not associated with any increase in cardiovascular events (but neither with a 
decrease), surprisingly and unexpectedly, the risk for hospitalization because of 
heart failure was increased(40). The explanation for this side effect is unclear.
So, it is quite remarkable that while we started our studies to solve the 
mechanism of action of thiazolidinedione-related fluid accumulation, the 
observation of increased risk of heart failure during treatment with a new 
hypoglycaemic agent in a way completes the circle of this thesis.
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Inleiding
De meeste geïnteresseerde vrienden, familieleden, collegae en kennissen 
zullen de teksten uit dit proefschrift niet gemakkelijk kunnen verteren. Het is 
namelijk in jargon geschreven, borduurt voort op een specialistisch denkkader en 
is nu eenmaal geen ‘pageturner’. Ook na omzetting naar Jip en Janneke taal zal het 
geen bestseller worden. Toch zullen we de komende bladzijden een poging doen 
om de kennis uit dit proefschrift toegankelijker te verwoorden en in perspectief 
te plaatsen. U wordt uitgenodigd ons te volgen.
Diabetes mellitus type 2 (ouderdomssuikerziekte) is een grote bedreiging voor 
de volksgezondheid. Iemand heeft suikerziekte als de suiker(glucose)concentratie 
in het bloed te hoog is. Normaal gesproken zorgt het hormoon insuline voor een 
daling van de bloedsuikerspiegel. Suikerziekte ontstaat als de productie van insuline 
te kort schiet of als het lichaam onvoldoende reageert op dit hormoon (resistentie). 
Ondanks verscheidene beschikbare medicamenteuze behandelingen is de ziekte 
progressief en leidt het tot invaliditeit, zoals door zenuwschade, en vroegtijdige 
dood, vaak door hart- en vaatziekte. Een fraaie omschrijving omtrent de aard van 
suikerziekte komt uit een Amerikaans rapport van het National Institute of Health: 
“Diabetes doodt niet snel of doelgericht, maar door een trage opeenstapeling van 
verborgen aanvallen die het lichaam schaadt. Daardoor wordt iemand beroofd 
van de mogelijkheid te kunnen zien, denken, lopen en vrijen”. Het zal duidelijk 
zijn dat er daarom gezocht werd en wordt naar een behandeling die niet alleen 
de bloedsuikerspiegel doet dalen, maar ook de schade op hart, bloedvaten en 
zenuwen vermindert of voorkomt. Een nieuwe klasse van geneesmiddelen 
diende zich twee decennia geleden aan. Het betrof de klasse van de PPAR-γ 
agonisten en dan met name een subgroep hiervan, de thiazolidinedionederivaten 
(TZD’s). Rosiglitazon en pioglitazon zijn vertegenwoordigers van deze subgroep. 
Het werkingsmechanisme wordt gekenmerkt door versterking van het effect van 
insuline, waardoor de bloedsuikerwaarde daalt. Daarnaast bestond het idee dat 
deze middelen ook bijkomende voordelen konden hebben, zoals het voorkomen 
of verminderen van schade aan zenuw, hart en bloedvaten. Daarentegen 
kleefden er direct ook nadelen aan de TZD’s. Mensen die een TZD gebruikten 
hielden namelijk vocht vast, met als gevolg dikke benen, maar soms zelfs ook 
kortademigheid door vochtophoping in de longen. Kortom, indien de oorzaak 
van de vochtophoping  achterhaald en behandeld zou kunnen worden, dan zou 
een ideaal middel ontstaan voor de behandeling van ouderdomssuikerziekte. 
Hier startte onze zoektocht. Het eerste deel van dit proefschrift richt zich op de 
oorzaak, risicofactoren en mogelijke behandeling van vochtophoping tijdens 
gebruik van rosiglitazon. Hoofdstuk zes en zeven richten zich op de mogelijke 
positieve effecten van rosiglitazon op zenuwenschade en op schade veroorzaakt 
door zuurstofgebrek, zoals bijvoorbeeld bij een infarct.  
Oorzaken vochtophoping en mogelijk aangrijpingspunt  
rosiglitazon
Grofweg kan de bron voor het vasthouden van vocht liggen hetzij in het hart, 
de nier of de bloedvaten. Als het hart niet goed werkt, ontstaat er ophoping van 
bloed (file) in de wegen (aders) naar het hart. De aders kunnen de hoeveelheid 
bloed niet verwerken, door de toegenomen druk treedt lekkage van vocht op 
naar de omringende weefsels. Onder invloed van de zwaartekracht is dat meestal 
het beste te zien in de benen. Anderzijds kan de nier ook de bron zijn van 
vochtophoping. Als de nier niet goed werkt en zout met water gaat vasthouden, 
wordt de druk in de bloedvaten ook opgevoerd en gelijk aan de beschrijving bij 
het hart zal er vocht uit de bloedvaten gaan lekken. Tot slot kan vochtophoping 
ook ontstaan als de kleine bloedvaatjes, de haarvaten, lek raken. Bij elke passage 
door de haarvaten moet er vocht, zout en voedingsstoffen afgegeven worden aan 
de weefsels. Als door het uitzetten van de aanvoerende bloedvaten de druk in 
het haarvat stijgt of als het haarvatfilter op zich lek is, neemt de stroom naar het 
weefsel toe. Bij aanvang van het proefschrift was reeds duidelijk dat de hartfunctie 
niet duidelijk slechter wordt tijdens behandeling met rosiglitazon. Kortom, op dat 
moment waren de belangrijkste verdachten voor het vasthouden van vocht onder 
invloed van een TZD de nier en de bloedvaten.
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Onderzoeksgereedschap (meetmethoden)
Dit proefschrift bevat een aantal onderzoeken waarbij rosiglitazon wordt 
vergeleken met een neppil (placebo). De onderzoeken zijn geblindeerd, zodat 
zowel de onderzoeker als de deelnemer niet weet wat hij slikt, en voorkomen 
wordt, dat je waarneemt wat je denkt te moeten waarnemen. Het effect van 
rosiglitazon treedt vrij langzaam in, zodat de testen pas na enkele weken kunnen 
plaatsvinden. In de tussentijd wordt het lichaam regelmatig doorgemeten, 
waardoor een uitspraak gedaan kan worden omtrent de hoeveelheid extra vocht 
in het lichaam en waar het zich bevindt. Hieronder volgt een korte beschrijving 
van de gebruikte meetmethodieken.
a). Voetvolume meting. De voet wordt op een gestandaardiseerde manier 
ondergedompeld in een bak met water die weer op een weegschaal rust. Op deze 
manier geeft de weegschaal niet het gewicht van de voet aan, maar het gewicht 
van de hoeveelheid water dat verplaatst is door de voet (Wet van Archimedes). 
Een indruk van deze methode kunt u krijgen op de plaatjes van hoofdstuk 1. 
b). Elektrische bio-impedantie meting. Hierbij wordt door middel van elektrische 
stroompjes de hoeveelheid water in het lichaam berekend. Onderliggend 
principe is dat water elektrische stroom beter geleidt dan vet. Een apparaat meet 
de stroomgeleiding van het lichaam en doet de berekening. 
c). Plasmavolume meting. De hoeveelheid water in het bloed van een deelnemer 
wordt met een verdunningsmethode bepaald. Radioactief eiwit wordt ingespoten 
en zal zich verdelen over het totale bloedvolume. Hierna wordt een bloedmonster 
afgenomen, waarin de hoeveelheid radioactiviteit wordt bepaald. De gemeten 
waarde zal lager liggen dan de ingespoten hoeveelheid, door verdunning in het 
bloed. Op basis van deze verdunning kan de hoeveelheid bloed worden berekend. 
De volgende twee testen werden verricht om meer inzicht in de functie van 
bloedvaten te verkrijgen. d). Permeabiliteit van de bloedvaten. De doorlaatbaarheid 
van haarvaten kan gemeten worden door na inspuiting van het genoemde 
radioactieve eiwit gedurende een uur bloed af te nemen. De hoeveelheid 
radioactiviteit in het bloed wordt alsmaar minder door lekkage van het eiwit 
naar de weefsels toe. De verdwijningsnelheid is dan een maat voor lekkage uit de 
bloedvaten. 
e). Vaatverwijding, bepaling door middel van plethysmografie. Hierbij 
wordt een arm kortdurend afgeklemd zodat er wel bloed in kan, maar niet uit. 
Het gevolg zal zijn dat de arm een beetje uitzet. Dit uitzetten kan nauwkeurig 
gemeten worden met een elektrische armband die mee uitrekt. Door uitrekking 
verandert de elektrische weerstand van de armband, en die wordt gemeten. Als 
deze veranderingen snel gaan, moet er in korte tijd veel bloed in de arm stromen 
en dat kan alleen als de bloedvaten wijdt open staan. 
f). Meting van de insuline gevoeligheid. De effecten van insuline kunnen 
nauwkeurig gemeten worden door een hoge dosis insuline toe te dienen. Het 
gevolg zal zijn dat de bloedsuikerwaarde daalt (denk aan het slot van de film 
‘Zwartboek’). Door tegelijkertijd glucose (suiker) toe te dienen in een dusdanige 
hoeveelheid dat de suikerspiegel gelijk blijft, verkrijgen we een maat voor 
de werkzaamheid van insuline (insuline gevoeligheid van het lichaam). Als 
er weinig suiker nodig is om de bloedwaarde gelijk te houden, is het lichaam 
insulineresistent. Deze test wordt een clamp genoemd. 
Overzicht van de beschreven onderzoeken
In het tweede hoofdstuk nemen we aan dat de oorzaak van vochtophoping 
tijdens behandeling met rosiglitazon gelegen is in bloedvaten. Eerder beschreven 
we al dat onder invloed van insuline de bloedsuikerwaarde daalt, maar daarnaast 
heeft insuline ook allerlei effecten op de bloedvaten. We vragen ons dan ook af of 
rosiglitazon niet alleen het effect van insuline op de bloedsuikerwaarde versterkt, 
maar ook de effecten van insuline op de bloedvaten. Daartoe lieten we mensen, 
waarbij insuline minder goed werkt (insulineresistentie), een periode rosiglitazon 
en een periode placebo gebruiken. Tijdens een experiment aan het einde van 
die periodes maten we de effecten van insuline tijdens gestandaardiseerde 
omstandigheden. Wat bleek, rosiglitazon versterkt de werking van insuline met 
betrekking tot de bloedsuikerwaarde, maar rosiglitazon versterkt niet de werking 
van insuline op de bloedvaten, zoals verwijding van de aanvoerende bloedvaten 
of lekkage van de haarvaten.
Ook in het derde hoofdstuk gaan we er van uit dat het wijder worden van de 
aanvoerende bloedvaten in ieder geval één van de routes is waardoor rosiglitazon 
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vochtophoping geeft. Normaal gesproken treedt in het lichaam een tegenreactie 
op van het onwillekeurige zenuwstelsel als je iets aan de vaatomvang verandert. 
Laat dat nu net een onderdeel zijn, dat wordt aangetast bij suikerziekte. Daarom 
onderzochten we in dit hoofdstuk of schade aan het onwillekeurige zenuwstelsel 
een risicofactor is voor het vasthouden van vocht tijdens behandeling met 
rosiglitazon. Gedurende 16 weken gebruikten mensen met suikerziekte, die 
tevens insuline spoten, een neppil of rosiglitazon. Deze personen hadden we 
verdeeld in mensen met en zonder zenuwschade. En inderdaad bleken mensen 
met zenuwschade meer lekkage van de bloedvaten te hebben tijdens behandeling 
met rosiglitazon dan mensen zonder zenuwschade. Door bloedvatverwijding en 
vochtlekkage zal de bloeddruk dalen, wat een signaal is voor de nier om vocht 
vast te gaan houden, waardoor het bloedvolume kan toenemen. Echter in ons 
onderzoek leidde de toename in vochtlekkage bij mensen met zenuwschade die 
behandeld werden met rosiglitazon niet tot een toename van het bloedvolume. We 
concluderen dat zenuwschade een risicofactor is voor rosiglitazon-gerelateerde 
vochtlekkage, maar niet voor extra vochtstapeling door de nier. 
In  hoofdstuk vier nemen we de nier onder de loep als mogelijk aangrijpingspunt 
voor de vochtstapeling tijdens behandeling met TZD’s. We vragen ons af of 
behandeling met een TZD leidt tot verminderde werking van plaspillen zoals 
eerder gesuggereerd werd in de literatuur. Dit is van belang voor de behandeling 
van vochtstapeling. Eigenlijk net als in hoofdstuk twee kregen vrijwilligers een 
periode placebo en een periode rosiglitazon. Aan het eind van iedere periode 
werd het zout afdrijvende vermogen van de plaspil furosemide bepaald. Deze 
plaspil zou in combinatie met een TZD zijn werkzaamheid verliezen, doordat een 
specifieke zoutpomp in de nier (ENaC) harder zou werken. Wij vonden echter 
dat furosemide even effectief was tijdens behandeling met rosiglitazon als tijdens 
behandeling met placebo. Verder onderzochten we in de urine het zoutgehalte 
en de aanwezige kapotte niercellen. Hierbij vonden we geen aanwijzingen voor 
verhoogde activiteit van de zoutpomp ENaC of voor een toename van het aantal 
pompjes (ENaC) in de nier.  Concluderend, TZD’s leiden niet tot stimulering 
van ENaC of vermindering van de werking van plaspillen. De klinische 
gevolgtrekking uit deze bevinding is dat TZD-gerelateerde vochtophoping kan 
worden behandeld met plaspillen.
 
Ter voorkoming van verdere complicaties is het van belang om bij patiënten 
die behandeld worden met TZD’s te letten op tekenen van vochtophoping. 
Vaak wordt daartoe het hematocriet, de verhouding van bloedcellen en vocht 
in het bloed (plasmavolume), vervolgd. In hoofdstuk vijf hebben we de relatie 
beschreven tussen veranderingen in hematocriet en plasmavolume tijdens 
behandeling met rosiglitazon. Hiervoor hebben we gebruik gemaakt van de 
gegevens van de onderzoeken beschreven in hoofdstukken twee en drie. In 
tegenstelling tot de gangbare mening, vonden we geen enkel verband tussen de 
verandering in hematocriet en verandering in plasmavolume tijdens chronische 
behandeling met rosiglitazon noch bij patiënten met insulineresistentie, noch 
bij patiënten met diabetes mellitus. De arts leert hiervan dat het bepalen van 
hematocriet bij het vervolgen van een individuele patiënt, geen meerwaarde 
heeft voor het vroegtijdig opsporen van vochtophoping tijdens behandeling met 
TZD’s. 
Een belangrijk onderwerp in dit proefschrift is schade aan het onwillekeurige 
zenuwstelsel. In hoofdstuk zes rapporteren we over functiemetingen van het 
onwillekeurig zenuwstelsel in patiënten met ouderdomssuikerziekte, met en 
zonder zenuwschade. Wij vonden dat bij patiënten met zenuwschade de functie 
in rust nog gespaard is, maar dat de functie tijdens piekbelasting duidelijk 
verminderd is ten opzichte van patiënten zonder schade. Bovendien vonden we 
enkele aanwijzingen dat rosiglitazon de functie van het beschadigde zenuwstelsel 
gunstig beïnvloedt. Dit effect trad op, onafhankelijk van het effect op de 
bloedsuiker.
Ten tijde van de start van de in dit proefschrift beschreven onderzoeken 
bestond de overtuiging dat TZD’s gunstig zouden zijn om schade aan hart en 
bloedvaten te voorkomen. Eén van de hypotheses volgens welk mechanisme dit 
positieve effect zou verlopen, was bescherming tegen schade door zuurstoftekort. 
Hoofdstuk zeven beschrijft de resultaten van een onderzoek naar de invloed 
van de behandeling met rosiglitazon op deze schade, gemeten aan de hand 
van aankleuring op foto’s gemaakt na toediening van een radioactief isotoop. 
Deelnemers moesten een zware knijpoefening verrichten terwijl de arm werd 
afgekneld, waardoor er dus zuurstofschuld kon ontstaan. Inderdaad bleken 
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deelnemers tijdens behandeling met rosiglitazon minder schade te hebben ten 
opzichte van behandeling met placebo. Dit suggereert inderdaad dat TZD’s 
beschermende effecten hebben op schade door zuurstofschuld.
Vochtophoping in kernwoorden en de nieuwe inzichten van dit  
proefschrift voor de klinische praktijk
Wetenschappelijk perspectief: Vochtophoping in zijn algemeenheid kent 
verschillende uitingsvormen in de kliniek. Het verschijnsel dat we in de klinische 
praktijk het frequentst tegenkomen tijdens behandeling met een TZD is 
vochtophoping in de huid (oedeem). Als we de literatuur op een rij zetten en daar 
de bevindingen uit dit proefschrift aan toevoegen, dan moeten we concluderen 
dat de drijvende kracht achter deze ophoping een disbalans in de bloedvaten 
is. Van de eerder genoemde hoofdverdachten vallen het hart en de nier dus af. 
De precieze aard van de disbalans in de bloedvaten is overigens niet duidelijk. 
Zowel toegenomen vaatverwijding, als ook toegenomen lekkage of  toename 
van het aantal actieve haarvaten kunnen een rol spelen bij TZD-gerelateerde 
vochtophoping. 
Klinisch perspectief: Drie nieuwe aandachtspunten met betrekking tot 
risicofactor-screening, vroegtijdige signalering en behandeling van TZD-
gerelateerde vochtophoping geeft dit proefschrift de clinicus mee. Allereerst 
blijkt de patiënt met schade aan het onwillekeurige zenuwstelsel gevoeliger voor 
het krijgen van oedeem. Ten tweede lijkt het vervolgen van het hematocriet in 
de individuele patiënt die wordt behandeld met een TZD niet bijdragend aan 
het vroegtijdig signaleren van ernstige vochtophoping. Ten slotte, mocht er 
onverhoopt sprake zijn van vochtophoping, dan zijn plaspillen even effectief in 
het afdrijven van zout en vocht als bij mensen die niet met een TZD behandeld 
worden.
Het liep anders
Op het moment van registratie werd van de TZD’s verwacht dat zij de kans op 
hart- en vaatziekten zouden reduceren. In de praktijk kon pioglitazon deze belofte 
een beetje inlossen, maar rosiglitazon zeker niet. In 2007 was de conclusie van 
een meta-analyse (dat is de overkoepelende conclusie van meerdere onderzoeken 
tezamen) dat rosiglitazon juist de kans op een hartinfarct vergroot. Tussen 2007 
en 2013 verschenen er talloze publicaties over dit onderwerp met tegenstrijdige 
conclusies waarbij de wetenschappelijke wereld werd opgedeeld in twee kampen: 
‘Rosiglitazon is bewezen slecht voor hart en bloedvaten’ en ‘Rosiglitazon is niet 
bewezen slecht voor hart en bloedvaten’. In de tussentijd werd het middel in Europa 
van de markt gehaald en mocht het in de VS alleen onder zware restricties in de 
handel blijven. Samengevat, alle wetenschappelijke bewijzen samengenomen, is 
er geen sluitend bewijs dat rosiglitazon schaadt, maar er is voldoende bewijs voor 
bezorgdheid omtrent rosiglitazon’s veiligheid voor hart en bloedvaten. Het feit dat 
rosiglitazon geen uniek gezondheidsvoordeel heeft ten opzichte van pioglitazon, 
rechtvaardigt beperking van het gebruik. Echter ook het gebruik van pioglitazon is 
aan banden gelegd vanwege een grotere kans op blaaskanker en botbreuken die je 
bij beide TZD’s ziet. Het oorspronkelijke idee dat vochtophoping de Achilleshiel 
van de TZD’s zou zijn werd niet bewaarheid. Enerzijds blijkt het oedeem meestal 
goedaardig. Anderzijds zijn er ernstigere bijwerkingen bijgekomen, zoals een 
toegenomen kans op blaaskanker, botbreuken en dus specifiek voor rosiglitazon 
een mogelijk toegenomen kans op een hartinfarct.
Toekomst PPAR-γ agonisten en dit proefschrift
Ondanks de bijwerkingen worden TZD’s nog steeds gebruikt, aan de ene 
kant vanwege de unieke eigenschappen, aan de andere kant vanwege de geringe 
kosten nu ze uit patent zijn.  In Europa is rosiglitazon vanwege twijfels omtrent 
de veiligheid van de markt gehaald, maar in de Verenigde Staten en andere delen 
van de wereld werd het gebruik slechts ingeperkt. Daarentegen staat het broertje 
pioglitazon nog steeds in internationale richtlijnen en wordt het wereldwijd nog 
regelmatig gebruikt, waarbij het marktaandeel in 2011 ongeveer tien procent 
bedroeg. TZD’s, vooral pioglitazon, worden ook gebruikt voor de behandeling 
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van niet-alcoholische vettige leverontsteking, polycysteus eierstoksyndroom en 
lipodystrofie in humane immunodeficiëntievirus (HIV) geïnfecteerde patiënten.
Nieuwere PPAR-γ agonisten worden de komende jaren waarschijnlijk op de 
markt gebracht ter behandeling van ouderdomssuikerziekte. Slechts een enkel 
middel lijkt gunstige effecten te hebben op de bloedsuikerwaarde zonder de voor de 
thiazolidinedionen kenmerkende bijwerkingen. Als één van deze geneesmiddelen 
geregistreerd gaat worden voor de behandeling van ouderdomssuikerziekte 
zal de kennis zoals beschreven in dit proefschrift bijdragen aan het toezicht op 
mogelijke vocht-gerelateerde bijwerkingen.
Echter, of één van deze nieuwe PPAR-γ agonisten daadwerkelijk voor 
behandeling van ouderdomssuikerziekte geregistreerd gaat worden is twijfelachtig, 
aangezien er in het afgelopen decennium concurrentie bij is gekomen van andere 
geneesmiddelgroepen. Dit zijn de incretines, vertegenwoordigd door de di-
peptidyl-peptidase-4-remmers (DPP-4) en de glucagon-like peptide-1-agonisten 
(GLP-1), en de natrium-glucose co-transporter-2 remmers (SGLT2). In ieder 
geval worden de namen er niet toegankelijker op. Als gevolg van de discussie 
over de cardiovasculaire veiligheid van rosiglitazon, worden deze nieuwe 
middelen zorgvuldig gevolgd op bijwerkingen van hart of bloedvaten. Onlangs 
zijn de resultaten van een dergelijk onderzoek van de DPP-4-remmer saxagliptin 
gepubliceerd. Onverwacht en vooralsnog onverklaard bleek saxagliptin de kans 
op ziekenhuisopname als gevolg van hartfalen te verhogen. Terugdenkend lijkt 
dit op het startpunt van het proefschrift dat nu voor u ligt. We begonnen immers 
deze zoektocht in een poging TZD-gerelateerde vochtophoping zoals hartfalen te 
verklaren. De waarneming dat een nieuw bloedsuikerverlagend middel de kans 
op verslechtering van hartfalen vergroot, voltooit in zekere zin de cyclus van dit 
proefschift.
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List of abbreviations
List of abbreviations used throughout this thesis
ANP:  Atrial Natriuretic Peptide
AUC:  Area Under the Curve
BMI:  Body Mass Index
CAN:  Cardiovascular Autonomic Neuropathy
DBP:  Diastolic Blood Pressure
ECV:  Extra Cellular Volume
ENaC: Epithelial Sodium Channel
FBF:  Forearm Blood Flow
FPG:  Fasting Plasma Glucose
FVR:  Forearm Vascular Resistance
GIR:  Glucose Infusion Rate
HbA1c:  Glycosylated Haemoglobin
HDL:  High Density lipoprotein
HOMA:  Homeostasis Model Assessment
HPLC: High-Performance Liquid Chromatography
I/R: Ischaemie/Reperfusion 
LBNP:  Lower Body Negative Pressure
L-NMMA:  N-MonoMethyl-L-Arginin-acetate
MCV:  Mean Corpuscular Volume
NO:  Nitric Oxide
PLAC:  Placebo
PPAR-γ: Peroxisome Proliferator Activated Receptor-γ
PV:  Plasma Volume
RAAS: Renin-Angiotensin-Aldosterone System
RSG:  Rosiglitazone
SBP:  Systolic Blood Pressure
TBW: Total Body Water
TERalb: Transcapillary Escape Rate of albumin
TZD:  Thiazolidinedione 
VEGF:  Vascular Endothelial Growth Factor
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Dankwoord
“In de wetenschap staan we op de schouders van reuzen”. Dat geldt natuurlijk 
ook voor mij, maar daarnaast heb ik duwtjes en zetjes van een groot aantal 
mensen gekregen. Zonder deze hulp waren de onderzoeken die beschreven staan 
in dit proefschrift nooit tot stand gekomen. Bovenal moet ik de proefpersonen 
(vrijwilligers en patiënten) die bereid waren mee te werken aan mijn onderzoeken 
in het zonnetje zetten.
Beste proefpersonen, ik heb warme herinneringen aan de boeiende gesprekken 
die ik heb gevoerd met u tijdens de lange onderzoekssessies. Verhalen over het 
leven als student onder het regime van Mubutu, over het leven als profwielrenner 
in de jaren ’50 of als politiek journalist in de jaren ’60. Maar ook gesprekken over 
de passie voor de muziek van Queen en over een motoraanrijding met een koe zijn 
mij bijgebleven en hebben mijn promotietraject verrijkt. Als academicus moet 
je immers het grote verband blijven zien. Ik hoop dat de warme herinneringen 
wederzijds zijn, al moest u zich wel infuuslijnen, bloedafnames en een aantal 
stresstesten laten welgevallen. Terzijde, de botsing met de koe was in ieder geval 
het meest originele adverse event uit mijn onderzoeken.
Mijn promotores:
Professor P.(A.B.M.) Smits. Beste Paul, het was in mijn eerste opleidingsjaar 
(1999) dat jij indruk op mij maakte tijdens het toenmalige COIG Farmacologie 
als jonge hoogleraar met een gelikte presentatie en voordracht. Daarna was 
het niet moeilijk mij te verleiden tot dit promotietraject op jouw afdeling. Dit 
bleek een juiste keuze, je hebt namelijk een neus voor het creëren van een goede 
sfeer in de werkomgeving.  Ik moet je danken voor de ruimte die je me gegeven 
hebt, ook na afronding van mijn interne opleiding, om het onderzoek voort 
te zetten. Je hebt mij oog gegeven voor detail en symmetrie in presentatie, en 
gevoel bijgebracht voor de grote lijn bij het opzetten van een onderzoek. Ook na 
je verhuizing naar de bovenste verdieping bleef de afstand overbrugbaar door je 
amicale en hartelijke manier van benadering en begeleiding. Terzijde, ik kijk met 
jaloerse blik naar je altijd opgeruimde bureau. Dat lukt mij helaas vaak niet. Ik 
klamp me dan maar vast aan de stelling die ik op de kalender thuis tegen kwam: 
“A clean house is a sign of a wasted life”. 
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Professor CJJ Tack. Beste Cees, wat zal jij blij zijn dat je van mijn lappen tekst 
af bent. Mijn woordliefde is wat groter dan de jouwe, gelukkig is jouw Engels 
een stuk beter dan het mijne. In het begin van mijn traject nooit te beroerd om 
bij een experiment bij te springen, op het einde van het traject naaste begeleider 
in de afronding van het boek. Maar ja, je was inmiddels ook doorgegroeid tot 
promotor. Ik bewonder je vermogen om zonder scrupules een afwijkende soms 
impopulaire mening te hebben en te verkondigen. Bij mij kom je daarmee weg 
door je eerlijkheid en je gemoedelijke motoriek. Terzijde, je telt nog wel eens 
de hoeveelheid e-mail die je tijdens een promotietraject van je promovendus 
ontvangt, op jaarbasis scoor ik laag denk ik.
Mijn paranimfen: 
Beste Niels, het was Peter Pickkers die je bij jouw komst op de afdeling Farmtox 
aankondigde als een groot onderzoekstalent. Niets bleek minder waar, maar 
belangrijker, je bent een geweldig sympathieke collega. Door de dagelijkse 
afblaassessies op de farmacologie raakten we al snel bevriend. Terzijde, dat is 
best opvallend aangezien jij amper geboren was toen Nederland werd geteisterd 
door een zware Siberische koude–aanval op de avond van 29 december 1978, 
de eerste associatie die ik had toen je jouw geboortejaar vertelde. Inmiddels zijn 
onze rollen veranderd en ben je zelfs mijn leidinggevende. Elkaars voetstappen 
herkennen we niet meer, maar dat komt meer door de vloerbedekking op de 
afdeling interne geneeskunde dan het feit dat ik je schoenenverzameling niet 
meer uit het hoofd ken. In je rol als leidinggevende blijf je geïnteresseerd in de 
beslommeringen van collega’s, ben je niet bang ruim baan te maken voor talenten 
van anderen en durf je, altijd wel onderbouwd, beslissingen te nemen. Kortom 
een L’Uomo Universalis. Nu nog hopen dat je het er als paranimf ook goed vanaf 
brengt.  
Beste Bas, ook bij mijn kennismaking met jou was ik de ervaren collega, maar 
dan in de kliniek. Het was ten tijde van mijn laatste klinische stage (hematologie) 
voor aanvang van mijn promotieonderzoek. Overigens had ik nog mijn best 
gedaan onder deze stage uit te komen, omdat ik altijd een beetje zeeziek wordt 
van het turen naar bloedcellen onder een microscoop. Gelukkig kwam ik er niet 
onderuit, want het werd uiteindelijk mijn leukste stage en daar speelde jij een 
duidelijke rol in. Ik heb genoten van je kleurrijke uitvoeringen van diverse imitaties 
tussen de bedrijven door. Ons contact kreeg verdieping tijdens een spekgladde 
kroegentocht naar café Jos. Het was dan ook een leuke gewaarwording om je 
later op de Farmtox weer tegen te komen. Uiteindelijk vertoont ons carrièrepad 
en opleidingsportfolio veel overeenkomsten. Alleen ben jij nog nooit paranimf 
geweest, maar dat hiaat wordt nu gevuld. Terzijde, het is misschien verstandig 
om je imitaties ten uitvoer te brengen in afwezigheid van familieleden van het 
subject. 
Afdeling Farmacologie (Farmtox):
Beste collega’s van de afdeling, wat een fijne jaren heb ik met jullie gehad. Na 
jaren doorjagen in de kliniek zonder tijd voor de inwendige mens (en dat in de 
opleiding tot inwendig geneeskundige) was het ritme op de afdeling Farmtox 
met een gezellige koffietafel een verademing. Het leek wel of het iedere dag 
een afdelingsuitje was. Maar het hoogtepunt van het jaar was toch wel het uitje 
zelf, samen met de collega’s uit de ‘Toren’. Op deze plek ook speciale dank voor 
de initiële opvang aan mijn kamergenoten van het eerste uur Peter Pickkers 
en Tanya Bisseling, voor de initiële opvang. Ja Peter, dat voelde als een tweede 
studententijd. Verder speciale dank aan Janny Peters, Petra van den Broek en Joke 
Verpalen voor de zorgvuldige uitvoering van de analyses,Gerard Rongen, Frans 
Russel en Roos Masereeuw voor de prettige samenwerking bij het onderzoek en 
natuurlijk Lilibeth Triebels, de spil en het geweten van de afdeling. Terzijde, ik ben 
geloof ik wel de enige met goede herinneringen aan het afdelingsuitje gesitueerd 
in het oude zwembad, aquarium, in Arnhem. Dat ik het zelf had georganiseerd 
speelde hierin mogelijk een rol, want verder zijn er verscheidene collega’s die 
jarenlang gekweld werden door nachtmerries over striemende lianen, ijskoud 
water en gevaarlijke grote vissen. De kans op revanche diende zich een paar jaar 
later aan toen er een calamiteit plaatsvond op de afdeling. Een reactievat dreigde 
te ontploffen waardoor een hele vleugel van de pre-kliniek ontruimt diende te 
worden. Iedereen? Nee, ondergetekende zat noest aan zijn onderzoek te werken 
in de belendende kamer en werd vergeten.
Medewerkers van andere afdelingen:
Dank aan Peter Deen en Yuedan Li voor de prettige samenwerking in 
de diureticastudie. Dank aan de medewerkers van het CRCN, nucleaire 
geneeskunde, klinische farmacie en het centraal klinisch laboratorium, waar 
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samples op voor hen onmogelijke tijden mochten worden aangeleverd. Speciale 
dank voor diëtiste Barbara Fabels voor haar nauwgezette berekening van de 
diverse maaltijdvoorschriften. Daarnaast grote waardering voor de verscheidene 
research nurses die ik heb meegemaakt in mijn onderzoekstraject. Speciaal wil 
ik bij dezen Aarnout Janssen van Rozendaal vermelden, mijn steun en toeverlaat 
tijdens de eerste onderzoeken. Terzijde Aarnout, er was wel eens wat tegenslag. 
Zo viel jij ooit van de trap, terwijl je mij aan het helpen was. Gelukkig bracht 
je het er zonder kleerscheuren van af. Helaas kon dat niet gezegd worden van 
mijn die dag gespaarde bloedstalen. Die eindigden met radioactiviteit en al in het 
trappenhuis.
Mede promovendi:
Een speciale plaats in dit hoofdstuk spelen mijn collega-onderzoekers in de 
onderzoekslijnen van de professoren Smits, Tack, Hopman en Rongen. Met 
wekelijkse besprekingen kwamen we met elkaars data in aanraking zodat het wiel 
niet telkens opnieuw hoefde worden uitgevonden. Patrick Meijer, Stijn Wouters, 
Marlies Bosselaar en Marc Gomes dank voor het inspringen op die momenten 
dat ik andere verplichtingen had.
GlaxoSmithKline:
Zonder financiële ondersteuning was er nooit een begin gemaakt aan dit project. 
Ik heb gezien dat onderzoek doen met de industrie niet vies hoeft te zijn en dan 
doel ik niet op de Bossche Bollen die een keer getrakteerd werden bij randomisatie 
van de laatste proefpersoon. De strikte controle op de onderzoeksdata in deze 
onderzoeken was zijn tijd vooruit. Het persoonlijk contact met de study monitors 
was hartelijk en prettig. Derhalve dank aan Anja van Ratingen, Tine Hendrickx 
en Hans Weimar. In addition, many thanks to Jill Donaldson for her energetic 
coordination of the project in the United Kingdom and Murray Stuart for his 
comments on basic physiology and the pharmacodynamics of rosiglitazone. 
Student:
Beste Dominique, dank voor je goede ondersteuning tijdens mijn laatste 
onderzoek.  Ondanks mijn klinische taken en opleidingverplichtingen hielp jij 
mij dit onderzoek draaiende te houden. 
Ouders aan de zijlijn:
Er waren momenten dat de eindstreep van dit proefschrift steeds verder achter de 
horizon dreigde te geraken. Weekenden slipten dicht met verplichtingen inherent 
aan het vaderschap. De belangstelling van ouders die naast mij aan de lijn stonden 
of met mij zaten te puffen aan de rand  van het zwembad zorgden voor die kleine 
duwtjes die ik op die momenten nodig had. De wijdlopige gesprekken met Klaas 
Landman, de prikkelende opmerkingen van het duo de Leeuw en de hartelijke 
belangstelling van Christoph Lüthy en Carla-Rita Palmerino waren me dierbaar.
Thijs Goverde:
Aan deze Nijmeegse kinderboekenschrijver ontleen ik het idee van de terzijdes. 
Hij weet zich door die verrukkelijke uitwijdingen te manifesteren als een 
Nederlandse García Márquez voor kinderen. Terzijde Cees, het is beter dat jij dat 
niet gaat lezen.
Mijn ouders:
Lieve paps en mams, in dit dankwoord zijn jullie de enigen waarvan ik het 
stelligst kan beweren dat zonder jullie er geen proefschrift zou zijn. Dank voor de 
goede start in mijn leven en het feit dat jullie daadwerkelijk er altijd voor mij zijn. 
Jullie waren nooit te beroerd om ja te zeggen als ik belde met de vraag of jullie 
konden oppassen, zodat ik aan mijn onderzoek kon werken. Daarom draag ik dit 
proefschrift dan ook aan jullie op. Jullie zijn schatten.
Schoonouders:
Lieve Thea en John, als schoonmoeder en (stief)schoonvader bleven jullie 
interesse houden in mijn project. Ik kan nu eindelijk zeggen dat het af is. Thea, 
ik heb er lang over gedaan, maar altijd nog korter dan dat jij wekelijks trouw op 
je kleinzonen kwam passen en ons gezin draaiende hield. Dit jaar vierde je jouw 
bronzen oppasjubileum. Dank je wel.
Gezin:
Lars, Sam, Boaz. Lieve jongens, eindelijk ligt het boekje bij de drukker. Dit zal in 
ieder geval niet meer de spelbreker zijn voor een potje voetbal na het eten. Wat 
een voorrecht is het om jullie om me heen te hebben. Jullie talenten, bravoure, 
drukte en gezelligheid maken mij heel blij. Veel blijer dan dit boekje.
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Lieve Gaby, aan jou heeft het niet gelegen dat mijn promotietraject wat overrijp 
raakte. Om mij te begrijpen hoef je echt dit proefschrift niet te lezen, je mag het 
bij deze alinea laten. Jij bent een (mijn) fantastische vrouw. Denk daar maar aan 
als het nodig is. De overige intimiteiten hoeven wat mij betreft niet gepubliceerd 
te worden, maar schrijf ik in je eigen exemplaar….. 
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Alexander Rennings werd geboren op 7 mei 1970 in Oudenbosch, een plaats 
in het westen van Noord-Brabant, bekend om zijn Rijke Roomse Leven en de 
kopie van de Sint Pieter in Rome. In het naburige Roosendaal ging hij naar 
het Norbertus Lyceum alwaar hij in 1988 het gymnasium diploma behaalde. 
In datzelfde jaar startte hij na een rondreis door Europa de studie ‘medicijnen’ 
aan de Rijksuniversiteit Leiden. Na klinische en fundamentele onderzoeksstages 
in de diabetologie bij respectievelijk dr. H. Brussaard (LUMC) en professor G. 
Shulman (Yale University) was de wetenschappelijke interesse gewekt. Toch 
koos hij voor klinisch werk en verhuisde hij in 1998 naar Nijmegen alwaar hij in 
2004 onder de bezielende leiding van professor J. van der Meer internist werd. 
Gefascineerd door de klinische farmacologie en de fysiologie van water en zout 
in ons lichaam startte hij in 2002 op de afdeling Farmacologie-Toxicologie de 
onderzoeken die beschreven zijn  in dit proefschrift. Zoals ook in de kliniek bleef 
de focus tijdens het onderzoek sterk liggen op het welbevinden van de mens. 
Inmiddels is hij geregistreerd als vasculair-geneeskundige (opleider: professor 
A. Stalenhoef) en klinisch-farmacoloog (opleider: professor P. Smits). Sinds 
2011 heeft hij een dubbele aanstelling. Als internist is hij verbonden aan de Sint 
Maartenskliniek, alwaar hij onder andere de opleiding tot klinisch-farmacoloog 
coördineert. In het Radboudumc legt hij zich speciaal toe op de erfelijke 
aangeboren stofwisselingsziekten en haemochromatose. Als arts probeert hij het 
perspectief van de patiënt niet uit het oog te verliezen en wil hij zijn kennis graag 
aan studenten overdragen. Maar de grootste passie blijft zijn gezinsleven, waarbij 
hij het huis deelt met zijn echtgenote Gaby van Welsem en hun drie zonen.
